QuickLinks -- Click here to rapidly navigate through this document

Exhibit 10.1

    For Purchases Direct From Supplier
Subject to Competitive Bid Process

SUPPLIER AGREEMENT

between

NOVATION, LLC

and

Specialty Laboratories, Inc.

LB00051

Replaces Agreement LAB442 for VHA members

     * CONFIDENTIAL TREATMENT IS REQUESTED FOR CONFIDENTIAL INFORMATION ENCLOSED
IN THE BRACKETS AND UNDERLINED.

--------------------------------------------------------------------------------

TABLE OF CONTENTS

 
   
   
  PAGE

--------------------------------------------------------------------------------

1.   INTRODUCTION   1
 
 
a.
 
Purchasing Opportunities for Members
 
1
 
 
b.
 
Supplier
 
1
 
 
c.
 
Bid
 
1
2.
 
CONTRACT AWARD
 
1
 
 
a.
 
Letter of Award
 
1
 
 
b.
 
Optional Purchasing Arrangement
 
1
 
 
c.
 
Market Competitive Terms
 
1
 
 
d.
 
Changes in Award Prices
 
2
 
 
e.
 
Notification of Changes in Pricing Terms
 
2
 
 
f.
 
Underutilized Businesses
 
2
3.
 
TERM AND TERMINATION
 
2
 
 
a.
 
Term
 
2
 
 
b.
 
Termination by Novation
 
2
 
 
c.
 
Termination by Supplier
 
3
4.
 
PRODUCT SUPPLY
 
3
 
 
a.
 
Delivery and Invoicing
 
3
 
 
b.
 
Product Fill Rates; Confirmation and Delivery Times
 
3
 
 
c.
 
Bundled Terms
 
3
 
 
d.
 
Discontinuation of Products; Changes in Packaging
 
3
 
 
e.
 
Replacement or New Products
 
3
 
 
f.
 
Member Services
 
4
 
 
g.
 
Product Deletion
 
4
 
 
h.
 
Return of Products
 
4
 
 
i.
 
Failure to Supply
 
4

i

--------------------------------------------------------------------------------

5.
 
PRODUCT QUALITY
 
4
 
 
a.
 
Free From Defects
 
4
 
 
b.
 
Product Compliance
 
4
 
 
c.
 
Patent Infringement
 
5
 
 
d.
 
Product Condition
 
5
 
 
e.
 
Recall of Products
 
5
 
 
f.
 
Shelf Life
 
5
6.
 
CENTURY COMPLIANCE
 
5
 
 
a.
 
Definitions
 
5
 
 
b.
 
Representations.
 
6
 
 
c.
 
Remedies
 
6
 
 
d.
 
Noncompliance Notice
 
6
 
 
e.
 
Survival
 
6
7.
 
REPORTS AND OTHER INFORMATION REQUIREMENTS
 
6
 
 
a.
 
Report Content
 
6
 
 
b.
 
Report Format and Delivery
 
7
 
 
c.
 
Other Information Requirements
 
7
8.
 
OBLIGATIONS OF NOVATION
 
7
 
 
a.
 
Information to Members
 
7
 
 
b.
 
Marketing Services
 
7
9.
 
MARKETING FEES
 
7
 
 
a.
 
Calculation
 
7
 
 
b.
 
Payment
 
8
10.
 
ADMINISTRATIVE DAMAGES
 
8
11.
 
NONPAYMENT OR INSOLVENCY OF A MEMBER
 
9

ii

--------------------------------------------------------------------------------

12.
 
INSURANCE
 
9
 
 
a.
 
Policy Requirements
 
9
 
 
b.
 
Self-Insurance
 
9
 
 
c.
 
Amendments, Notices and Endorsements
 
9
13.
 
COMPLIANCE WITH LAW AND GOVERNMENT PROGRAM PARTICIPATION
 
9
 
 
a.
 
Compliance With Law
 
9
 
 
b.
 
Government Program Participation
 
9
14.
 
RELEASE AND INDEMNITY
 
10
15.
 
BOOKS AND RECORDS; FACILITIES INSPECTIONS
 
10
16.
 
USE OF NAMES, ETC
 
10
17.
 
CONFIDENTIAL INFORMATION
 
11
 
 
a.
 
Nondisclosure
 
11
 
 
b.
 
Definition
 
11
18.
 
MISCELLANEOUS
 
11
 
 
a.
 
Choice of Law
 
11
 
 
b.
 
Not Responsible
 
11
 
 
c.
 
Third Party Beneficiaries
 
11
 
 
d.
 
Notices
 
11
 
 
e.
 
No Assignment
 
12
 
 
f.
 
Severability
 
12
 
 
g.
 
Entire Agreement
 
12

iii

--------------------------------------------------------------------------------

INDEX OF DEFINED TERMS

 
  PAGE

--------------------------------------------------------------------------------

Agreed Percentage   10 Award Letter   1 Award Prices   1 Bid   1
Calendar-Related   7 Century Noncompliance   7 Clients   1 Confidential
Information   14 Effective Date   3 FDA   12 Federal health care program   12
Gregorian calendar   7 Guidebook   9 Indemnitees   12 Legal Requirements   12
Marketing Fees   9 Members   1 Non-Price Specifications   1 Novation   1
Novation Database   1 Reporting Month   8 Special Conditions   1 Systems   7
Term   3 timely   8

--------------------------------------------------------------------------------

NOVATION, LLC

SUPPLIER AGREEMENT

1.  INTRODUCTION.

    a.  Purchasing Opportunities for Members.  Novation, LLC ("Novation") is
engaged in providing purchasing opportunities with respect to high quality
products and services to participating health care providers ("Members").
Members are entitled to participate in Novation's programs through their
membership or other participatory status in any of the following client
organizations: VHA Inc., University HealthSystem Consortium, and HealthCare
Purchasing Partners International, LLC (collectively, "Clients"). Novation is
acting as the exclusive agent for each of the Clients and certain of each
Client's subsidiaries and affiliates, respectively, (and not collectively), with
respect to this Agreement. A current listing of Members is maintained by
Novation in the electronic database, described in the Guidebook referred to in
Subsection 7.c below ("Novation Database"). A provider will become a "Member"
for purposes of this Agreement at the time Novation adds the provider to the
Novation Database and will cease to be a "Member" for such purposes at the time
Novation deletes the provider from the Novation Database.

    b.  Supplier.  Supplier is the manufacturer of products listed on Exhibit A,
the provider of installation, training and maintenance services for such
products, and the provider of any other services listed on Exhibit A (such
products and/or services are collectively referred to herein as "Products").

    c.  Bid.  Supplier has responded to Novation's Invitation to Bid by
submitting its written offer ("Bid") to Novation consisting of this Agreement,
the listing of Products and pricing therefor ("Award Prices") attached hereto as
Exhibit A, the other specifications attached hereto as Exhibit B ("Non-Price
Specifications"), the Special Conditions attached hereto as Exhibit C ("Special
Conditions"), and any other materials required to be submitted in accordance
with the Bid Instructions.

2.  CONTRACT AWARD.

    a.  Letter of Award.  By executing and delivering the Letter of Award
attached hereto as Exhibit D ("Award Letter") to Supplier, Novation will have
accepted the Bid, and Novation and Supplier therefore agree that Supplier will
make the Products available for purchase by the Members at the Award Prices in
accordance with the terms of this Agreement; provided, however, that Novation's
award of this Agreement to Supplier will not constitute a commitment by any
person to purchase any of the Products. No obligations of Novation set forth in
this Agreement will be valid or enforceable against Novation unless and until
the Award Letter has been duly executed by Novation and attached as an exhibit
hereto. Supplier acknowledges that, in making its award to Supplier, Novation
has materially relied on all representations, warranties and agreements made by
Supplier as part of the Bid and that all such representations, warranties and
agreements will survive acceptance of the Bid.

    b.  Optional Purchasing Arrangement.  Novation and Supplier agree that each
Member will have the option of purchasing the Products under the terms of this
Agreement or under the terms of any other purchasing or pricing arrangement that
may exist between such Member and Supplier at any time during the Term;
provided, however, that, regardless of the arrangement, Supplier will comply
with Sections 7 and 9 below. If any Member uses any other purchasing or pricing
arrangement with Supplier when ordering products covered by any contract between
Supplier and Novation, Supplier will notify such Member of the pricing and other
significant terms of the applicable Novation contract.

    c.  Market Competitive Terms.  Supplier agrees that the prices, quality,
value and technology of all Products purchased under this Agreement will remain
market competitive at all times during the Term. Supplier agrees to provide
prompt written notice to Novation of all [***]* Supplier will [***]* applicable
to the purchase of the Products as necessary to assure market competitiveness.
If at any time

1

--------------------------------------------------------------------------------

during the Term Novation receives information from any source suggesting that
[***]*, Novation may provide written notice of such information to Supplier, and
Supplier will, [***]*.

    d.  Changes in Award Prices.  Unless otherwise expressly agreed in any
exhibit to this Agreement, the Award Prices will not be increased and any
discount will not be eliminated or reduced during the Term. In addition to any
changes made to assure market competitiveness, Supplier may lower the Award
Prices or increase any discount applicable to the purchase of the Products at
any time.

    e.  Notification of Changes in Pricing Terms.  Supplier will provide not
less than sixty (60) days' prior written notice to Novation and not less than
forty-five (45) days' prior written notice to all Members of any change in
pricing terms permitted or required by this Agreement. For purposes of the
foregoing notification requirements, a change in pricing terms will mean any
change that affects the delivered price to the Member, including, without
limitation, changes in list prices, discounts or pricing tiers or schedules.
Such prior written notice will be provided in such format and in such detail as
may be required by Novation from time to time, and will include, at a minimum,
sufficient information to determine line item pricing of the Products for all
affected Members.

    f.  Underutilized Businesses.  Certain Members may be required by law,
regulation and/or internal policy to do business with underutilized businesses
such as Minority Business Enterprises (MBE), Disadvantaged Business Enterprises
(DBE), Small Business Enterprises (SBE), Historically Underutilized Businesses
(HUB) and/or Women-owned Business Enterprises (WBE). To assist Novation in
helping Members meet these requirements, Supplier will comply with all Novation
policies and programs with respect to such businesses and will provide, on
request, Novation or any Member with statistical or other information with
respect to Supplier's utilization of such businesses as a vendor, distributor,
contractor or subcontractor.

3.  TERM AND TERMINATION.

    a.  Term.  This Agreement will be effective as of the effective date set
forth in the Award Letter ("Effective Date"), and, unless sooner terminated,
will continue in full force and effect for the initial term set forth in the
Non-Price Specifications and for any renewal terms set forth in the Non-Price
Specifications by Novation's delivery of written notice of renewal to Supplier
not less than ten (10) days prior to the end of the initial term or any renewal
term, as applicable. The initial term, together with the renewal terms, if any,
are collectively referred to herein as the "Term."

    b.  Termination by Novation.  Novation may terminate this Agreement at any
time for any reason whatsoever by delivering not less than ninety (90) days'
prior written notice thereof to Supplier. In addition, Novation may terminate
this Agreement immediately by delivering written notice thereof to Supplier upon
the occurrence of either of the following events:

    (1) Supplier breaches this Agreement; or

    (2) Supplier becomes bankrupt or insolvent or makes an unauthorized
assignment or goes into liquidation or proceedings are initiated for the purpose
of having a receiving order or winding up order made against Supplier, or
Supplier applies to the courts for protection from its creditors.

Novation's right to terminate this Agreement due to Supplier's breach in
accordance with this Subsection is in addition to ally other rights and remedies
Novation, the Clients or the Members may have resulting from such breach,
including, but not limited to, Novation's and the Clients' right to recover all
loss of Marketing Fees resulting from such breach through the date of
termination and for one hundred eighty (180) days thereafter.

2

--------------------------------------------------------------------------------

    c.  Termination by Supplier.  Supplier may terminate this Agreement at any
time for any reason whatsoever by delivering not less than one hundred eighty
(180) days' prior written notice thereof to Novation.

4.  PRODUCT SUPPLY.

    a.  Delivery and Invoicing.  On and after the Effective Date, Supplier
agrees to deliver Products ordered by the Members to the Members, FOB
destination, and will direct its invoices to the Members in accordance with this
Agreement. Supplier agrees to prepay and absorb charges, if any, for
transporting Products to the Members. Payment terms are [***]*. Supplier will
make whatever arrangements are reasonably necessary with the Members to
implement the terms of this Agreement; provided, however, Supplier will not
impose any purchasing commitment on any Member as a condition to the Member's
purchase of any Products pursuant to this Agreement.

    b.  Product Fill Rates; Confirmation and Delivery Times.  Supplier agrees to
provide product fill rates to the Members of greater than [***]*, calculated as
line item orders. Supplier will provide confirmation of orders from Members via
the electronic data interchange described in the Guidebook referred to in
Subsection 7.c below within two (2) business days after placement of the order
and will deliver the Products to the Members within ten (10) business days after
placement of the order.

    c.  Bundled Terms.  Supplier agrees to give Novation prior written notice of
any offer Supplier makes to any Member to sell products that are not covered by
this Agreement in conjunction with Products covered by this Agreement under
circumstances where the Member has no real economic choice other than to accept
such bundled terms.

    d.  Discontinuation of Products; Changes in Packaging.  Supplier will have
no unilateral right to discontinue any of the Products or to make any changes in
packaging which render any of the Products substantially different in use,
function or distribution. Supplier may request Novation in writing to agree to a
proposed discontinuation of any Products or a proposed change in packaging for
any Products at least ninety (90) days prior to the proposed implementation of
the discontinuation or change. Under no circumstances will any Product
discontinuation or packaging changes be permitted under this Agreement without
Novation's agreement to the discontinuation or change. In the event Supplier
implements such proposed discontinuation or change without Novation's agreement
thereto in writing, in addition to any other rights and remedies Novation or the
Members may have by reason of such discontinuation or change, (i) Novation will
have the right to terminate any or all of the Product(s) subject to such
discontinuation or change or to terminate this Agreement in its entirety
immediately upon becoming aware of the discontinuation or change or any time
thereafter by delivering written notice thereof to Supplier; (ii) the Members
may purchase products equivalent to the discontinued or changed Products from
other sources and Supplier will be liable to the Members for all reasonable
costs in excess of the Award Prices plus any other damages which they may incur;
and (iii) Supplier will be liable to Novation and the Clients for any loss of
Marketing Fees resulting from such unacceptable discontinuation or change plus
any other damages which they may incur.

    e.  Replacement or New Products.  Supplier will have no unilateral right to
replace any of the Products listed in Exhibit A with other products or to add
new products to this Agreement. Supplier may request Novation in writing to
agree to a replacement of any of the Products or the addition of a new product
that is closely related by function or use to an existing Product at least sixty
(60) days prior to the proposed implementation of the replacement or to the new
product introduction. Under no circumstances will any Product replacement or new
product addition to this Agreement be permitted without Novation's agreement to
the replacement or new product.

3

--------------------------------------------------------------------------------

    f.  Member Services.  Supplier will consult with each Member to identify the
Member's policies relating to access to facilities and personnel. Supplier will
comply with such policies and will establish a specific timetable for sales
calls by sales representatives to satisfy the needs of the Member. Supplier will
promptly respond to Members' reasonable requests for verification of purchase
history. If requested by Novation or any Members, Supplier will provide, at
Supplier's cost, on-site inservice training to Members' personnel for pertinent
Products.

    g.  Product Deletion.  Notwithstanding anything to the contrary contained in
this Agreement, Novation may delete any one or more of the Products from this
Agreement at any time, at will and without cause, upon not less than sixty
(60) days' prior written notice to Supplier.

    h.  Return of Products.  Any Member, in addition to and not in limitation of
any other rights and remedies, will have the right to return Products to
Supplier under any of the following circumstances: (1) the Product is ordered or
shipped in error; (2) the Product is no longer needed by the Member due to
deletion from its standard supply list or changes in usage patterns, provided
the Product is returned at least six (6) months prior to its expiration date and
is in a re-salable condition; (3) the Product is received outdated or is
otherwise unusable; (4) the Product is received damaged, or is defective or
nonconforming; (5) the Product is one which a product manufacturer or supplier
specifically authorizes for return; and (6) the Product is recalled. Supplier
agrees to accept the return of Products under these circumstances without charge
and for full credit.

    i.  Failure to Supply.  In the event of Supplier's failure to perform its
supply obligations in accordance with the terms of this Section 4, the Member
may purchase products equivalent to the Products from other sources and Supplier
will be liable to the Member for all reasonable costs in excess of the Award
Prices plus any other damages which they may incur. In such event, Supplier will
also be liable to Novation and the Clients for any loss of Marketing Fees
resulting from such failure plus any other damages which they may incur. The
remedies set forth in this Subsection are in addition to any other rights and
remedies Novation, the Clients or the Members may have resulting from such
failure.

5.  PRODUCT QUALITY

    a.  Free From Defects.  Supplier warrants the Products against defects in
material, workmanship, design and manufacturing. Supplier will make all
necessary arrangements to assign such warranty to the Members. Supplier further
represents and warrants that the Products will conform to the specifications,
drawings, and samples furnished by Supplier or contained in the Non-Price
Specifications and will be safe for their intended use. If any Products are
defective and a claim is made by a Member on account of such defect, Supplier
will, at the option of the Member, either replace the defective Products or
credit the Member. Supplier will bear all costs of returning and replacing the
defective Products, as well as all risk of loss or damage to the defective
Products from and after the time they leave the physical possession of the
Member. The warranties contained in this Subsection will survive any inspection,
delivery, acceptance or payment by a Member. In addition, if there is at any
time wide-spread failure of the Products, the Member may return all said
Products for credit or replacement, at its option. This Subsection and the
obligations contained herein will survive the expiration or earlier termination
of this Agreement. The remedies set forth in this Subsection are in addition to
and not a limitation on any other rights or remedies that may be available
against Supplier.

    b.  Product Compliance.  Supplier represents and warrants to Novation, the
Clients and the Members that the Products are, if required, registered, and will
not be distributed, sold or priced by Supplier in violation of any federal,
state or local law. Supplier represents and warrants that as of the date of
delivery to the Members all Products will not be adulterated or misbranded
within the meaning of the Federal Food, Drug and Cosmetic Act and will not
violate or cause a violation of any applicable law, ordinance, rule, regulation
or order. Supplier agrees it will comply with all applicable Good

4

--------------------------------------------------------------------------------

Manufacturing Practices and Standards contained in 21 C.F.R. Parts 210, 211,
225, 226, 600, 606, 610, 640, 660, 680 and 820. Supplier represents and warrants
that it will provide adequate warnings and instructions to inform users of the
Products of the risks, if any, associated with the use of the Products.
Supplier's representations; warranties and agreements in this Subsection will
survive the expiration or earlier termination of this Agreement.

    c.  Patent Infringement.  Supplier represents and warrants that sale or use
of the Products will not infringe any United States patent. Supplier will, at
its own expense, defend every suit which will be brought against Novation or a
Member for any alleged infringement of any patent by reason of the sale or use
of the Products and will pay all costs, damages and profits recoverable in any
such suit. This Subsection and the obligations contained herein will survive the
expiration or earlier termination of this Agreement. The remedies set forth in
this Subsection are in addition to and not a limitation on any other rights or
remedies that may be available against Supplier.

    d.  Product Condition.  Unless otherwise stated in the Non-Price
Specifications or unless agreed upon by a Member in connection with Products it
may order, all Products will be new. Products which are demonstrators, used,
obsolete, seconds, or which have been discontinued are unacceptable unless
otherwise specified in the Non-Price Specifications or the Member accepts
delivery after receiving notice of the condition of the Products.

    e.  Recall of Products.  Supplier will reimburse Members for any cost
associated with any Product corrective action, withdrawal or recall requested by
Supplier or required by any governmental entity. In the event a product recall
or a court action impacting supply occurs, Supplier will notify Novation in
writing within twenty-four (24) hours of any such recall or action. Supplier's
obligations in this Subsection will survive the expiration or earlier
termination of this Agreement.

    f.  Shelf Life.  Sterile Products and other Products with a limited shelf
life sold under this Agreement will have the longest possible shelf life and the
latest possible expiration dates. Unless required by stability considerations,
there will not be less than an eighteen (18) month interval between a Product's
date of delivery by Supplier to the Member and its expiration date.

6.  CENTURY COMPLIANCE.

    a.  Definitions.  For purposes of this Section, the following terms have the
respective meanings given below:

    (1) "Systems" means any of the Products, systems of distribution for
Products and Product manufacturing systems that consist of or include any
computer software, computer firmware, computer hardware (whether general or
special purpose), documentation, data, and other similar or related items of the
automated, computerized, and/or software systems that are provided by or through
Supplier or utilized to manufacture or distribute the Products provided by or
through Supplier pursuant to this Agreement, or any component part thereof, and
any services provided by or through Supplier in connection therewith.

    (2) "Calendar-Related" refers to date values based on the "Gregorian
calendar" (as defined in the Encyclopedia Britannica, 15th edition, 1982, page
602) and to all uses in any manner of those date values, including without
limitation manipulations, calculations, conversions, comparisons, and
presentations.

    (3) "Century Noncompliance" means any aspects of the Systems that fail to
satisfy the requirements set forth in Subsection 6.b below.

5

--------------------------------------------------------------------------------

    b.  Representations.  Supplier warrants, represents and agrees that the
Systems satisfy the following requirements:

    (1) In connection with the use and processing of Calendar-Related data, the
Systems will not malfunction, will not cease to function, will not generate
incorrect data, and will not produce incorrect results.

    (2) In connection with providing Calendar-Related data to and accepting
Calendar-Related data from other automated, computerized, and/or software
systems and users via user interfaces, electronic interfaces, and data storage,
the Systems represent dates without ambiguity as to century.

    (3) The year component of Calendar-Related data that is provided by the
Systems to or that is accepted by the Systems from other automated,
computerized, and/or software systems and user interfaces, electronic
interfaces, and data storage is represented in a four-digit CCYY format, where
CC represents the two digits expressing the century and YY represents the two
digits expressing the year within that century (e.g., 1996 or 2003).

    (4) Supplier has verified through testing that the Systems satisfy the
requirements of this Subsection including, without limitation, testing of each
of the following specific dates and the transition to and from each such date:
September 9, 1999; September 10, 1999; December 31, 1999; January 1, 2000;
February 28, 2000; February 29, 2000; March 1, 2000; December 31, 2000;
January 1, 2001; December 31, 2004; and January 1, 2005.

    c.  Remedies.  In the event of any Century Noncompliance in the Systems in
any respect, in addition to my other remedies that may be available to Novation
or the Members, Supplier will, at no cost to the Members, promptly under the
circumstances (but, in all cases, within thirty (30) days after receipt of a
written request from any Member, unless otherwise agreed by the Member in
writing) eliminate the Century Noncompliance from the Systems.

    d.  Noncompliance Notice.  In the event Supplier becomes aware of (i) any
possible or actual Century Noncompliance in the Systems or (ii) any
international, governmental, industrial, or other standard (proposed or adopted)
regarding Calendar-Related data and/or processing, or Supplier begins any
significant effort to conform the Systems to any such standard, Supplier will
promptly provide the Members with all relevant information in writing and will
timely provide the Members with updates to such information. Supplier will
respond promptly and fully to inquiries by the Members, and timely provide
updates to any responses provided to the Members, with respect to (i) any
possible or actual Century Noncompliance in the Systems or (ii) any
international, governmental, industrial, or other standards. In the foregoing,
the use of "timely" means promptly after the relevant information becomes known
to or is developed by or for Supplier.

    e.  Survival.  Supplier's representations, warranties and agreements in this
Section will continue in effect throughout the Term and will survive the
expiration or earlier termination of this Agreement.

7.  REPORTS AND OTHER INFORMATION REQUIREMENTS.

    a.  Report Content.  Within twenty (20) days after the end of each full and
partial month during, the Term ("Reporting Month"), Supplier will submit to
Novation a report in the form of a diskette containing the following information
in form and content reasonably satisfactory to Novation:

    (1) the name of Supplier, the Reporting Month and year and the Agreement
number (as provided to Supplier by Novation);

    (2) with respect to each Member (described by LIC number (as provided to
Supplier by Novation), health industry number (if applicable), full name, street
address, city, state, zip

6

--------------------------------------------------------------------------------

code and, if applicable, tier and committed status), the number of units sold
and the amount of net sales for each Product on a line item basis, and the sum
of net sales and the associated Marketing Fees for all Products purchased by
such Member directly or indirectly from Supplier during the Reporting Month,
whether under the pricing and other terms of this Agreement or under the terms
of any other purchasing or pricing arrangements that may exist between the
Member and Supplier;

    (3) the sum of the net sales and the associated Marketing Fees for all
Products sold to all Members during the Reporting Month; and

    (4) such additional information as Novation may reasonably request from time
to time.

    b.  Report Format and Delivery.  The reports required by this Section will
be submitted electronically in Excel Version 7 or Access Version 7 and in
accordance with other specifications established by Novation from time to time
and will be delivered to:

Novation
Attn: SRIS Operations
220 East Las Colinas Boulevard
Irving, TX 75039

    c.  Other Information Requirements.  In addition to the reporting
requirements set forth in Subsections 7.a and 7.b above, the parties agree to
facilitate the administration of this Agreement by transmitting and receiving
information electronically and by complying with the information requirements
set forth in Exhibit E attached hereto. Supplier further agrees that, except to
the extent of any inconsistency with the provisions of this Agreement, it will
comply with all information requirements set forth in the Novation Information
Requirements Guidebook ("Guidebook"). On or about the Effective Date, Novation
will provide Supplier with a current copy of the Guidebook and will thereafter
provide Supplier with updates and/or revisions to the Guidebook from time to
time.

8.  OBLIGATIONS OF NOVATION.

    a.  Information to Members.  After issuing the Award Letter, Novation, in
conjunction with the Clients, will deliver a summary of the purchasing
arrangements covered by this Agreement to each Member and will, from time to
time, at the request of Supplier, deliver to each Member reasonable and
appropriate amounts and types of materials supplied by Supplier to Novation
which relate to the purchase of the Products.

    b.  Marketing Services.  Novation, in conjunction with the Clients, will
market the purchasing arrangements covered by this Agreement to the Members.
Such promotional services may include, as appropriate, the use of direct mail,
contact by Novation's field service delivery team, member support services, and
regional and national meetings and conferences. As appropriate, Novation, in
conjunction with the Clients, will involve Supplier in these promotional
activities by inviting Supplier to participate in meetings and other reasonable
networking activities with Members.

9.  MARKETING FEES.

    a.  Calculation.  Supplier will pay to Novation, as the authorized
collection agent for each of the Clients and certain of each Client's
subsidiaries and affiliates, respectively (and not collectively), marketing fees
("Marketing Fees") belonging to any of the Clients or certain of their
subsidiaries or affiliates equal to the Agreed Percentage of the [***]* of the
Products to the Members directly or indirectly from Supplier, whether under the
pricing and other terms of this Agreement or under the terms of any other
purchasing or pricing arrangements that may exist between the Members and

7

--------------------------------------------------------------------------------

Supplier. Such [***]*, and will include, but not be limited to, [***]*. The
"Agreed Percentage" will be defined in the Award Letter.

    b.  Payment.  On or about the Effective Date, Novation will advise Supplier
in writing of the amount determined by Novation to be Supplier's monthly
estimated Marketing Fees. Thereafter, Supplier's monthly estimated [***]* from
time to time upon written notice from Novation based on [***]*. No later than
the tenth (10th) day of each month, Supplier will remit the monthly estimated
Marketing Fees for such month to Novation. Such payment will be adjusted to
reflect the reconciliation between the actual Marketing Fees payable for the
second month prior to such month with the estimated Marketing Fees actually paid
during such prior month. Supplier will pay all estimated and adjusted Marketing
Fees by check made payable to "Novation, LLC." All checks should reference the
Agreement number. Supplier will include with its check the reconciliation
calculation used by Supplier to determine the payment adjustment, with separate
amounts shown for each Client's component thereof. Checks sent by first class
mail will be mailed to the following address:

Novation
75 Remittance Dr., Suite 1420
Chicago, IL 60675-1420

Checks sent by courier (Federal Express, United Parcel Service or messenger)
will be addressed as follows:

The Northern Trust Company
350 North Orleans Street
Receipt & Dispatch 8th Floor
Chicago, IL 60654
Attn: Novation, LLC, Lockbox Number 1420
Telephone: (312) 444-3576

10. ADMINISTRATIVE DAMAGES.  Novation and Supplier agree that Novation would
incur additional administrative costs if Supplier fails to provide notice of
change in pricing terms as required in Subsection 2.e above, fails to provide
reports as required in Section 7 above, or fails to pay Marketing Fees as
required in Section 9 above, in each case within the time and manner required by
this Agreement. Novation and Supplier further agree, that the additional
administrative costs incurred by Novation by reason of any such failure to
Supplier is uncertain, and they therefore agree that the following schedule of
administrative damages constitutes a reasonable estimation of such costs and
were determined according to the principles of just compensation:

1st failure   [***]* 2nd failure:   [***]* 3rd failure:   [***]* 4th failure:  
[***]* 5th failure:   [***]* 6th & each subsequent failure:   [***]*

Novation's right to recover administrative damages in accordance with this
Section is in addition to any other rights and remedies Novation or the Clients
may have by reason of Supplier's failure to pay the Marketing Fees or provide
the reports or notices within the time and manner required by this Agreement.

8

--------------------------------------------------------------------------------

11. NONPAYMENT OR INSOLVENCY OF A MEMBER.  If a Member fails to pay Supplier for
Products, or if a Member becomes bankrupt or insolvent or makes an assignment
for the benefit of creditors or goes into liquidation, or if proceedings are
initiated for the purpose of having a receiving order or winding up order made
against a Member, or if a Member applies to the court for protection from its
creditors, then, in any such case, this Agreement will not terminate, but
Supplier will have the right, upon prior written notice to Novation and the
Member, to discontinue selling Products to that Member.

12. INSURANCE.

    a.  Policy Requirements.  Supplier will maintain and keep in force during
the Term product liability, general public liability and property damage
insurance against any insurable claim or claims which might or could arise
regarding Products purchased from Supplier. Such insurance will contain a
minimum combined single limit of liability for bodily injury and property damage
in the amounts of not less than [***]*; will name Novation, the Clients and the
Members, as their interests may appear, as additional insureds, and will contain
an endorsement providing that the carrier will provide directly to all named
insured copies of all notices and endorsements. Supplier will provide to
Novation in its Bid and thereafter within fifteen (15) days after Novation's
request, an insurance certificate indicating the foregoing coverage, issued by
an insurance company licensed to do business in the relevant states and signed
by an authorized agent.

    b.  Self-Insurance.  Notwithstanding anything to the contrary in Subsection
12.a above, Supplier may maintain a self-insurance program for all or any part
of the foregoing liability risks, provided such self-insurance policy in all
material respects complies with the requirements applicable to the product
liability, general public liability and property damage insurance set forth in
Subsection 12.a. Supplier will provide Novation in its Bid, and thereafter
within fifteen (15) days after Novation's request: (1) the self-insurance
policy; (2) the name of the company managing the self-insurance program and
providing reinsurance, if any; (3) the most recent annual reports on claims and
reserves for the program; and (4) the most recent annual actuarial report on
such program.

    c.  Amendments, Notices and Endorsements.  Supplier will not amend, in any
material respect that affects the interests of Novation, the Clients of the
Members, or terminate said liability insurance or self-insurance program except
after thirty (30) days' prior written notice to Novation and will provide to
Novation copies of all notices and endorsements as soon as practicable after it
receives or gives them.

13. COMPLIANCE WITH LAW AND GOVERNMENT PROGRAM PARTICIPATION.  

    a.  Compliance With Law.  Supplier represents and warrants that to the best
of its knowledge, after due inquiry, it is in compliance with all federal, state
and local statutes, laws, ordinances and regulations applicable to it ("Legal
Requirements") which are material to the operation of its business and the
conduct of its affairs, including Legal Requirements pertaining to the safety of
the Products, occupational health and safety, environmental protection,
nondiscrimination, antitrust, and equal employment opportunity. During the Term,
Supplier will: (1) promptly notify Novation of any lawsuits, claims,
administrative actions or other proceedings asserted or commenced against it
which assert in whole or in part that Supplier is in noncompliance with any
Legal Requirement which is material to the operation of its business and the
conduct of its affairs and (2) promptly provide Novation with true and correct
copies of all written notices of adverse findings from the U.S. Food and Drug
Administration ("FDA") and all written results of FDA inspections which pertain
to the Products.

    b.  Government Program Participation.  Supplier represents and warrants that
it is not excluded from participation, and is not otherwise ineligible to
participate, in a "Federal health care program" as defined in 42 U.S.C. §
1320a-7b(f) or in any other government payment program. In the event Supplier is
excluded from participation, or becomes otherwise ineligible to participate in
any such program

9

--------------------------------------------------------------------------------

during the Term, Supplier will notify Novation in writing within three (3) days
after such event, and upon the occurrence of such event, whether or not such
notice is given to Novation, Novation may immediately terminate this Agreement
upon written notice to Supplier.

14. RELEASE AND INDEMNITY.  SUPPLIER WILL RELEASE, INDEMNIFY, HOLD HARMLESS,
AND, IF REQUESTED DEFEND NOVATION, THE CLIENTS AND THE MEMBERS, AND THEIR
RESPECTIVE OFFICERS, DIRECTORS, REGENTS, AGENTS, SUBSIDIARIES, AFFILIATES AND
EMPLOYEES (COLLECTIVELY, THE "INDEMNITEES"), FROM AND AGAINST ANY CLAIMS,
LIABILITIES, DAMAGES, ACTIONS, COSTS AND EXPENSES (INCLUDING, WITHOUT
LIMITATION, REASONABLE ATTORNEYS' FEES, EXPERT FEES AND COURT COSTS) OF ANY KIND
OR NATURE, WHETHER AT LAW OR IN EQUITY, INCLUDING CLAIMS ASSERTING STRICT
LIABILITY, ARISING FROM OR CAUSED IN ANY PART BY (1) THE BREACH OF ANY
REPRESENTATION, WARRANTY, COVENANT OR AGREEMENT OF SUPPLIER CONTAINED IN THIS
AGREEMENT OR IN THE BID; (2) THE CONDITION OF ANY PRODUCT, INCLUDING A DEFECT IN
MATERIAL, WORKMANSHIP, DESIGN OR MANUFACTURING; OR (3) THE WARNINGS AND
INSTRUCTIONS ASSOCIATED WITH ANY PRODUCT. SUCH OBLIGATION TO RELEASE, INDEMNIFY,
HOLD HARMLESS AND DEFEND WILL APPLY EVEN IF THE CLAIMS, LIABILITIES, DAMAGES,
ACTIONS, COSTS AND EXPENSES ARE CAUSED BY THE NEGLIGENCE, GROSS NEGLIGENCE OR
OTHER CULPABLE CONDUCT OF INDEMNITEES; PROVIDED, HOWEVER, THAT SUCH
INDEMNIFICATION, HOLD HARMLESS AND RIGHT TO DEFENSE WILL NOT BE APPLICABLE WHERE
THE CLAIM, LIABILITY, DAMAGE, ACTION, COST OR EXPENSE ARISES SOLELY AS A RESULT
OF AN ACT OR FAILURE TO ACT OF INDEMNITEES. THIS SECTION AND THE: OBLIGATIONS
CONTAINED HEREIN WILL SURVIVE THE EXPIRATION OR EARLIER TERMINATION OF THIS
AGREEMENT. THE REMEDIES SET FORTH IN THIS SECTION ARE IN ADDITION TO AND NOT A
LIMITATION ON ANY OTHER RIGHTS OR REMEDIES THAT MAY BE AVAILABLE AGAINST
SUPPLIER.

15. BOOKS AND RECORDS; FACILITIES INSPECTIONS.  Supplier agrees to keep,
maintain and preserve complete, current and accurate books, records and accounts
of the transactions contemplated by this Agreement and such additional books,
records and accounts as are necessary to establish and verify Supplier's
compliance with this Agreement. All such books, records and accounts will be
available for inspection and audit by Novation representatives at any time
during the Term and for two (2) years thereafter, but only during reasonable
business hours and upon reasonable notice. Novation agrees that its routine
audits will not be conducted more frequently than twice in any consecutive
twelve (12) month period, subject to Novation's right to conduct special audits
whenever it deems it to be necessary. In addition, Supplier will make its
manufacturing and packaging facilities available for inspection from time to
time during the Term by Novation representatives, but only during reasonable
business hours and upon reasonable notice. The exercise by Novation of the right
to inspect and audit is without prejudice to any other or additional rights or
remedies of either party.

16. USE OF NAMES, ETC.  Supplier agrees that it will not use in any way in its
promotional, informational or marketing activities or materials (i) the names,
trademarks, logos, symbols or a description of the business or activities of
Novation or any Client or Member without in each instance obtaining the prior
written consent of the person owning the rights thereto; or (ii) the award or
the content of this Agreement without in each instance obtaining the prior
written consent of Novation.

10

--------------------------------------------------------------------------------

17. CONFIDENTIAL INFORMATION.

    a.  Nondisclosure.  Supplier agrees that it will:

    (1) keep strictly confidential and hold in trust all Confidential
Information, as defined in Subsection 17.b below, of Novation. the Clients and
the Members;

    (2) not use the Confidential Information for any purpose other than the
performance of its obligations under this Agreement, without the prior written
consent of Novation;

    (3) not disclose the Confidential Information to any third party (unless
required by law) without the prior written consent of Novation; and

    (4) not later than thirty (30) days after the expiration or earlier
termination of this Agreement, return to Novation, the Client or the Member, as
the case may be, the Confidential Information.

    b.  Definition.  "Confidential Information," as used in Subsection 17.a
above, will consist of all information relating to the prices and usage of the
Products (including all information contained in the reports produced by
Supplier pursuant to Section 7 above) and all documents and other materials of
Novation, the Clients and the Members containing information relating to the
programs of Novation, the Clients or the Members of a proprietary or sensitive
nature not readily available through sources in the public domain. In no event
will Supplier provide to any person any information relating to the prices it
charges the Members for Products ordered pursuant to this Agreement without the
prior written consent of Novation.

18. MISCELLANEOUS.

    a.  Choice of Law.  This Agreement will be governed by and construed in
accordance with the internal substantive laws of the State of Texas and the
Texas courts will have jurisdiction over all matters relating to this Agreement;
provided, however, the terms of any agreement between Supplier and a Member will
be governed by and construed in accordance with the choice of law and venue
provisions set forth in such agreement.

    b.  Not Responsible.  Novation and the Clients and their subsidiaries and
affiliates will not be responsible or liable for any Member's breach of any
purchasing commitment or for any other actions of any Member. In addition, none
of the Clients will be responsible or liable for the obligations of another
Client or its subsidiaries or affiliates or the obligations of Novation or
Supplier under this Agreement.

    c.  Third Party Beneficiaries.  All Clients and Members are intended third
party beneficiaries of this Agreement. All terms and conditions of this
Agreement which are applicable to the Clients will inure to the benefit of and
be enforceable by the Clients and their respective successors and assigns All
terms and conditions of this Agreement which are applicable to the Members will
inure to the benefit of and be enforceable by the Members and their respective
successors and assigns.

    d.  Notices.  Except as otherwise expressly provided herein, all notices or
other communications required or permitted under this Agreement will be in
writing and will be deemed sufficient when

11

--------------------------------------------------------------------------------

mailed by United States mail, or delivered in person to the party to which it is
to be given, at the address of such party set forth below:

If to Supplier:

    To the address set forth by Supplier in the Bid

If to Novation:

Novation
Attn: General Counsel
125 John Carpenter Freeway
Irving, TX 75062-2324

or such other address as the party will have furnished in writing in accordance
with the provisions of this Subsection.

    e.  No Assignment.  No assignment of all or any part of this Agreement may
be made without the prior written consent of the other party; except that
Novation may assign its rights and obligations to any affiliate of Novation. Any
assignment of all or any part of this Agreement by either party will not relieve
that party of the responsibility of performing its obligations hereunder to the
extent that such obligations are not satisfied in full by the assignee. This
Agreement will be binding upon and inure to the benefit of the parties'
respective successors and assigns.

    f.  Severability.  Whenever possible, each provision of this Agreement will
be interpreted in such a manner as to be effective and valid under applicable
law, but if any provision of this Agreement will be prohibited by or invalid
under applicable law, such provision will be ineffective to the extent of such
prohibition or invalidity without invalidating the remainder of such provision
or the remaining provisions of this Agreement. Each party will, at its own
expense, take such action as is reasonably necessary to defend the validity and
enforceability of this Agreement and will cooperate with the other party as is
reasonably necessary in such defense.

    g.  Entire Agreement.  This Agreement, together with the exhibits listed
below, will constitute the entire agreement between Novation and Supplier. This
Agreement, together with the exhibits listed below and each Member's purchase
order will constitute the entire agreement between each Member and Supplier. In
the event of any inconsistency between this Agreement and a Member's purchase
order, the terms of this Agreement will control, except that the Member's
purchase order will supersede Sections 4 and 5 of this Agreement in the event of
any inconsistency with such Sections. No other terms and conditions in any
document, acceptance, or acknowledgment will be effective or binding unless
expressly agreed to in writing. The following exhibits are incorporated by
reference in this Agreement.

12

--------------------------------------------------------------------------------

Exhibit A   Product and Service Description and Pricing    
Exhibit B
 
Non-Price Specifications
 
 
Exhibit C
 
Special Conditions
 
 
Exhibit D
 
Award Letter
 
 
Exhibit E
 
Other Information Requirements
 
 
[Other Exhibits Listed, if any]
 
 
Exhibit F
 
Supplier Agreement, Exception Response Form
 
 
SUPPLIER:
 
Specialty Laboratories, Inc.
 
 
ADDRESS:
 
2211 Michigan Avenue
Santa Monica, California 90404-3900
 
  SIGNATURE:            

--------------------------------------------------------------------------------

   
TITLE:
 
Director, Contract Administration
 
DATE: May 4, 2000

13

--------------------------------------------------------------------------------

EXHIBIT A

PRODUCT AND SERVICE DESCRIPTION AND PRICING

Pricing:   A Letter of Participation is required to activate pricing for this
Agreement by Members that are not currently utilizing Supplier and is attached
as Exhibit B-1. Members that are currently using Supplier under the VHA
agreement are waived from signing the Letter of Participation.
 
 
[***]*, as published in the Price List current at the time the testing is
ordered, will be granted for all tests not listed on Exhibit A. Tests that are
unique to Supplier and tests that are referred to another reference laboratory
are not included in the [***]*. Supplier [***]* for tests referred to other
laboratories. To maintain compliance with current California regulations,
Supplier is required to charge Members for all testing referred to another
laboratory at the price charged to Supplier. In the event a test currently being
performed by Supplier is discontinued and referred to another laboratory,
Supplier will be required to charge the Member the price Supplier is being
charged.
Commitment:
 
If necessary to meet competitive situations, upon mutual consent of both
Novation and Supplier, Supplier may [***]* from Exhibit A to Participating
Members that commit at least [***]*. Supplier retains the right to identify
which tests are further discountable. Additional discounts may include:
 
 
1.
 
Additional discounts of up to [***]*. The selection of these tests must be
agreed upon by Member and Supplier prior to pricing being implemented.
 
 
2.
 
Additional discounts of up to [***]* may be offered to [***]* from a
multi-hospital system. The selection of these tests must be agreed upon by
Member and Supplier prior to pricing being implemented.
 
 
3.
 
Additional discounts of more than [***]* referenced above may be agreed upon by
mutual consent of Novation and Supplier.
 
 
After utilizing the Agreement for one year, Member and Supplier have the option
to review the list and make adjustments if necessary.
 
 
Participating Members shall be deemed to be part of a system or network if they
meet either of the following criteria:
 
 
1.
 
Are listed in VHA or UHC membership as part of a system or network under one
"parent" member AND are owned, managed, controlled or leased by "parent" member.
 
 
2.
 
Have joined together with other Participating Members in local or regional
effort to reduce supply chain costs through standardization. Examples of this
might include consolidation logistics centers, local integrated delivery
networks (LIDN) or regional networks of unrelated VHA or UHC facilities who
agree to commit and standardize on one Supplier. Eligibility under this
criterion will be determined by Novation.
Price:
 
[***]*
Price Protection:
 
Pricing on Exhibit A will not [***]* of the Agreement with the [***]*. Supplier
agrees that [***]* if Novation so chooses to use them. Prices of tests that are
referred to another laboratory are subject to change at any time. Supplier
agrees to provide best efforts to notify Members of changes of prices of tests
referred to other laboratories within 30 days of the change.
Handling Fees:
 
For tests being referred to another reference laboratory, Supplier will [***]*
No additional fees or handling charges will be added.

--------------------------------------------------------------------------------

* CONFIDENTIAL TREATMENT IS REQUESTED FOR CONFIDENTIAL INFORMAITON ENCLOSED IN
THE BRACKETS AND UNDERLINED.

--------------------------------------------------------------------------------

Exhibit A

Specialty Laboratories, Inc.

* CONFIDENTIAL TREATMENT IS REQUESTED FOR CONFIDENTIAL INFORMAITON ENCLOSED IN
THE BRACKETS AND UNDERLINED.

1

--------------------------------------------------------------------------------

Test #

--------------------------------------------------------------------------------

  CPT#

--------------------------------------------------------------------------------

  Product Description

--------------------------------------------------------------------------------

  u/m

--------------------------------------------------------------------------------

  Contract Price

--------------------------------------------------------------------------------

1000   83520; 86038; 86160x2; 86225; 86235x5; 86376; 86431   ANAlyzer®   each  
[***]* 1002   86256x6   Tissue Total Autoabs Screen [TAbS]   each   [***]* 1003
  86038; 86160x2; 86225; 86235x4   Antinuclear Abs Panel   each   [***]* 1004  
86038; 86160x2; 86225; 86235x7   Rheumatic Evaluation   each   [***]* 1005  
83520; 86160x2; 86225; 86235x5; 86376; 86431   ANAlyzer® without ANA   each  
[***]* 1006   83520; 86038; 86160x2; 86225; 86235x5; 86376   ANAlyzer® without
Rheumatoid Factor   each   [***]* 1007   86235x2   SS-A & SS-B IgG Autoabs  
each   [***]* 1008   86256x6; 86376   Tissue Total Autoabs Screen Plus Thyroid
Peroxidase   each   [***]* 1010   84550; 86038; 86431x2   Arthritis Evaluation B
  each   [***]* 1012   86431x3   Rheumatoid Factor IgG; IgM; & IgA
Autoantibodies   each   [***]* 1015   86431x2   Rheumatoid Factor Autoabs
Evaluation   each   [***]* 1016   86376; 86800   Thyroid Autoabs   each   [***]*
1020   86160x3   Complement Evaluation   each   [***]* 1021   86160x3; 86162  
Complement Evaluation Plus CH50   each   [***]* 1025   83519; 86256   Myasthenia
Gravis Evaluation   each   [***]* 1027   83520   Transglutaminase IgG Autoabs
[EIA]   each   [***]* 1028   83520   Transglutaminase IgM Autoabs [EIA]   each  
[***]* 1029   83520   Transglutaminase IgA Autoabs [EIA]   each   [***]* 1030  
83520x3   Transglutaminase IgG; IgM & IgA Autoabs Evaluation [EIA]   each  
[***]* 1031   86337; 86341x2   Diabetes Evaluation   each   [***]* 1032   83519;
86337; 86341x2   Diabetes Mellitus Autoantibody Evaluation   each   [***]* 1033
  83519   Glutamic Acid Decarboxylase [GAD] Autoabs   each   [***]* 1035  
86813; 86817   HLA: A; B; C & D Typing; Complete   each   [***]* 1036   86337;
86341x2; 86812x2; 86816x2   Diabetes; Genetic Evaluation   each   [***]* 1040  
86160x2; 86332x4   Circulating Immune Complex Detector   each   [***]* 1043  
86609x4; 86648; 86774   Humoral Immune Evaluation   each   [***]* 1045   82784x3
  IgA; IgG & IgM Immunoglobulin Quantitation   each   [***]* 1048   82784x3;
82785; 82787; 86609x4; 86648; 86774   Humoral Immune Status Survey (Pneumo 4)  
each   [***]* 1051   83520   Glial Fibrillary Acidic Protein Autoabs [GFAP]  
each   [***]* 1052   83520   Neurofilament-heavy Subunit [NF-H] Autoabs   each  
[***]* 1053   83520   Tubulin Autoabs   each   [***]* 1055   82040; 82784x6;
83873; 83883; 83916   Multiple Sclerosis Evaluation   each   [***]* 1056   83520
  Myelin Basic Protein Autoantibodies [MbP]   each   [***]*

2

--------------------------------------------------------------------------------

1057   82040; 82784x6; 83520x3; 83873; 83883; 83916; 86160; 88180   Lupus CNS
Evaluation CSF & Serum   each   [***]* 1060   86353x3   Lymphocyte Mitogen
Proliferation Analysis   each   [***]* 1062   86353x6   Lymphocyte Antigen &
Mitogen Proliferation Analysis   each   [***]* 1065   86038; 86160; 86225;
86235x5; 86376   Antinuclear Abs Evaluation w/ C4   each   [***]* 1066   86038;
86160; 86225; 86235x5; 86376   Antinuclear Abs Evaluation w/ C3   each   [***]*
1070   86618x2; 86625; 86631; 86632; 86768x3; 86771; 86793x3; 86812   Reactive
Arthritis Evaluation   each   [***]* 1076   83520x2; 86256x2   Celiac Disease
Abs Evaluation   each   [***]* 1077   83520x3; 86256x2   Celiac Disease EvaluatR
  each   [***]* 1078   83891; 83894x3; 83901x3; 83912   Celiac Disease Genotypr
  each   [***]* 1080   85613; 86147x3; 86148x3   Antiphospholipid Syndrome
Evaluation   each   [***]* 1082   83520x9; 85613; 86147x3; 86148x3  
Antiphospholipid Syndrome Evaluation; Expanded   each   [***]* 1083   83520x3  
[GPI]   each   [***]* 1085   82164; 86353; 86360   Sarcoidosis Evaluation   each
  [***]* 1086   86609x4; 86648; 86684; 86774   Humoral Immune Eval + H.
influenzae b   each   [***]* 1090   83519; 84443   Thyrotropin Binding
Inhibitory Immunoglobulins   each   [***]* 1091   84443; 84445   Thyroid
Stimulating Immunoglobulins   each   [***]* 1092   84445   Thyroid Stimulating
Immunoglobulins w/o TSH   each   [***]* 1093   83519   Thyrotropin Binding
Inhibitory Immunoglobulins w/o TSH   each   [***]* 1094   85810; 86160x2; 86225
  Lupus Activity Reporter   each   [***]* 1096   83520x2; 86160x3; 86225   Lupus
Monitor   each   [***]* 1100   86038   Antinuclear Abs w/ International Units &
Pattern   each   [***]* 1102   86256   Mitochondrial Total Autoabs   each  
[***]* 1103   86256   Myocardial Total Autoabs   each   [***]* 1104   86256  
Parietal Cell Total Autoabs   each   [***]* 1105   86256   Reticulin Total
Autoabs   each   [***]* 1106   86256   Smooth Muscle Total Autoabs   each  
[***]* 1107   86256   Striational Total Autoabs   each   [***]* 1109   86255  
Centromere Autoabs   each   [***]* 1110   86800   Thyroglobulin Autoabs   each  
[***]* 1113   86431   Rheumatoid Factor IgM Autoabs [IHA]   each   [***]* 1114  
86256x2   Epidermal   each   [***]* 1115   86376   Liver-Kidney-Microsome
Autoabs   each   [***]* 1116   86256   Brush Border Total Autoabs   each  
[***]* 1118   86038   ANAlyzer® Reflexive Testing [with Tissue Abs]   each  
[***]*

3

--------------------------------------------------------------------------------

1120   86038   Antinuclear Abs Reflex to Profile #1   each   [***]* 1121   86038
  Antinuclear Abs Reflex to Profile   each   [***]* 1122   86038   Antinuclear
Abs w/ International Units & Titer   each   [***]* 1124   86038   TPO   each  
[***]* 1125   86038; 86160x2; 86225; 86235x3   Antinuclear Abs Profile #1   each
  [***]* 1126   86038; 86160x2; 86225; 86235x5; 86431   Antinuclear Abs Profile
  each   [***]* 1127   86038; 86225; 86235x5   ANA; DsDna; SS-A/SS-B; ENA;
Scl-70 Autoabs   each   [***]* 1130   86256   Adrenal Total Autoantibodies  
each   [***]* 1136   83520   Glomerular Basement Membrane IgG Autoabs   each  
[***]* 1138   83520   Cystatin C   each   [***]* 1140   83520   Histone-DNA
Complex IgG Autoabs   each   [***]* 1145   82784   IgD   each   [***]* 1150  
82585   Cryofibrinogens with Reflex   each   [***]* 1151   82585  
Cryofibrinogen   each   [***]* 1152   82585   Cryofibrinogenemia Reflexive
Evaluation   each   [***]* 1155   82595   Cryoglobulins with Reflex   each  
[***]* 1156   82595   Cryoglobulin   each   [***]* 1157   82595  
Cryoglobulinemia Reflexive Evaluation   each   [***]* 1158   82585; 82595  
Cryoglobulin & Cryofibrinogen   each   [***]* 1160   82668   Erythropoietin  
each   [***]* 1162   86256   Reticulin IgA Autoabs   each   [***]* 1165   86341
  Islet Cell IgG Cytoplasmic Antibodies   each   [***]* 1166   86341   Abs  
each   [***]* 1168   86256   Neuronal Nuclear IgG Abs Type I (Hu)   each  
[***]* 1171   86256x2   Paraneoplastic Syndrome Evaluation   each   [***]* 1176
  86256   Purkinje Cell Cytoplasmic IgG Autoabs Type I (Yo)   each   [***]* 1178
  86256   Ovary IgG Autoabs   each   [***]* 1180   86256   Testes IgG Autoabs  
each   [***]* 1186   83520   Neuronal Nuclear Abs Type I (Hu)   each   [***]*
1187   84181   Purkinje Cell Cytoplasmic Autoabs Type I (Yo)   each   [***]*
1191   86256   Endomysial IgA Autoabs   each   [***]* 1198   83520   Neuronal
IgG Autoabs for CNS Lupus   each   [***]* 1201   86225   DNA Autoabs;
Double-stranded   each   [***]* 1203   86256   DNA Autoantibodies (Crithidia);
Double Stranded   each   [***]* 1204   86235   SS-A IgG Autoabs   each   [***]*
1205   86235   SS-B IgG Autoabs   each   [***]* 1207   86235   Jo-1 Abs [DD]    
    1208   86235   Jo-1 IgG Autoabs [EIA]   each   [***]* 1210   86235x2  
Extractable Nuclear Ag (ENA) IgG Autoabs   each   [***]* 1215   86235   U1
RNP/snRNP IgG Autoabs   each   [***]* 1220   86235   Sm (Smith) IgG Autoabs  
each   [***]* 1222   86235   Ku Autoantibodies   each   [***]* 1223   86235   OJ
Autoantibodies   each   [***]*

4

--------------------------------------------------------------------------------

1224   86235   PL-12 Autoantibodies   each   [***]* 1225   86235   EJ
Autoantibodies   each   [***]* 1226   86235   PL-7 Autoantibodies   each  
[***]* 1227   86235   SRP Autoantibodies   each   [***]* 1228   86235   U2 SnRNP
Autoantibodies   each   [***]* 1230   86332   Immune Complex Assay; Raji Cell  
each   [***]* 1232   86235   Sm Autoabs Quant   each   [***]* 1233   86235   U1
RNP/SnRNP Autoabs Quant   each   [***]* 1234   86235x2   [Ha]   each   [***]*
1235   86235   Scl-70 IgG Autoabs   each   [***]* 1240   85810   Viscosity Serum
  each   [***]* 1245   82785   IgE   each   [***]* 1251   86256   Proliferating
Cell Nuclear Ag Abs   each   [***]* 1257   86235   PM-ScI Autoabs   each  
[***]* 1261   83520   Gliadin IgG Abs   each   [***]* 1266   83520x2   Gliadin
IgG & IgA Abs   each   [***]* 1271   83520   Ribosomal P Protein IgG Autoabs  
each   [***]* 1273   82040; 82784x2; 83520x2; 83883   Ribosomal P Protein IgG
Antibody Index   each   [***]* 1281   86235   Jo-1 IgG Autoabs   each   [***]*
1286   83520   Gliadin IgA Abs   each   [***]* 1290   86226   DNA Autoabs;
Single-stranded   each   [***]* 1310   84550   Uric Acid   each   [***]* 1320  
82565   Creatinine   each   [***]* 1322   82575   Creatinine Clearance   each  
[***]* 1324   84155   Protein; Total   each   [***]* 1331   86648; 86774  
Tetanus & Diphtheria Toxoid IgG Abs Single Serum   each   [***]* 1334   86774  
Tetanus Toxoid IgG Abs Single Serum   each   [***]* 1337   86609   Streptococcus
pyogenes; Group A Abs (Streptozyme)   each   [***]* 1340   86615; 86648; 86774  
Immune Status Panel—DPT   each   [***]* 1341   86735; 86762; 86765   Immune
Status Panel—MMR   each   [***]* 1345   84450   AST (SGOT)   each   [***]* 1346
  86753   Entamoeba histolytica IgG Abs   each   [***]* 1347   84460   ALT
(SGPT)   each   [***]* 1349   86813   HLA: A &B Typing; Complete   each   [***]*
1350   86812   HLA: B27 Typing   each   [***]* 1351   86813   HLA: A; B; C
Typing; Complete   each   [***]* 1352   86817   HLA: DR Typing; Complete   each
  [***]* 1353   86816   HLA: DR3—Celiac Disease   each   [***]* 1354   86812  
HLA: BB-Primary Sclerosing Cholangitis   each   [***]* 1355   86812x2; 86816x2  
HLA: Diabetes-associated   each   [***]* 1356   86812   HLA: A or B Typing
(specify antigen)   each   [***]* 1357   86816   HLA: DR Single Antigen   each  
[***]* 1358   86816x2   Arthritis RX SelectR   each   [***]* 1362   86812   HLA:
B5 Typing   each   [***]* 1364   83891; 83894; 83901; 83912   HLA B27 GenotypR  
each   [***]* 1365   86160x2   Complement: C4 Allotyping   each   [***]*

5

--------------------------------------------------------------------------------

1375   88180   Recurrent Spontaneous Abortion: Crossmatch   each   [***]* 1382  
88180   Neutrophil Function: Myeloperoxidase   each   [***]* 1383   88180x4  
Neutrophil Function: Adherence [CD11a; CD11b; CD11c; CD18]   each   [***]* 1386
  83520   Myeloperoxidase Autoabs   each   [***]* 1392   82085   Aldolase   each
  [***]* 1396   83520   Proteinase-3Autoabs   each   [***]* 1398   82955  
Glucose-6-Phosphate Dehydrogenase [G-6-PDH]   each   [***]* 1401   86332  
Immune Complex Assay Clq Binding; Fluid Phase   each   [***]* 1402   86332  
Conglutinin Solid Phase Immune Complex Assay   each   [***]* 1403   86332  
Immune Complex Assay; Polyethylene Glycol   each   [***]* 1410   83519  
Acetylcholine Receptor Binding Autoantibodies   each   [***]* 1412   83519  
Acetylcholine Receptor Blocking Autoantibodies   each   [***]* 1413   83519  
Acetylcholine Receptor Modulating Autoantibodies   each   [***]* 1415   86648  
Diphtheria Toxoid IgG Abs Single Serum   each   [***]* 1426   85384   Fibrinogen
  each   [***]* 1431   82784; 83520   IgA Fibronectin Aggregates & Serum IgA  
each   [***]* 1436   82784; 83520x2   IgA Nephropathy Evaluation   each   [***]*
1438   83520   IgG Fibronectin Aggregates   each   [***]* 1440   82731   Fetal
Fibronectin by Semi-Quantitative EIA   each   [***]* 1441   83520   Ganglioside
Monosialic Acid Autoabs   each   [***]* 1470   86353x8   Beryllium-induced
Lymphocyte Proliferation   each   [***]* 1474   83520   Collagen Type II IgG
Autoabs   each   [***]* 1476   83520x2   Collagen Type I & IV IgG Autoabs   each
  [***]* 1477   83520   Collagen Type I IgG Autoabs   each   [***]* 1478   83520
  Collagen Type IV IgG Autoabs   each   [***]* 1481   83520   Hyaluronic Acid  
each   [***]* 1486   86160   Complement Split Product Concentration: C3a   each
  [***]* 1491   85420   Plasminogen; Quantitative   each   [***]* 1492   85420  
Plasminogen Activity   each   [***]* 1494   83520   RNA Polymerases I; II and
III IgG Autoabs   each   [***]* 1498   83520x2   IgA (Autoantibodies) IgG & IgM
Ab Panel   each   [***]* 1501   86160   Complement Protein Concentration: C3  
each   [***]* 1504   86160   Complement Protein Concentration: C4   each  
[***]* 1505   82784   IgG   each   [***]* 1506   82784   IgA   each   [***]*
1508   82784   IgM   each   [***]* 1510   82040   Albumin   each   [***]* 1511  
86160   Complement Protein Concentration: Factor B   each   [***]* 1512   83883
  Alpha-2-Macroglobulin   each   [***]* 1513   82103   Alpha-1-Antitrypsin  
each   [***]* 1514   82104   Alpha-1-Antitrypsin Phenotyping   each   [***]*

6

--------------------------------------------------------------------------------

1516   82390   Ceruloplasmin   each   [***]* 1517   83010   Haptoglobin   each  
[***]* 1519   84466   Transferrin   each   [***]* 1520   83520   Transferrin
Receptor (TFR); Soluble   each   [***]* 1523   84311  
N-Acetyl-B-D-Glucosaminidase   each   [***]* 1525   82985   Alpha-1-Acid
Glycoprotein   each   [***]* 1529   86160; 86161   Angioedema Evaluation   each
  [***]* 1530   86160   Inhibitor   each   [***]* 1531   86161   Complement
Functional Activity: C1 Esterase Inhibitor   each   [***]* 1533   83520x4  
T-Cell Helper Types 1 & 2 Evaluation   each   [***]* 1535   86140   C-Reactive
Protein   each   [***]* 1536   86140   C-Reactive Protein Ultraquant
(High-Sensitivity CRP)   each   [***]* 1537   82131; 86140; 86631   Treatable
Ischemia PredictR (TIP)   each   [***]* 1540   86431   Rheumatoid Factor Autoabs
  each   [***]* 1549   84134   Prealbumin   each   [***]* 1550   82040; 82784x2;
83883   IgG Synthesis Rate; CNS Index   each   [***]* 1555   82040; 83883  
Albumin Quotient   each   [***]* 1557   83916   Oligoclonal Immunoglobulins
[IEF/IFIX]   each   [***]* 1559   83916   Oligoclonal Immunoglobulins [AE]  
each   [***]* 1580   84165   Electrophoresis; Protein   each   [***]* 1592  
82664x2; 82784x3; 84165   Bence-Jones Protein Evaluation (Qual w/Reflex to
Quant)   each   [***]* 1599   83986   Gastric pH   each   [***]* 1600   86162  
Complement: CH50 Total Functional Activity; Classic Pathway   each   [***]* 1605
  86160   Complement Protein Concentration: C2   each   [***]* 1610   86160  
Complement Protein Concentration: C5   each   [***]* 1612   86160; 86161  
Complement: C3 Nephritic Factor   each   [***]* 1615   86160   Complement
Protein Concentration: Clq   each   [***]* 1621   83520   Granulocyte Colony
Stimulating Factor   each   [***]* 1622   86021   Granulocyte Autoabs   each  
[***]* 1623   82784; 82787   IgG Subclasses 1, 2, 3, & 4   each   [***]* 1625  
83883   IgG Subclass 1   each   [***]* 1627   83883   IgG Subclass 2   each  
[***]* 1628   83883   IgG Subclass 3   each   [***]* 1629   83883   IgG Subclass
4   each   [***]* 1630   86023x3   Platelet-associated IgG; IgM & IgA Autoabs  
each   [***]* 1631   86022x3   Platelet IgG; IgM & IgA Autoabs   each   [***]*
1634   88180x4   Terminal Deoxynucleotidyl Transferase Bone Marrow or Tissue  
each   [***]* 1635   88180x4   Terminal Deoxynucleotidyl Transferase with
Immunophenotyping   each   [***]* 1636   86022x3; 86023x3   Platelet Autoabs
Evaluation   each   [***]* 1638   86353; 86821x2   Human Mixed Lymphocyte
Reaction; One Way [MLR]   each   [***]* 1639   86353; 86821x2   Human Mixed
Lymphocyte Reaction; Two Way [MLR]   each   [***]* 1640   86353   Lymphocyte
Mitogen Proliferation Analysis; PHA   each   [***]*

7

--------------------------------------------------------------------------------

1641   86353   Lymphocyte Mitogen Proliferation Analysis; PWM   each   [***]*
1642   86353   Lymphocyte Mitogen Proliferation Analysis; ConA   each   [***]*
1643   86353   Lymphocyte Antigen Proliferation Analysis; Candida   each  
[***]* 1644   86353   Lymphocyte Antigen Proliferation Assays; Tetanus   each  
[***]* 1645   86353   Lymphocyte Antigen Proliferation Assays; PPD (Tuberculin)
  each   [***]* 1646   86353   Borrelia burgdorferi Lymphocyte Proliferation
Analysis   each   [***]* 1648   86353x3   Lymphocyte Antigen Proliferation
Analysis   each   [***]* 1650   85048; 85595; 88180x5; 86360   Cellular Immune
Dysfunction Evaluation   each   [***]* 1651   85048; 85595; 86663; 86664;
86665x2; 86790x2; 88180x4; 86360   Chronic Fatigue & Immune Dysfunction Syndrome
Evaluation   each   [***]* 1652   85048; 86663; 86664; 86665x2; 86790x2; 86849;
88180x4; 86360   Chronic Fatigue & Immune Dysfunction Syndrome with NK Cell  
each   [***]* 1655   85048; 85595; 86359; 86360   Lymphocyte Enumeration; T Cell
  each   [***]* 1656   85048; 85595; 86361   Lymphocyte Enumeration;
Helper/Inducer   each   [***]* 1657   85048; 85595; 86360   Lymphocyte
Enumeration; Helper/Suppressor   each   [***]* 1658   85048; 85595; 86359; 88180
  Lymphocyte Enumeration; T&B Cell   each   [***]* 1659   85048; 85595; 86360  
(Limited)   each   [***]* 1660   85048; 85595; 86359; 86360; 88180x8  
Lymphocyte Enumeration; Naïve Memory Cell   each   [***]* 1661   88342x8  
Lymphoma Panel   each   [***]* 1662   88342x4   Undifferentiated Tumor Panel  
each   [***]* 1666   86359; 86360; 88180x17   Leukemia / Lymphoma Tissue or Body
Fluid Evaluation   each   [***]* 1667   86359; 86360; 88180x24   Leukemia /
Lymphoma Bone Marrow Evaluation   each   [***]* 1668   85048; 85595; 88180x3;
86360   Lymphocyte Enumeration; Basic & NK Cells   each   [***]* 1670   85048;
86359; 88180x24; 86360   Leukemia / Lymphoma Blood Evaluation   each   [***]*
1671   85048; 85595; 88180x2; 86360   Lymphocyte Enumeration; Basic   each  
[***]* 1672   85048; 86359; 88180x25; 86360   Leukemia / Lymphoma Blood
Reflexive Evaluation   each   [***]* 1674   85048; 86359; 88180x19; 86360  
Leukemia / Lymphoma Evaluation Blood   each   [***]* 1676   85048; 86359;
88180x19; 86360   Leukemia / Lymphoma: Comprehensive Blood   each   [***]* 1677
  86360; 88180x18   Leukemia / Lymphoma; Comprehensive Bone Marrow or Tissue  
each   [***]*

8

--------------------------------------------------------------------------------

1678   88180x2   Additional Surface markers   each   [***]* 1679   86360;
88180x18   Leukemia / Lymphoma Evaluation Bone Marrow or Tissue   each   [***]*
1682   88180x15   Leukemia / Lymphoma Panel; Chronic Bone Marrow or Tissue  
each   [***]* 1683   86359   CD3 Surface Marker   each   [***]* 1684   86361  
CD4 Surface Marker   each   [***]* 1685   86360   CD8 Surface Marker   each  
[***]* 1686   88180   CD15/30 Surface Marker   each   [***]* 1687   88180  
CD16/56 Surface Marker   each   [***]* 1688   88180   CD19 Surface Marker   each
  [***]* 1689   88180   CD38 Surface Marker   each   [***]* 1690   88180   CD41
Surface Marker   each   [***]* 1691   88180   CD42 Surface Marker   each  
[***]* 1692   88180   CD103 Surface Marker   each   [***]* 1693   88180  
Glycophorin-A   each   [***]* 1694   88180   Terminal Deoxynucleotidyl
Transferase Bone Marrow or Tissue   each   [***]* 1705   83891; 83901X4;
83894X4; 83912   Narcolepsy EvaluatR   each   [***]* 1706   86817   HLA: DR2 &
DQ1—Narcolepsy Evaluation   each   [***]* 1711   86148x3   Phosphatidyserine
IgG; IgM & IgA Autoantibodies   each   [***]* 1721   86160; 86161   Complement:
C4 Nephritic Factor   each   [***]* 1723   86160x2; 86161x2   Complement: C3 &
C4 Nephritic Factors Evaluation   each   [***]* 1726   83520x3; 86021; 86038;
86060; 86160x2   Rapidly Progressive Glomerulonephritis Evaluation   each  
[***]* 1751   83520x3   Phosphatidylcholine IgG; IgM & IgA Abs   each   [***]*
1771   83520x3   Phosphatidic Acid IgG; IgM & IgA Abs   each   [***]* 1774  
86148x3   Phosphatidylinositol IgG; IgM; and IgA Autoantibodies   each   [***]*
1775   84081x3   Autoantibodies   each   [***]* 1776   83520x9; 84081x3;
86147x3; 86148x6   Antiphospholipid Eval & Phosphoglycerol/Phosphoinositol  
each   [***]* 1791   83520x3   Phosphatidylethanolamine IgG; IgM & IgA Abs  
each   [***]* 1804   84233; 84234; 88182   Breast Cancer Profile 1—Paraffin  
each   [***]* 1811   82387; 84233; 84234; 88182; 88342x2   Breast Cancer Profile
6—Paraffin   each   [***]* 1812   84233; 84234; 88182; 88342x2   Breast Cancer
Profile 5—Paraffin   each   [***]* 1813   82387; 84233; 84234; 88182   Breast
Cancer Profile 2—Paraffin   each   [***]* 1816   82387; 84233; 84234; 88182;
88342x4   Breast Cancer Profile 7—Paraffin   each   [***]* 1817   84233; 84234;
88182; 88342   Breast Cancer Profile 4—Paraffin   each   [***]* 1818   84233;
84234; 88182; 88342   Breast Cancer Profile 3 With Her-2/Neu Reflex   each  
[***]*

9

--------------------------------------------------------------------------------

1819   84233; 84234; 88182; 88342   Breast Cancer Profile 3—Paraffin   each  
[***]* 1820   87620   Human Papillomavirus DetectR   each   [***]* 1822   87622
  Human Papillomavirus GenotypR   each   [***]* 1824   87621   Human
Papillomavirus DetectR reflx to GenotypR   each   [***]* 1830   84233; 84234  
Estrogen & Progesterone Receptor Paraffin [IHC]   each   [***]* 1831   84233  
Estrogen Receptor   each   [***]* 1832   84234   Progesterone Receptor   each  
[***]* 1834   88342   IHC EGFR Block   each   [***]* 1840   84233; 84234; 88342
  Breast Cancer Panel; Basic   each   [***]* 1842   84233; 84234; 88342   ER/PGR
and Her2/Neu With Reflex to Fish   each   [***]* 1852   82387   IHC Cathepsin D
Block   each   [***]* 1862   86021; 86038   Antineutrophil Cytoplasmic
Autoantibodies (ANCA)   each   [***]* 1866   83520x2; 86021; 86038   PAN-ANCA
Evaluation   each   [***]* 1868   83520x4; 86021; 86038   PAN-ANCA PLUS   each  
[***]* 1871   85245   Ristocetin Cofactor Function   each   [***]* 1872   85048;
85595; 88180   Natural Killer Cell Quantitation   each   [***]* 1880   83890;
83892x3; 83894; 83896; 83897; 83912   T-Cell Receptor Gene Rearrangement   each
  [***]* 1882   83890; 83892x3; 83894; 83896; 83897; 83912   Immunoglobulin Gene
Rearrangement; Heavy -chain JH probe   each   [***]* 1884   83890; 83892X3;
83894; 83896; 83897; 83912   Immunoglobulin Gene Rearrangement; Kappa
Light-chain Probe   each   [***]* 1888   83890; 83892x3; 83894; 83896; 83897;
83912   bcl-2 Gene Translocation [SB]   each   [***]* 1890   83890; 83892x3;
83894; 83896; 83912   bcr/abl Gene Rearrangement [SB]   each   [***]* 1891  
82040; 82784x2; 83883   IgM (loc) CNS   each   [***]* 1896   82040; 82784x2;
83883   IgA (loc) CNS   each   [***]* 1900   82172x3   Apolipoprotein Evaluation
  each   [***]* 1901   82172   Apolipoprotein A-1   each   [***]* 1903   82172  
Apolipoprotein B   each   [***]* 1905   85246; 85247   von Willebrand Factor
Multimers Panel   each   [***]* 1906   85247   von Willebrand Multimers   each  
[***]* 1907   85246   von Willebrand Factor Ag   each   [***]* 1911   85613  
Lupus Anticoagulant: DRVVT   each   [***]* 1915   85597   Lupus Anticoagulant:
Hexagonal Phase   each   [***]* 1916   83890; 83892; 83894; 83898; 83912   Apo E
GenotypR (for all purp except late-onset Alzheimers)   each   [***]* 1926  
83520   Myelin-Associated Glycoprotein (MAG) IgM Autoabs   each   [***]* 1931  
82784; 8352x2   IgA Subclasses 1 & 2   each   [***]* 1938   86160   Complement
Protein Concentration: C5a   each   [***]* 1941   85210   Factor II Activity  
each   [***]* 1942   86161   Complement Functional Activity: C2   each   [***]*
1943   85220   Factor V Activity   each   [***]* 1944   86161   Complement
Functional Activity: C3   each   [***]*

10

--------------------------------------------------------------------------------

1945   85230   Factor VII Activity   each   [***]* 1946   86161   Complement
Functional Activity: C4   each   [***]* 1947   85240   Factor VIII Activity  
each   [***]* 1948   86161   Complement Functional Activity: C5   each   [***]*
1949   85250   Factor IX Activity   each   [***]* 1950   86161   Complement
Functional Activity: C6   each   [***]* 1951   85260   Factor X Activity   each
  [***]* 1952   86161   Complement Functional Activity: C7   each   [***]* 1953
  85270   Factor XI Activity   each   [***]* 1954   86161   Complement
Functional Activity: C8   each   [***]* 1955   85280   Factor XII Activity  
each   [***]* 1956   86161   Complement Functional Activity: C9   each   [***]*
1957   85290   Factor XIII Activity Qual w/ relex Quantitation   each   [***]*
1959   85280   Factor XIIa; (Activated)   each   [***]* 1960   86162  
Complement: AH50 Total Factor Activity Alternate Pathway   each   [***]* 1962  
86161   Complement: Alternate Pathway Function   each   [***]* 1964   83520  
Factor IX Ag   each   [***]* 1965   83520   Factor X Ag   each   [***]* 1966  
83890; 83892; 83894; 83898; 83912   Factor V Mutation (Leiden)   each   [***]*
1967   85240; 85335   Factor VIII Inactivator   each   [***]* 1968   83520  
Complement Split Product Concentration: Factor Bb Fragment   each   [***]* 1971
  84999   Tissue Factor   each   [***]* 1976   86160   Complement Protein
Concentration: C6   each   [***]* 1978   86160   Complement Protein
Concentration: C7   each   [***]* 1980   86160   Complement Protein
Concentration: C8   each   [***]* 1982   86160   Complement Protein
Concentration: C9   each   [***]* 1984   86160   Complement Protein
Concentration: Factor H   each   [***]* 1986   86160   Complement Protein
Concentration: Factor I   each   [***]* 1988   86160   Complement Protein
Concentration: Properdin   each   [***]* 1990   86160x2   Complement: C4d/C4
Ratio   each   [***]* 1992   83520   Complex   each   [***]* 1994   83520  
Complement: C1r:C1s:C1 Inhibitor Complex   each   [***]* 1995   86329  
Complement: C4 Binding Protein   each   [***]* 1996   86161   Complement:
C3b:Bb:Properdin Complex   each   [***]* 1998   83520   Complement Split Product
Concentration: iC3b   each   [***]* 2011   86631; 86632; 86713x12; 86738x3  
Atypical Pneumonia Abs Evaluation   each   [***]* 2016   82627; 83001; 83002;
84144; 84146; 84443   Infertility: Endocrine Evaluation (Female)   each   [***]*
2017   83001; 83002; 84146; 84402; 84403   Infertility: Endocrine Evaluation
(Male)   each   [***]* 2019   82627; 82670; 83001; 83002; 84146   Anovulatory
Evaluation   each   [***]*

11

--------------------------------------------------------------------------------

2020   83001; 83002   Follicle-Stimulating Hormone & Luteinizing Hormone Eval  
each   [***]* 2023   82627; 83001; 83002; 84402; 84403   Polycystic Ovary
Evaluation   each   [***]* 2025   82627; 84146; 84403; 84443   Recurrent
Spontaneous Abortion: Endocrine Evaluation   each   [***]* 2026   86812x2;
86816x2; 88180   Recurrent Spontaneous Abortion: Immunology Evaluation   each  
[***]* 2027   86631x3; 87109; 87490   Recurrent Spontaneous Abortion: Infectious
Disease Evaluation   each   [***]* 2028   85613; 86147x3; 86143x3   Recurrent
Spontaneous Abortion: Autoimmune Evaluation   each   [***]* 2030   86635x3  
Coccidioides Total Abs Evaluation   each   [***]* 2034   87109; 87490; 87590  
Sexually Transmitted Disease Agents   each   [***]* 2050   82040; 82784x2;
83883; 86762x2; 86765x3; 86787x2   MRZ Reaction Evaluation   each   [***]* 2101
  86256   Antibody-coated Bacteria   each   [***]* 2102   86781   Treponema
pallidum IgM Abs; FTA   each   [***]* 2104   86781   Treponema pallidum Total
Abs; FTA   each   [***]* 2106   87299   Cytomegalovirus Immediate-early Ag Whole
Blood   each   [***]* 2116   86665   Epstein-Barr Virus Viral Capsid Ag (VCA)
IgG Abs   each   [***]* 2121   86665   Epstein-Barr Virus Viral Capsid Ag (VCA)
IgM Abs   each   [***]* 2122   86665x2   Abs   each   [***]* 2126   86663  
Epstein-Barr Virus Early Ag (EA) IgG Abs; diff/rest patterns   each   [***]*
2131   86663   Epstein-Barr Virus Early Ag (EA) IgA Abs   each   [***]* 2136  
86753   Babesia microti IgG Abs   each   [***]* 2141   86753   Babesia microti
IgM Abs   each   [***]* 2146   87207   Babesia spp. Organism Detection   each  
[***]* 2151   86753x2; 87207   Babesiosis Evaluation   each   [***]* 2152  
86713x4   Legionella Non-Pneumophila IgG & IgM Abs   each   [***]* 2153  
86713x28   Legionella pneumophila IgG & IgM Abs; Serotypes 1-14   each   [***]*
2154   86713x14   Legionella pneumophila IgG Abs; Serotypes 1-14   each   [***]*
2156   86713x12   Legionella pneumophila IgG & IgM Abs; Serotypes 1-6   each  
[***]* 2159   86713x14   Legionella pneumophila IgM Abs; Serotypes 1-14   each  
[***]* 2161   86753x2   Babesia microti IgG & IgM Abs   each   [***]* 2199  
87290   Varicella-zoster Virus Ag Detection   each   [***]* 2211   86663; 86664;
86665x2   Epstein-Barr Virus Evaluation   each   [***]*

12

--------------------------------------------------------------------------------

2231   86645;86694; 86695; 86762; 86778   TORCH IgM Abs Evaluation   each  
[***]* 2261   86777x2; 86778x2   Toxoplasma Antibody Evaluation   each   [***]*
2266   86664   Epstein-Barr Virus Nuclear Ag (EBNA) IgG Abs   each   [***]* 2271
  86664   Epstein-Barr Virus Nuclear Ag (EBNA) IgM Abs   each   [***]* 2316  
86606x2   Aspergillus Evaluation   each   [***]* 2321   86609   Teichoic Acid
Abs   each   [***]* 2326   866606   Aspergillus Abs [DD]   each   [***]* 2328  
86612   Blastomyces Total Abs [DD]   each   [***]* 2330   86628   Candida
albicans Total Abs   each   [***]* 2332   86635   Coccidioides Total Abs [DD]  
each   [***]* 2334   86698x2   Histoplasma Abs [DD]   each   [***]* 2343  
86628x3   Candida albicans Evaluation without Ag   each   [***]* 2344   86628x3;
87449   Candida albicans Evaluation   each   [***]* 2346   86628   Candida
albicans Abs-Titer   each   [***]* 2351   86215   Antideoxyribonuclease-B Abs  
each   [***]* 2360   87207   Filaria Organism Detection   each   [***]* 2361  
87177   Ova & Parasite: Routine Exam   each   [***]* 2362   87177; 88313   Ova &
Parasite: Comprehensive Exam w/ Coccidia Evaluation   each   [***]* 2363  
87206; 88313   Ova & Parasite: Coccidia Evaluation   each   [***]* 2364   86592
  Rapid Plasma Reagin [RPR]   each   [***]* 2366   86592   VDRL   each   [***]*
2367   87208   Ova & Parasite: Arthropod Identification   each   [***]* 2368  
87208   Ova & Parasite: Worm Identification   each   [***]* 2370   86609x4  
Streptococcus pneumoniae IgG Abs; 4 Serotypes   each   [***]* 2376   86060  
Antistreptolysin O Abs (ASO)   each   [***]* 2381   87449   Escherichia coli K1
/ N. meningitidis Type B Ag   each   [***]* 2386   866609x12   Streptococcus
pneumoniae IgG Abs; 12 Serotypes   each   [***]* 2398   87070; 87166  
Leptospira Culture & Darkfield Microscopy   each   [***]* 2399   87109  
Mycoplasma Hominis Culture   each   [***]* 2400   87110   Chlamydia trachomatis
Culture   each   [***]* 2401   87110   Chlamydia pneumoniae Culture   each  
[***]* 2402   87252   Herpes Simplex Virus Types 1 & 2 Culture   each   [***]*
2403   87081   Helicobacter pylori Culture   each   [***]* 2404   87070  
Legionella spp. Culture   each   [***]* 2406   87109   Mycoplasma pneumoniae
Culture   each   [***]* 2407   87070   Corynebacterium diphtheriae Culture  
each   [***]* 2408   87109   Culture   each   [***]* 2410   87252   Viral
Culture   each   [***]* 2411   87075   Clostridium difficile Culture   each  
[***]* 2412   87230   Clostridium difficile Toxin B Detection   each   [***]*
2413   87040   Bartonella spp. Culture   each   [***]* 2414   87081   Neisseria
gonorrhoeae Culture   each   [***]* 2415   87040   Borrelia spp. Culture   each
  [***]* 2416   87081x2   Bordetella pertussis/parapertussis Culture   each  
[***]*

12

--------------------------------------------------------------------------------

2417   87117x2   AFB Culture   each   [***]* 2418   87252   Cytomegalovirus
Culture   each   [***]* 2419   87117x2; 87206   AFB Culture & Stain   each  
[***]* 2421   87299   Cytomegalovirus Ag Detection   each   [***]* 2422   87278
  Legionella pneumophila Ag Detection   each   [***]* 2423   87276; 87299  
Influenza Virus; Types A & B Detection   each   [***]* 2424   87299x3  
Parainfluenza Virus Types 1-3 Detection   each   [***]* 2425   87260; 87276;
87280; 87299x4   Respiratory Infection Evaluation; Viral   each   [***]* 2426  
87274   Herpes Simplex Virus Types 1 & 2 Ag Detection [DFA]   each   [***]* 2428
  87265x2   Bordetella pertussis/parapertussis Ag Detection   each   [***]* 2430
  87081x2; 87265x2   Bordetella pertussis/parapertussis Evaluation   each  
[***]* 2432   87070; 87278   Legionella pneumophila Evaluation   each   [***]*
2433   87081   Streptococcus; Beta Group B Culture Screen   each   [***]* 2434  
87070   Acanthamoeba Culture   each   [***]* 2436   86609   Toxic Shock Syndrome
Abs   each   [***]* 2437   87174   Toxic Shock Syndrome Evaluation   each  
[***]* 2438   87205   Gram Stain   each   [***]* 2439   87328   Cryptosporidium
Ag Detection   each   [***]* 2440   87270   Chlamydia trachomatis Ag Detection
[DFA]   each   [***]* 2442   87301; 87425   Viral Diarrhea Ag Detection   each  
[***]* 2443   87338   Helicobacter pylori Specific Ag   each   [***]* 2444  
87301   Adenovirus Enteric Types 40/41 Ag Detection   each   [***]* 2445   86803
  Hepatitis C Virus IgG Abs w/ reflex RIBA   each   [***]* 2446   86803  
Hepatitis C Virus IgG Abs   each   [***]* 2447   86804   Hepatitis C Virus Abs
RIBA Confirmation   each   [***]* 2448   86706   Hepatitis B Virus Surface Ab
Quantitation   each   [***]* 2449   87340   Hepatitis B Virus Surface Ag
Neutralization   each   [***]* 2450   86708   Hepatitis A Virus Total Abs   each
  [***]* 2451   86709   Hepatitis A Virus IgM Abs   each   [***]* 2452   86704  
Hepatitis B Virus Core Total Abs   each   [***]* 2453   86706   Hepatitis B
Virus Surface Total Abs   each   [***]* 2454   87340   Hepatitis B Virus Surface
Ag   each   [***]* 2455   86707   Hepatitis Be Virus Total Abs   each   [***]*
2456   87350   Hepatitis Be Virus Ag   each   [***]* 2457   86705   Hepatitis B
Virus Core IgM Abs   each   [***]* 2458   86692   Hepatitis Delta Virus Total
Abs   each   [***]* 2459   86692   Hepatitis Delta Virus IgM Abs   each   [***]*
2460   86708   Hepatitis A Virus Total & IgM Abs   each   [***]* 2461   86704;
86706; 87340   Hepatitis B Virus Evaluation   each   [***]* 2462   86707; 87350
  Hepatitis Be Virus Antigen/Antibody Evaluation   each   [***]* 2463   86704;
86706; 86707; 86708; 87340; 87350   Hepatitis A & B Virus Evaluation   each  
[***]* 2464   86704; 80074; 86706; 86708   Hepatitis A; B; & C Virus Evaluation
  each   [***]* 2465   86692x2   Hepatitis Delta Virus Total & IgM Abs   each  
[***]* 2466   86790x2   Hepatitis E IgG & IgM Evaluation   each   [***]*

13

--------------------------------------------------------------------------------

2467   86790   Hepatitis E IgG   each   [***]* 2468   87526   Hepatitis G Virus
RNA DetectR   each   [***]* 2469   86790   Hepatitis E IgM   each   [***]* 2470
  87340   Hepatitis B Virus Surface Ag without confirmation   each   [***]* 2472
  87425   Rotavirus Ag Detection   each   [***]* 2473   87272  
Giardia/Cryptosporidium Ag Detection [DFA]   each   [***]* 2475   86762  
Rubella IgM Abs   each   [***]* 2476   86704   Hepatitis B Virus Core Total Abs
w/reflex IgM   each   [***]* 2486   86645   Cytomegalovirus IgM Abs   each  
[***]* 2490   84182   Creutzfeldt-Jakob Disease DetectR   each   [***]* 2491  
86793   Yersinia enterocolitica IgG Abs   each   [***]* 2496   86793   Yersinia
enterocolitica IgM Abs   each   [***]* 2501   86603   Adenovirus Abs   each  
[***]* 2504   87070   Legionella Culture: Environmental   each   [***]* 2506  
86606   Aspergillus Total Abs [CF]   each   [***]* 2509   87260   Adenovirus Ag
Detection   each   [***]* 2511   86612   Blastomyces Total Abs [CF]   each  
[***]* 2516   86609   Neisseria gonorrhoeae Abs   each   [***]* 2521   86631  
Chlamydia spp. Total Abs [CF]   each   [***]* 2526   86635   Coccidioides Total
Abs [CF]   each   [***]* 2536   86658x4   Coxsackievirus A Abs; Serotypes 7; 9;
10; 16   each   [***]* 2541   86658x6   Coxsackievirus B Abs; Serotypes 1-6  
each   [***]* 2546   86658x10   Coxsackievirus A & B Abs Evaluation   each  
[***]* 2551   86644   Cytomegalovirus Total Abs   each   [***]* 2566   86658x4  
Echovirus Abs; Serotypes 4; 9; 11 & 30   each   [***]* 2571   86694   Herpes
Simplex Virus Total Abs [CF]   each   [***]* 2581   86698x2   Histoplasma Abs
[CF]   each   [***]* 2586   86710   Influenza Virus Abs; Type A   each   [***]*
2591   86710   Influenza Virus Abs; Type B   each   [***]* 2594   83901x2; 83912
  Influenza A & B MultiplexR   each   [***]* 2601   86727   Lymphocytic
Choriomeningitis Abs   each   [***]* 2606   86729   Lymphogranuloma Venereum Abs
  each   [***]* 2621   86790x3   Parainfluenza Virus Types 1-3 Abs   each  
[***]* 2626   86658x3   Poliovirus Abs Serotypes 1-3   each   [***]* 2631  
86631   Chlamydia spp. Total Abs   each   [***]* 2641   86790   Reovirus Abs  
each   [***]* 2646   86756   Respiratory Syncytial Virus Total Abs   each  
[***]* 2650   87798   Enterovirus RNA DetectR [PCR]   each   [***]* 2651   87798
  Enterovirus RNA DetectR reflex to Speciation   each   [***]* 2654   87798  
Flavivirus Rna DetectR   each   [***]* 2655   87798   Flavivirus DetectR Reflex
to Speciation   each   [***]* 2676   86790   Polyomavirus Abs   each   [***]*
2701   86603; 86631; 86710x2; 86738; 86790x3   Respiratory Infection Abs; Adult
  each   [***]* 2704   87280   Respiratory Syncytial Virus Detection [DFA]  
each   [***]* 2711   86603; 86631; 86710x2; 86738; 86756; 86790x3   Respiratory
Infection Abs; Child/Infant   each   [***]*

14

--------------------------------------------------------------------------------

2726   86694; 86727; 86735x2; 86765x2; 86787x2   Encephalitis Virul Abs   each  
[***]* 2731   86606; 86612; 86635; 86698x2   Fungal Abs [CF]   each   [***]*
2741   86710x2   Influenza Virus Abs; Types A & B   each   [***]* 2746  
86658x17   Paralytic Viral Ab Evaluation   each   [***]* 2771   86603; 86644;
86651; 86652; 86653; 86654; 86658x14; 86694; 86710x2; 86727; 86735x2; 86765x2;
86787x2   Meningoencephalomyelitis Viral Ab Evaluation   each   [***]* 2780  
86612; 86635; 86698x2   Fungal Antibody Panel: Invasive   each   [***]* 2785  
86606; 86635; 86641; 86698x2; 87449   Fungal Antibody Panel: Opportunistic  
each   [***]* 2790   86612; 86635; 86641; 86698x2; 87449   Fungal Antibody
Panel: Systemic   each   [***]* 2871   86317; 86622; 86632; 86645; 86668; 86778
  Lymphadenopathy; Infectious IgM Abs Evaluation   each   [***]* 2920   87541  
Legionella pneumophila DNA DetectR   each   [***]* 2922   87486   Chlamydia
pneumoniae DNA DetectR   each   [***]* 2924   87581   Mycoplasma pneumoniae DNA
DetectR   each   [***]* 2925   87490   Chlamydia trachomatis Detection rRNA  
each   [***]* 2927   87490; 87590   rRNA   each   [***]* 2928   87486; 87541;
87581   Atypical Pneumonia DNA DetectR   each   [***]* 2929   87798x3  
Mycoplasma MultiplexR   each   [***]* 2930   87590   Neisseria gonorrhoeae
Detection rRNA   each   [***]* 2932   87591   Neisseria gonorrhoeae DNA LCR  
each   [***]* 2934   84999x2; 87798   Staph Resist MultipleXR   each   [***]*
2935   87555; 87560   AFB Identification Mycobacterium spp. rRNA   each   [***]*
2940   87106   Fungus Identification; rRNA   each   [***]* 2941   87205   Fungus
Stain   each   [***]* 2945   87207   Malaria Organism Detection   each   [***]*
2948   87207   Giemsa Stain   each   [***]* 2950   87072   Bacterial
Identification; Aerobic Organism ID   each   [***]* 2955   87070   Haemophilus
ducreyi Culture   each   [***]* 2960   87205   Fecal Leukocytes   each   [***]*
3012   86689   HIV-1 Abs Confirmation Immunoblot   each   [***]* 3015   86689x2
  HIV-1 & 2 IgG Abs Confirmation [IB]   each   [***]* 3017   84275; 86316  
Uterine Cancer Monitor   each   [***]* 3020   82607; 82746   Vitamin B12
(Cyanocobalamin) & Folate   each   [***]* 3021   86689   HIV-1 Abs Confirmation
Immunoblot Plus Conf HIV-2 Abs IB   each   [***]* 3024   82378; 86316  
Colorectal Cancer Monitor   each   [***]* 3028   82105; 84702  
Alpha-Fetoprotein & Human Chorionic Gonadotropin   each   [***]* 3030   82550;
84066; 84153   ProstAsure   each   [***]* 3032   84066; 84153   Prostate Cancer
Monitor   each   [***]* 3051   88342; 88358   Micrometastases DetectrR   each  
[***]*

15

--------------------------------------------------------------------------------

3060   83519; 84443; 84445x2; 86376; 86800   Thyroid Autoabs Evaluation   each  
[***]* 3062   86376   Thyroid Peroxidase Autoabs   each   [***]* 3066   86341  
Islet Cell Autoantibodies; Complement Fixing   each   [***]* 3069   86341x2  
Islet Cell Autoabs Evaluation   each   [***]* 3070   82570; 83497; 84260x2  
Carcinoid Evaluation   each   [***]* 3072   84439; 84443; 84480   Thyroid Panel;
Hyperthyroidism   each   [***]* 3074   84439; 84443   Thyroid Panel;
Hypothyroidism [MEIA/ICMA]   each   [***]* 3076   84439; 84443   Thyroid Screen
  each   [***]* 3080   83520; 85048; 86361   HIV-1 Immune Status Monitor   each
  [***]* 3090   82105   Alpha-Fetoprotein—Maternal; 2.5 Mom   each   [***]* 3091
  82105; 82677; 84702   Screen)   each   [***]* 3092   82105; 82677; 84702  
Alpha-Fetoprotein Quad Screen; 2.5 Mom (incl. Inhibin s/o @ $25)   each   [***]*
3100   84066   Prostatic Acid Phosphatase   each   [***]* 3102   82024  
Adrenocorticotropic Hormone   each   [***]* 3104   82088   Aldosterone   each  
[***]* 3106   82154   Androstanediol Glucuronide   each   [***]* 3108   82105  
Alpha-Fetoprotein—Maternal; Serum   each   [***]* 3109   82105  
Alpha-Fetoprotein—Tumor Marker   each   [***]* 3110   82105; 82677; 84702  
Screen)   each   [***]* 3111   82106   Alpha-Fetoprotein—Prenatal; Amniotic
Fluid   each   [***]* 3112   82157   Androstenedione   each   [***]* 3114  
82164   Angiotensin Converting Enzyme   each   [***]* 3116   84588  
Antidiuretic Hormone   each   [***]* 3119   86316   CA 15-3   each   [***]* 3120
  86316   CA 19-9   each   [***]* 3121   86316   CA 125 [MEIA]   each   [***]*
3123   82480   Cholinesterase Serum   each   [***]* 3124   82634  
11-Deoxycortisol   each   [***]* 3125   86334   Monoclonal Gammapathies; Serum  
each   [***]* 3126   82308   Calcitonin   each   [***]* 3127   84379  
Disaccharidases   each   [***]* 3128   82533   Cortisol   each   [***]* 3131  
84311   Adenosine Deaminase   each   [***]* 3134   86316   CA27.29   each  
[***]* 3136   82533   Cortisol Plasma [HPLC]   each   [***]* 3140   84681  
C-Peptide   each   [***]* 3143   82232   Beta-2-Microglobulin   each   [***]*
3146   82626   Dehydroepiandrosterone   each   [***]* 3150   82627  
Dehydroepiandrosterone-Sulfate   each   [***]* 3154   82679   Estrone   each  
[***]* 3155   82670   Estradiol   each   [***]* 3156   82677   Estriol;
Unconjugated   each   [***]* 3158   82677   Estriol; Total   each   [***]* 3163
  84144   Progesterone   each   [***]* 3164   82672   Estrogens; Total   each  
[***]* 3166   82671   Estrogens; Fractionated   each   [***]* 3170   82728  
Ferritin   each   [***]*

16

--------------------------------------------------------------------------------

3172   82728; 86316   Neuroblastoma Monitor   each   [***]* 3174   83001  
Follicle-Stimulating Hormone   each   [***]* 3176   82941   Gastrin   each  
[***]* 3181   82985   Glycosylated Albumin   each   [***]* 3182   83003   Growth
Hormone   each   [***]* 3184   84702   Human Chorionic Ganadotropin   each  
[***]* 3186   83632   Human Placental Lactogen   each   [***]* 3187   84702  
Beta-hCG Pregnancy   each   [***]* 3188   82154; 82627; 83498; 84402; 84403  
Hirsutism Evaluation; Female   each   [***]* 3190   83498  
17-Hydroxyprogesterone   each   [***]* 3192   83525   Insulin   each   [***]*
3193   83525; 83527   Insulin; Free and Bound   each   [***]* 3196   86340  
Intrinsic Factor Blocking Autoabs   each   [***]* 3198   83002   Luteinizing
Hormone   each   [***]* 3204   83930   Osmolality Serum   each   [***]* 3206  
84146   Prolactin   each   [***]* 3208   82310; 82330; 83970   PTH; C Terminal;
including Ionized & Total Calcium   each   [***]* 3209   83970   PTH;
Mid-Molecule only   each   [***]* 3210   82310; 82330; 83970   PTH;
Mid-Molecule; including Ionized & Total Calcium   each   [***]* 3211   82310;
82330; 83970x2   PTH; Mid-Molecule & Intact; incl. Ionized & Total Calcium  
each   [***]* 3213   82310; 82330; 83970x2   PTH; C Terminal & Intact including
Ionized & Total Calcium   each   [***]* 3214   84244   Renin Activity Plasma  
each   [***]* 3218   84270   Sex Hormone Binding Globulin   each   [***]* 3220  
84305   Insulin-like Growth Factor 1   each   [***]* 3222   84307   Somatostatin
  each   [***]* 3224   84480   Triiodothyronine (T3)   each   [***]* 3225  
84480; 84481   T3 Free; Tracer Dialysis   each   [***]* 3226   84436   Thyroxine
(T4)   each   [***]* 3228   84439   Thyroxine; Free   each   [***]* 3232   84479
  T Uptake   each   [***]* 3234   84481   Triiodothyronine; Free   each   [***]*
3236   84482   Reverse Triidothyronine (RT3)   each   [***]* 3238   84442  
Thyroxine Binding Globulin   each   [***]* 3240   83519; 86235x7   Myositis
AssessR   each   [***]* 3241   83519   Mi-2 Autoantibodies   each   [***]* 3242
  83519; 86235x8   Myositis AssessR Plus Jo-1 Autoantibodies   each   [***]*
3244   84403   Testosterone; Total   each   [***]* 3247   84402   Testosterone;
Free   each   [***]* 3248   84402; 84403   Testosterone; Free & Total   each  
[***]* 3250   84443   Thyroid Stimulating Hormone; 3rd Generation   each  
[***]* 3251   84432; 86800   Thyroglobulin   each   [***]* 3252   84586  
Vasoactive Intestinal Peptide   each   [***]* 3253   85301   Antithrombin III
Plasma Ag   each   [***]* 3254   82378; 86316   Small-cell Carcinoma Monitor;
Lung   each   [***]* 3255   84432   Thyroglobulin Serum   each   [***]*

17

--------------------------------------------------------------------------------

3258   82378   Carinoembryonic Ag [CEA]   each   [***]* 3261   82088; 84132;
84244   Hyperaldosteronism Evaluation   each   [***]* 3262   82382; 82570; 83835
  Pheochromocytoma Evaluation   each   [***]* 3264   82024; 82533   Hypertension
IV: Cushing Syndrome Evaluation   each   [***]* 3265   82088; 82157; 82533;
82634;83498; 84402; 84403   Congenital Adrenal Hyperplasia Evaluation   each  
[***]* 3270   82383   Epinephrine Plasma   each   [***]* 3272   84202  
Erythrocyte Protoporphyrin   each   [***]* 3275   84202   Zinc Protoporphyrin  
each   [***]* 3280   85410   Alpha-2-Antiplasmin   each   [***]* 3282   83520  
Neopterin   each   [***]* 3286   84260   5-Hydroxytryptamine [Serotonin]   each
  [***]* 3288   85415   Tissue Plasminogen Activator Ag   each   [***]* 3290  
83520   Interferon-alpha   each   [***]* 3292   83520   Interferon-gamma   each
  [***]* 3294   82397   Tumor Necrosis Factor-alpha Plasma   each   [***]* 3295
  83520   Interferon-Beta Autoabs (Anti-Interferon-B)   each   [***]* 3296  
85420   Tissue Plasminogen Activator Inhibitor   each   [***]* 3297   83520  
Interferon-Beta 1A IgG Autoantibodies   each   [***]* 3298   85384; 85415;
85420x2   Thrombotic Risk Evaluation 4   each   [***]* 3304   82384  
Catecholamines; Fractionated Plasma   each   [***]* 3310   82570; 83497  
5-Hydroxyindoleacetic Acid 24hr Urine   each   [***]* 3315   82570; 83835  
Metanephrines; Fractionated 24hr Urine   each   [***]* 3316   82570; 83835  
Metanephrines; Total 24hr Urine   each   [***]* 3319   84585   Vanillylmandelic
Acid—Pediatric   each   [***]* 3320   82975   L-Glutamine CSF   each   [***]*
3334   82131   Homocyst(e)ine UltraQuant   each   [***]* 3346   84478  
Triglycerides   each   [***]* 3350   82465   Cholesterol; Total   each   [***]*
3351   83721   Direct LDL Cholesterol   each   [***]* 3352   83718   Cholesterol
HDL   each   [***]* 3354   83088   Histamine   each   [***]* 3356   86280  
Isohemagglutinin Titer   each   [***]* 3360   80164   Valproic Acid   each  
[***]* 3361   80299   Valproic Acid Free   each   [***]* 3364   80299  
Gabapentin   each   [***]* 3369   83690   Lipase   each   [***]* 3371   86147x3
  Cardiolipin IgG; IgM & IgA Autoabs   each   [***]* 3372   86147   Cardiolipin
IgG Autoabs   each   [***]* 3373   86147   Cardiolipin IgM Autoabs   each  
[***]* 3374   86147   Cardiolipin IgA Autoabs   each   [***]* 3390   84484  
Troponin (I&T) DetectR   each   [***]* 3392   84484   Troponin T   each   [***]*
3393   84484   Troponin I   each   [***]* 3420   86717   Leishmania IgG Abs  
each   [***]* 3441   82042; 82043   Microalbumin; 24Hr Urine   each   [***]*
3442   82043; 82570   Microalbumin Random Urine   each   [***]* 3445   83715  
Lipoprotein Electrophoresis   each   [***]* 3446   82172   Lipoprotein (a)  
each   [***]*

18

--------------------------------------------------------------------------------

3452   83615   Lactate Dehydrogenase   each   [***]* 3453   83625   Lactate
Dehydrogenase (LD) Isoenzymes   each   [***]* 3454   80061   Cholesterol
Evaluation   each   [***]* 3460   83520   Tryptase   each   [***]* 3462   83520
  Immunoreactive Trypsin   each   [***]* 3492   82131   2-Methylcitric Acid  
each   [***]* 3494   82131   Cystathionine   each   [***]* 3496   83918  
Methylmalonic Acid   each   [***]* 3500   84252   Vitamin B2 (Riboflavin)
Functional Assessment   each   [***]* 3502   84590   Vitamin A   each   [***]*
3504   82607   Vitamin B12 (Cyanocobalamin)   each   [***]* 3505   84207  
Pyridoxal Phosphate (Vitamin B6)   each   [***]* 3508   82180   Vitamin C
(Ascorbic Acid)   each   [***]* 3515   84425   Vitamin B1   each   [***]* 3518  
84311   Vitamin B1 Functional Assessment   each   [***]* 3519   84311; 84425  
Vitamin B1 & Transketolase   each   [***]* 3520   82652   Vitamin D; 1;
25-Dihydroxy (Calcifidol)   each   [***]* 3521   82306   Vitamin D; 25-Hydroxy
(Calciferol)   each   [***]* 3522   82746   Folate   each   [***]* 3530   84446
  Vitamin E   each   [***]* 3532   83540   Iron   each   [***]* 3534   83540;
83550   Iron Binding Capacity & % Saturation   each   [***]* 3535   82728;
83520; 83540; 83550   Iron Status MonitR   each   [***]* 3536   83540   Iron
Liver Tissue   each   [***]* 3546   84153   Prostate-Specific Ag   each   [***]*
3547   84153; 84154   Prostate-Specific Antigen; Free & Total   each   [***]*
3550   83937   Osteocalcin   each   [***]* 3554   82247   Bilirubin; Total  
each   [***]* 3556   83520   Elastase Abs   each   [***]* 3560   84311  
Antioxidant AssessR   each   [***]* 3562   82180; 83735; 84255; 84446; 84590;
84630   Antioxidant Index, Blood   each   [***]* 3565   82978   Glutathione
Peroxidase   each   [***]* 3575   84311   Beta-Hydroxybutrate   each   [***]*
3587   82784; 83883x2   IgG Subclasses 2 & 4   each   [***]* 3616   82943  
Glucagon   each   [***]* 3624   85130   Endotoxin Plasma   each   [***]* 3700  
86003x4   RAST Food—Pediatric Panel   each   [***]* 3701   82785; 86003x4   RAST
Food—Pediatric Panel + Total IgE   each   [***]* 3702   86003x10   RAST Food
Panel   each   [***]* 3703   82785; 86003x10   RAST Food Panel + Total IgE  
each   [***]* 3704   86003x6   RAST Mold Panel   each   [***]* 3705   82785;
86003x6   RAST Mold Panel + Total IgE   each   [***]* 3710   86003x10   RAST
Southern California Panel   each   [***]* 3711   82785; 86003x10   RAST Southern
California Panel + Total IgE   each   [***]* 3712   86003x10   RAST Northern
California Panel   each   [***]* 3713   82785; 86003x10   RAST Nothern
California Panel + Total IgE   each   [***]* 3714   86003x10   RAST Southwest
Panel   each   [***]* 3715   82785; 86003x10   RAST Southwest Panel + Total IgE
  each   [***]*

19

--------------------------------------------------------------------------------

3716   86003x10   RAST Midwest Panel   each   [***]* 3717   82785; 86003x10  
RAST Midwest Panel + Total IgE   each   [***]* 3718   86003x10   RAST Northeast
Panel   each   [***]* 3719   82785; 86003x10   RAST Northeast Panel + Total IgE
  each   [***]* 3720   86003x10   RAST Southeast Panel   each   [***]* 3721  
82785; 86003x10   RAST Southeast Panel + Total IgE   each   [***]* 3722  
86003x12   RAST West Coast Panel   each   [***]* 3723   82785; 86003x12   RAST
West Coast Panel + Total IgE   each   [***]* 3745   86003   RAST—Phadiatop  
each   [***]* 3812   83520   Interleukin-12   each   [***]* 3814   83520  
Interleukin-4   each   [***]* 3816   83520   Interleukin-1 RA   each   [***]*
3822   83520   Interleukin-8   each   [***]* 3823   83520   Interleukin-10  
each   [***]* 3827   83520   Interleukin-5   each   [***]* 3828   83520  
Interleukin-6   each   [***]* 3830   83520   Mannose-binding Protein   each  
[***]* 3832   83520   Interleukin-2 Receptor; Soluble   each   [***]* 3836  
85303   Protein C Activity   each   [***]* 3837   85306   Protein S Activity  
each   [***]* 3844   82150   Amylase   each   [***]* 3846   82150x3   Amylase
Isoenzymes   each   [***]* 3851   82550   Creatine Kinase Isoenzymes (CK)   each
  [***]* 3852   82550; 82553   Creatine Kinase-MB Mass & Relative Index   each  
[***]* 3856   86329   Immunosuppressive Acidic Protein   each   [***]* 3857  
84275; 86316   Melanoma Monitor   each   [***]* 3858   84275   Lipid-Associated
Sialic Acid   each   [***]* 3860   86316   Neuron-specific Enolase   each  
[***]* 3868   83520   Interleukin-1 beta   each   [***]* 3870   83520  
Interleukin-2   each   [***]* 3872   83520   Pancreatitis DetectR   each  
[***]* 3876   86337   Insulin Antibodies   each   [***]* 3882   83520  
Macrophage Inflammatory Protein-1 alpha   each   [***]* 3883   83520  
Macrophage Inflammatory Protein-1 beta   each   [***]* 3885   83520   Rantes  
each   [***]* 3886   83520x3   Beta-chemokine Panel   each   [***]* 3892   85610
  Prothrombin Time (PTT)   each   [***]* 3893   85610; 85611x2   Prothrombin
Time Mixing Studies   each   [***]* 3895   85730   Partial Thromboplastin Time
(PT)   each   [***]* 3896   85730; 85732x2   Partial Thromboplastin Time Mixing
Studies   each   [***]* 3900   83873   Myelin Basic Protein CSF   each   [***]*
3904   82397   Eosinophil Cationic Protein   each   [***]* 3908   83520   Tumor
Necrosis Factor-binding Proteins   each   [***]* 3916   84402; 84403  
Testosterone; Bioavailable   each   [***]* 3917   84402; 84403   Testosterone;
Weakly Binding   each   [***]* 3930   84075   Alkaline Phosphatase; Total   each
  [***]* 3934   82985   Fructosamine   each   [***]* 3941   83970   PTH; Intact
only   each   [***]* 3943   82310; 83970   PTH; Intact including Total Calcium
only   each   [***]* 3944   82310; 82330; 83970   PTH; Intact including Ionized
& Total Calcium   each   [***]*

20

--------------------------------------------------------------------------------

3945   82310; 83970   PTH; C Terminal; including Total Calcium only   each  
[***]* 3946   83150   Homovanillic Acid; 24hr Urine   each   [***]* 3947   83150
  Homovanillic Acid; Pediatric   each   [***]* 3952   83519   Chromogranin-A  
each   [***]* 3954   84436; 84439   Thyroxine (T4) Free; Direct Dialysis   each
  [***]* 3959   83519   Insulin-like Growth Factor Binding Protein (IGFBP-3)  
each   [***]* 3973   82523; 82570   Deoxypyridinoline Cross-links   each  
[***]* 3974   84075   Alkaline Phosphatase; Bone Specific   each   [***]* 3976  
82550   Creatine Phosphokinase   each   [***]* 3978   85540   Leukocyte Alkaline
Phosphatase Stain   each   [***]* 3984   83520   Inhibin   each   [***]* 3990  
83519   PTH-related Protein   each   [***]* 3996   84080   Alkaline Phosphatase
Isoenzymes   each   [***]* 3998   82380x2   Carotenes; alpha and beta   each  
[***]* 3999   84181   Carbohydrate-deficient Transferrin; Qualitative   each  
[***]* 4002   84181   Transferrin Genetic D Variants   each   [***]* 4004  
84181   Tau-Transferrin   each   [***]* 4005   83883   Carbohydrate-Deficient
Transferrin (CDT) Ultraquant   each   [***]* 4006   83520   Ganglioside GD1a
Autoabs   each   [***]* 4007   83883   CDT UltraQuant with reflex to Genetic D
Variants   each   [***]* 4011   83520   Ganglioside Asialo-GM1 Autoabs   each  
[***]* 4020   83520x7; 83883; 86256; 86334   Motor & Sensory Neuropathy EvaluatR
  each   [***]* 4021   83520x7; 86256; 86334   Motor & Sensory Neuropathy
Evaluation   each   [***]* 4026   83520x7; 86334   Motor Neuropathy Evaluation  
each   [***]* 4030   83520x2; 83883; 86256; 86334   Sensory Neuropathy EvaluatR
  each   [***]* 4031   83520x2; 86256; 86334   Sensory Neuropathy Evaluation  
each   [***]* 4041   83520   Ganglioside GD1b Autoabs   each   [***]* 4043  
83520   Ganglioside GQ1b Autoabs   each   [***]* 4046   83520   Sulfoglucuronyl
Paragloboside Autoabs   each   [***]* 4051   83520x2   Myelin-Assoc Glycoprot &
Sulfoglucuronyl Paragloboside Eval   each   [***]* 4056   83520x5   Ganglioside
Autoabs Evaluation   each   [***]* 4058   83520x3   Ganglioside GM1 Triple
Evaluation   each   [***]* 4061   84181   Myelin-Associated Glycoprotein (MAG)
Autoabs   each   [***]* 4070   83520   Lysosomal-associated Membrane Protein IgG
Autoantibodies   each   [***]* 4072   83520x3   Bacterial
Permeability-increasing (BPI) Protein Autoabs Eval   each   [***]* 4073   80299
  Benztropine [cogentin]   each   [***]* 4080   82175; 83655; 83825   Heavy
Metal Panel; Serum   each   [***]* 4095   84150   Prostaglandin E2 (PGE2) EIA  
each   [***]* 4100   82003   Acetaminophen   each   [***]* 4102   82055  
Alcohol; Ethyl   each   [***]*

21

--------------------------------------------------------------------------------

4103   80101   Lysergic Acid Diethylamide (LSD) Screen   each   [***]* 4108  
80100   Barbiturates   each   [***]* 4110   80101   Benzodiazepine Screen Serum
  each   [***]* 4114   80156   Carbamazepine   each   [***]* 4116   80156  
Carbamazepine; Free   each   [***]* 4118   80100   Cocaine Metabolites Screen;
Serum   each   [***]* 4120   80299   Digitoxin   each   [***]* 4122   80162  
Digoxin   each   [***]* 4124   80299   Disopyramide   each   [***]* 4125   80100
  Drugs of Abuse Screen Serum   each   [***]* 4126   80168   Ethosuximide   each
  [***]* 4128   83605   Lactic Acid Plasma   each   [***]* 4130   80176  
Lidocaine   each   [***]* 4132   80100   Cannabinoids Screen; Serum   each  
[***]* 4135   80299   Methotrexate   each   [***]* 4138   80100   Opiates
Screen; Serum   each   [***]* 4142   80184   Phenobarbital   each   [***]* 4144
  80185; 80186   Phenytoin Free & Total   each   [***]* 4146   80188   Primidone
  each   [***]* 4147   80299   Amiodarone and Metabolites   each   [***]* 4148  
80192   Procainamide + NAPA   each   [***]* 4150   80194   Quinidine   each  
[***]* 4152   80196   Salicylate   each   [***]* 4155   82365   Stone Analysis;
Kidney   each   [***]* 4156   80198   Theophylline   each   [***]* 4158   80101
  Tricyclics Screen   each   [***]* 4160   82365   Stone-A-Lyzer   each   [***]*
4162   82108; 82175; 82300; 83655; 83825   Toxic Element Analysis Whole Blood  
each   [***]* 4163   82379   Carnitine Evaluation   each   [***]* 4165   82525;
83735; 83785; 84132; 84255; 84630   Minerals Analysis RBC w/K+   each   [***]*
4168   82340; 82436; 82507; 82570; 83735; 83935; 83945; 83986; 84105; 84133;
84300; 84560   Kidney Stone Risk AssessR   each   [***]* 4174   83915  
5-Nucleotidase   each   [***]* 4195   80299   Sertraline [Zoloft]   each  
[***]* 4196   80299   Lamotrigine   each   [***]* 4200   85378   D-Dimer   each
  [***]* 4204   85362   Fibrin Monomer; Soluble   each   [***]* 4208   85362  
Fibrinolytic Degradation Product   each   [***]* 4210   85670   Thrombin Time  
each   [***]* 4212   83520   Thrombin Anti-Thrombin [TAT] Complex   each  
[***]* 4311   80158   Cyclosporine A and Metabolites Whole Blood [FPIA]   each  
[***]* 4313   80158   Cyclosporine A [HPLC]   each   [***]* 4397   83018  
Antimony   each   [***]* 4426   82705   Fecal Fat (Lipids); Qualitative   each  
[***]* 4427   82710   Fecal Fat; Quantitative   each   [***]* 4428   82710  
Fecal Fat Acid Steatocrit   each   [***]*

22

--------------------------------------------------------------------------------

4500   82232; 82300x2; 82570   Cadmium Exposure Panel—OSHA—24hr Urine   each  
[***]* 4556   83890; 83892x3; 83894x3; 83898x3; 83912   Obstetric Complications
AssessR   each   [***]* 4558   83890; 83892; 83894; 83898; 83912  
5;10-Methylenetetrahydrofolate Reductase (MTHFR) C677T Mutation   each   [***]*
4559   83890; 83892; 83894; 83898; 83912   MTHFR A1298C Mutation   each   [***]*
4560   83890; 83892x2; 83894x2; 83898x2; 83912   5;10-MTHFR C677T Mutation
Reflex to A1298C Mutation   each   [***]* 4831   82330   Calcium; Ionized   each
  [***]* 4834   83519   Voltage-Gated Calcium Channel IgG Autoabs   each  
[***]* 4836   82310   Calcium; Total   each   [***]* 4859   82525   Copper Liver
Tissue   each   [***]* 4861   83655   Lead Serum   each   [***]* 4862   82108  
Aluminum Serum   each   [***]* 4866   83735   Magnesium Serum   each   [***]*
4867   82175   Arsenic Serum   each   [***]* 4868   82300   Cadmium Serum   each
  [***]* 4870   82525   Copper Serum   each   [***]* 4871   80178   Lithium
Serum   each   [***]* 4872   83785   Manganese   each   [***]* 4873   83825  
Mercury Serum   each   [***]* 4875   84255   Selenium   each   [***]* 4877  
84630   Zinc Serum   each   [***]* 4900   80150   Amikacin   each   [***]* 4901
  80170   Gentamicin   each   [***]* 4902   80200   Tobramycin   each   [***]*
4903   80202   Vancomycin   each   [***]* 4904   80299   Fluconazole   each  
[***]* 4905   80299   Itraconazole   each   [***]* 4906   80299   Ketoconazole  
each   [***]* 4908   80299   5-Fluorocytosine   each   [***]* 4910   82491  
Mycophenolic Acid   each   [***]* 4912   80154   Alprazolam   each   [***]* 4914
  80152; 80182   Amitriptyline and Nortriptyline   each   [***]* 4915   80299  
Isoniazid   each   [***]* 4916   80154   Chlordiazepoxide [Librium]   each  
[***]* 4918   80154   Clonazepam   each   [***]* 4919   80299   Rifampin   each
  [***]* 4920   80299   Desalkylflurazepam   each   [***]* 4921   80299  
Flecainide [HPLC]   each   [***]* 4922   80160   Desipramine [Norpramin]   each
  [***]* 4924   80166; 80299   Doxepin & Nordoxepin   each   [***]* 4925   80201
  Topiramate   each   [***]* 4926   80154   Diazepam & Nordiazepam   each  
[***]* 4928   80154   Nordiazepam [Zofran]   each   [***]* 4930   80182  
Nortriptyline   each   [***]*

23

--------------------------------------------------------------------------------

4932   80160; 80174   Imipramine & Desipramine [Norpramin]   each   [***]* 4934
  80154   Oxazepam [Serax]   each   [***]* 4950   80299x2   Fluoxetine &
Norfluoxetine [Prozac]   each   [***]* 4951   80299   Nelfinavir MonitR   each  
[***]* 4952   80299   Ritonavir MonitR   each   [***]* 4953   80299   Stavudine
(d4T) MonitR   each   [***]* 4954   80299   Nevirapine MonitR   each   [***]*
4956   80299   Delavirdine MonitR   each   [***]* 4957   80299   Didanosine
(ddl) MonitR   each   [***]* 4958   80299   Zalcitabine (DDC) MonitR   each  
[***]* 4959   80299   Zidovudine (AZT) MonitR   each   [***]* 4960   80299  
Trazodone   each   [***]* 4962   80299x2   Clomipramine [Anafranil] & each  
each   [***]* 4964   80299   Clozapine Plasma   each   [***]* 4965   80299  
Indinavir MonitR   each   [***]* 4966   80299   Lamivudine (3TC) MonitR   each  
[***]* 4967   80299   Saquinavir MonitR   each   [***]* 4970   83021  
Beta-Thalassemia and Hemoglobinopathy Screen   each   [***]* 4972   83036  
Hemoglobin A1c   each   [***]* 4974   83021   Hemoglobin A2; Quantitative   each
  [***]* 4976   83021   Hemoglobin F; Quant   each   [***]* 4978   83021  
Hemoglobin S Screen   each   [***]* 4982   83020; 83021   Hemoglobin Variant
Screen   each   [***]* 4986   85660   Sickle Cell Screen   each   [***]* 4988  
83874   Myoglobin   each   [***]* 4991   82139   Amino Acid Profile Quant Plasma
  each   [***]* 4992   82131; 83918; 86256   Pernicious Anemia AssessR   each  
[***]* 4993   82139   Amino Acid Profile Quant Plasma with Interpretation   each
  [***]* 4994   82131; 83918   Megaloblastic Anemia AssessR   each   [***]* 4995
  82131x3; 83918   Megaloblastic Anemia EvaluatR   each   [***]* 5001   84550;
85810; 86038; 86431   Arthritis Evaluation #1   each   [***]* 5002   85810;
86038; 86431   Arthritis Evaluation A   each   [***]* 5003   84550; 85810; 86038
  Arthritis Evaluation #3   each   [***]* 5004   85810; 86038   Arthritis
Evaluation   each   [***]* 5011   84550; 85810; 86038; 86431; 86812  
Arthritis-Spondylitis Evaluation   each   [***]* 5012   85810; 86038; 86431;
86812   Arthritis-Spondylitis Evaluation #2   each   [***]* 5013   84550; 85810;
86038; 86812   Arthritis-Spondylitis Evaluation #3   each   [***]* 5014   85810;
86038; 86812   Arthritis-Spondylitis Evaluation #4   each   [***]* 5015   85810;
86812   Arthritis-Spondylitis Evaluation #5   each   [***]* 5021   82565; 84165;
86160x3; 86225   Lupus Renal Evaluation #1   each   [***]* 5022   82565; 84165;
86160x2; 86225   Lupus Renal Evaluation #2   each   [***]* 5023   86160x2; 86225
  Lupus Renal Evaluation B   each   [***]* 5031   86160x3; 86225   Lupus Renal
Evaluation A   each   [***]*

24

--------------------------------------------------------------------------------

5036   83520x2; 86160x3; 86225   Lupus CNS Evaluation   each   [***]* 5045  
86147x3; 86148x3; 86235   Lupus Pregnancy Monitor   each   [***]* 5050   83520;
85810; 86160; 86431; 86816x2   Rheumatoid Arthritis Prognosticator   each  
[***]* 5052   83520; 85810; 86140; 86160; 86431   Rheumatoid Arthritis
Monitor #2   each   [***]* 5053   83520; 85810; 86160   Rheumatoid Arthritis
Monitor #3   each   [***]* 5110   85025   Complete Blood Count; Platelet Count &
Differential   each   [***]* 5111   85025   Complete Blood Count & Differential
  each   [***]* 5112   85014; 85018   Hemoglobin & Hematocrit   each   [***]*
5116   85018   Hemoglobin   each   [***]* 5150   85999   Lupus Erythematosus
Cell Preparation   each   [***]* 5160   85595   Platelet Count   each   [***]*
5180   85651   Erythrocyte Sedimentation Rate   each   [***]* 5200   81003  
Urinalysis   each   [***]* 5225   89325   Sperm IgG Autoabs   each   [***]* 5250
  82270   Occult Blood (Hemoccult)   each   [***]* 5295   82947   Glucose 2 hour
Post Tolerance   each   [***]* 5297   82947   Glucose 2 hour Post Prandial  
each   [***]* 5300   82374   Bicarbonate   each   [***]* 5301   82947   Glucose
  each   [***]* 5302   82977   GGT   each   [***]* 5303   82435   Chloride  
each   [***]* 5306   84295   Sodium   each   [***]* 5308   84100   Phosphorus
Inorganic   each   [***]* 5311   84132   Potassium   each   [***]* 5313   82247;
82248   Bilirubin Fractionated   each   [***]* 5314   82040; 82310; 80048; 84100
  Renal Function Panel   each   [***]* 5315   80048   Metabolic Panel; Basic  
each   [***]* 5316   82374; 82435; 84132; 84295   Electrolyte Panel   each  
[***]* 5317   80053   Metabolic Panel; Comprehensive   each   [***]* 5318  
80076   Hepatic Function Panel   each   [***]* 5319   84520   Urea Nitrogen  
each   [***]* 5320   87206   AFB Stain   each   [***]* 5322   87102; 87205  
Fungus Culture & Stain   each   [***]* 5324   87106   Fungus Identification  
each   [***]* 5350   83890x4; 89894x3; 83898x2; 83912   bcr/abl Gene
Translocation (PCR)   each   [***]* 5362   83890; 83892x3; 83894x3; 83896x2;
83897x2; 83898; 83912   Fragile X DNA Probe Analysis [SB/PCR]   each   [***]*
5364   83890; 82892x3; 83894x3; 83896x2; 83897; 83912; 88248; 83898   Fragile X
DNA Probe Analysis with Chromosome Analysis   each   [***]*

25

--------------------------------------------------------------------------------

5368   83890; 83894; 83898; 83912   CC-CKR5 Delta 32 Mutation   each   [***]*
5369   83890; 83893x4; 83896x4; 83901; 83912   Hemochromatosis DNA GenotypR  
each   [***]* 5372   83890; 83892; 83894; 83898 83912   Prothrombin G20210A
Mutation   each   [***]* 5374   83890; 83892; 83894; 83898x3; 83912   Cytochrome
P450 2D6 EvaluatR—Poor-Metabolizers   each   [***]* 5402   88182   DNA Ploidy  
each   [***]* 5420   86849   Natural Killer Cell Function   each   [***]* 5421  
86821; 86849   Natural Killer Cell & LAK Cell Function   each   [***]* 5422  
85048; 85595; 86849; 88180   Natural Killer Cell Evaluation   each   [***]* 5635
  87147x6   Salmonella Serotyping   each   [***]* 5636   87147x4   Shigella
Serotyping   each   [***]* 5637   87147x6   Haemophilus influenzae Serotyping  
each   [***]* 5639   87045   Escherichia coli Enterohemorrhagic (0157:H7) Stool
Culture   each   [***]* 5640   87147   Escherichia coli 0157:H7 Culture
Confirmation   each   [***]* 5641   87230x3   Escherichia coli Pathogenicity
Evaluation for Diarrhea   each   [***]* 5642   87230   Escherichia coli
Enteroinvasive Toxin   each   [***]* 5643   87230   Escherichia coli
Enterotoxigenic Toxin   each   [***]* 5644   87230   Escherichia coli Verotoxin
  each   [***]* 5645   87147   Escherichia coli Enteropathogenic Toxin   each  
[***]* 5646   87190x7   Prop]   each   [***]* 5647   87190x6   Prop]   each  
[***]* 5648   87118   AFB Identification Mycobacterium ssp. by HPLC   each  
[***]* 5649   87190x6   Panel   each   [***]* 5650   87190x6   AFB Suscept M.
tuberculosis Secondary Radiometric Panel   each   [***]* 5651   87190x7   AFB
Suscept: MAI (MAC) Radiometric MIC Panel   each   [***]* 5652   87190x11   AFB
Suscept: Mycobacterium ssp. Rapid Grower Panel   each   [***]* 5653   87190x21  
AFB Suscept: Mycobaceterium ssp. Panel   each   [***]* 5656   87190x21   AFB
Suscept: MAI (MAC) Synergy Study (Drug Combination)   each   [***]* 5657  
87190x11   AFB Suscept M. tuberculosis Comprehensive Panel [Agar Prop]   each  
[***]* 5659   87190x10   AFB Suscept: MAI (MAC) Comprehensive Panel [Agar Prop]
  each   [***]* 5660   87192x5   Fungus Susceptibility: MIC Panel   each  
[***]* 5665   87184x2   urine   each   [***]* 5666   87184x2   Aerobic Suscept:
Gram Positive Panel Urine/Non-urine   each   [***]* 5667   87184   urine   each
  [***]* 5677   87194   Antimicrobial Serum Inhibitory-Cidal Level   each  
[***]* 5680   87999   Viral Susceptibility: Acyclovir   each   [***]*

26

--------------------------------------------------------------------------------

5681   80299   Viral Susceptibility: Foscarnet   each   [***]* 5682   80299  
Viral Susceptibility: Ganciclovir   each   [***]* 5683   80299   Viral
Susceptibility: Penciclovir   each   [***]* 5685   87186   Aerobic Suscept: Gram
Negative MIC Panel Urine/Non-urine   each   [***]* 5686   87186   Aerobic
Suscept: Gram Positive MIC Panel Urine/Non-urine   each   [***]* 5687   87186  
Aerobic Suscept: Gram Neg Resist MIC Panel Urine/Non-Urine   each   [***]* 5690
  87106   Fungus Identification; Exoantigen   each   [***]* 5695   87449  
Entamoeba histolytica Ag Detection   each   [***]* 5697   87420   Respiratory
Synctial Virgus Ag Detection [EIA]   each   [***]* 5700   87045   Aerobic
Bacterial Culture: Stool Comprehensive   each   [***]* 5702   87070   Yersinia
Culture   each   [***]* 5704   87045   Campylobacter Culture   each   [***]*
5708   87075x2   Anaerobic Bacterial Culture   each   [***]* 5709   87076  
Anaerobic Bacterial Identification   each   [***]* 5711   87186   Anaerobic
Bacterial MIC Susceptibility   each   [***]* 5712   87186   Aerobic Suscept:
Streptococcus pneumoniae MIC panel   each   [***]* 5713   87186   Aerobic
Suscept: Haemophilus influenzae MIC Panel   each   [***]* 5714   87186   Aerobic
Suscept:Aminoglycoside MIC; High Level   each   [***]* 5720   87207  
Microsporidia Spore Stain   each   [***]* 5723   87252x3; 87390x3   HIV-1
Anti-Viral Drug Study: Phenotypic Resistence   each   [***]* 5725   87252  
HIV-1 Culture; Qualitative   each   [***]* 5727   87252   HIV-1 Culture;
Quantitative   each   [***]* 5729   87252   HIV-1 Culture; Quantitative; Plasma
  each   [***]* 5732   87536   HIV-1 Proviral DNA Accuquant   each   [***]* 5742
  88230; 88262; 88271; 88273; 88291   Chromosome Analysis: KAL Gene Deletion by
FISH   each   [***]* 5771   87070x2; 87205   Aerobic Bacterial Culture; Routine
Miscellaneous   each   [***]* 5772   87060x2   Aerobic Bacterial Culture: Throat
  each   [***]* 5773   87086x2   Aerobic Bacterial Culture: Urine   each  
[***]* 5774   87070x2   Aerobic Bacterial Culture: Blood   each   [***]* 5775  
87070x2; 87205   Aerobic Bacterial Culture; Respiratory   each   [***]* 5776  
87070x2   Aerobic Bacterial Culture; Genital   each   [***]* 5777   87081  
Streptococcus; Beta Group A Culture Screen   each   [***]* 5778   87070  
Gardnerella vaginalis & Grp B Streptococcus Culture Screen   each   [***]* 5779
  87102   Fungus Culture: Yeast Screen   each   [***]* 5800   88237; 88264;
88291   Chromosome Analysis: Hematological Disorders I   each   [***]* 5801  
87070x2; 87205   Aerobic Bacterial Culture: Eye/Ear   each   [***]* 5802  
87020x2   Aerobic Bacterial Culture: Environmental   each   [***]*

27

--------------------------------------------------------------------------------

5806   88230; 88233; 88237; 88263; 88291   Chromosome Analysis: Mosaicism   each
  [***]* 5808   88237; 88271; 88275; 88291   Chromosome Analysis; Trisomy 8 by
FISH   each   [***]* 5810   83890; 83892; 83894; 83898x2; 83912; 88237; 88264  
Chromosome Analysis: Hematological Disorders II   each   [***]* 5812   88237;
88271; 88275; 88291   Chromosome Analysis: Trisomy 12 by FISH   each   [***]*
5814   88230; 88262; 88291   Chromosome Analysis: Cogenital Disorders; Blood  
each   [***]* 5818   88233; 88262; 88291   Chromosome Analysis: Products of
Conception/Skin Biopsies   each   [***]* 5822   88235; 88267; 88280; 88291  
Chromosome Analysis: Amniotic Fluid   each   [***]* 5830   88230; 88262; 88271;
88273; 88291   Chromosome Analysis: FISH for Genetic Diseases   each   [***]*
5832   88230; 88262; 88271; 88273; 88291   Chromosome & FISH for Genetic
Disorders Evaluation   each   [***]* 5834   88237; 88271; 88275; 88291  
Chromosome Analysis: bcr/abl Gene Rearrangement by FISH   each   [***]* 5836  
88342   Chromosome Analysis: HER-2/neu Gene Amplification   each   [***]* 5838  
88237; 88271x2; 88275; 88291   Chromosome Analysis: X and Y Probe for Opposite
Sex Bone Marrow Transplant   each   [***]* 5840   88237; 88271; 88275  
Chromosome Analysis: Acute Promyelo Leukemia   each   [***]* 5842   88342x2  
Her-2/neu [IHC] and Gene Amplification [FISH]   each   [***]* 5844   88230;
88262; 88271; 88273; 88291   Chromosome Analysis: STS Gene Detection   each  
[***]* 5846   88342   Her-2/neu [IHC] reflex to Gene Amplification [FISH]   each
  [***]* 5900   85335   Activated Protein C Resistance   each   [***]* 5902  
86162x2   Complement Deficiency Detector Evaluation   each   [***]* 5910   83520
  OKT3 (Anti-) IgG Abs   each   [***]* 5912   83520   OKT3 Ab Quantitation  
each   [***]* 5914   83519   Human Anti-Mouse Abs [for Cytogen use only]   each
  [***]* 5915   83519   Human Anti-Mouse Abs   each   [***]* 5916   83520x2;
86038; 86256; 86376x3; 87522   Autoimmune Hepatits EvaluatR PLUS   each   [***]*
5917   83520   Cytokeratin Autoabs   each   [***]* 5918   83520x2; 86376x3  
Autoimmune Hepatitis EvaluatR   each   [***]* 5920   83520   F-actin IgG Autabs
  each   [***]* 5922   86376   Liver Cytosol Autoabs   each   [***]* 5923  
86376   Liver-Specific Membrane Lipoprotein Autabs   each   [***]* 5926   83789
  S-Adenosyl-Methionine [Sam(E)] AssessR   each   [***]* 5932   85302   Protein
C Ag   each   [***]* 5933   85302; 85303   Protein C Evaluation 1   each  
[***]* 5935   85306   Protein S Antigen; Free   each   [***]*

28

--------------------------------------------------------------------------------

5937   85305   Protein S Antigen; Total   each   [***]* 5938   85305; 85306  
Protein S Evaluation 1   each   [***]* 5939   83520   Prothrombin Fragment 1.2  
each   [***]* 5940   85576x4   Platelet Autoabs; Drug-induced including Heparin
  each   [***]* 5941   83520   Beta-Thromboglobulin   each   [***]* 5942   83520
  Platelet Factor 4   each   [***]* 5943   85130   Heparin Antifactor Xa   each
  [***]* 5945   83520   Heparin-Induced Thrombocytopenia (HIT Assay)   each  
[***]* 5948   80197   Tacrolimus   each   [***]* 5951   85300   Antithrombin III
Functional   each   [***]* 5952   85300; 85301   Antithrombin III Evaluation  
each   [***]* 5955   86022   Platelet Glycoprotein Ib/IX Total Autoantibodies  
each   [***]* 5956   86022   Platelet Glycoprotein IIb/IIIa Total Autoantibodies
  each   [***]* 5957   86022   Platelet Glycoprotein Ia/IIa Total Autoantibodies
  each   [***]* 5958   86022x3   Platelet Glycoprotein Autoantibody AssessR  
each   [***]* 5960   85240; 85245; 85246; 85730   von Willebrand Profile with
reflex to Multimers   each   [***]* 5961   85240; 85245; 85246; 85730   von
Willebrand Profile   each   [***]* 5962   85597; 85610; 85611x2; 85613; 85670;
85730; 85732x2   Lupus Anticoagulant Screen 3   each   [***]* 5963   85613;
85730; 85732x2; 86147x3   Lupus Anticoagulant Screen 1   each   [***]* 5964  
85240; 85246   Hemophilia A Carrier Screen   each   [***]* 5965   85300; 85303;
85306   Hereditary Thrombosis Screen A; No Heparin or Coumadin   each   [***]*
5966   83520; 85300; 85302; 85305; 85306   Hereditary Thrombosis Screen B;
Patients on Coumadin   each   [***]* 5967   83520; 85576x5   Platelet Function
Evaluation   each   [***]* 5968   85305; 85306x2; 86329   Protein S Evaluation 3
  each   [***]* 5969   83520; 85250   Hemophilia B Carrier Screen   each  
[***]* 5971   82131; 85300; 85303; 85306; 85335; 85384   Thrombotic Risk
Evaluation 2   each   [***]* 5972   85300; 85303; 85306; 85335   Thrombotic Risk
Evaluation 1   each   [***]* 5973   82131; 82172; 85300; 85301; 85302; 85303;
85305; 85306x2; 85335; 85384; 85410; 85415; 85420   Thrombotic Risk Evaluation 3
  each   [***]* 5975   82131   Venous Thromboembolism (VTE) AssessR   each  
[***]* 5976   85597; 85610; 85613; 85670; 85730; 86147x3   Lupus Anticoagulant:
Screen 2   each   [***]* 5977   85362; 85378; 85410; 85415; 85420x2  
Fibrinolysis Evaluation   each   [***]*

29

--------------------------------------------------------------------------------

5978   83520; 85378   Thrombotic Markers Evaluation   each   [***]* 5980  
85300; 85362; 85378; 85610; 85730   Disseminated Intravascular Coagulopathy
Evaluation   each   [***]* 5981   85240; 85245; 85246; 85247   von Willebrand
Evaluation with Multimers   each   [***]* 5983   85210; 85220; 85230; 85240;
85250; 85260; 85270; 85280; 85384; 85610; 85611x2 85613; 85730; 85732x2   Factor
Deficiency Detector   each   [***]* 5984   85240; 85245; 85246   von Willebrand
Evaluation without Multimers   each   [***]* 5985   83520   Thrombus Precursor
Prot   each   [***]* 5988   83520; 85302; 85303   Protein C Evaluation 2   each
  [***]* 5989   83520; 85302   Protein C Evaluation 3   each   [***]* 5990  
82131; 82172; 85384   Thrombotic Risk AssessR   each   [***]* 5991   82172;
85246; 85384; 85420   Cadiovascular Thrombotic Risk AssessR   each   [***]* 5992
  85303; 85306   Protein C&S Activity   each   [***]* 5993   83520; 85305; 85306
  Protein S Evaluation 2   each   [***]* 5994   83520; 85305   Protein S
Evaluation 4   each   [***]* 5995   86022x6; 86023x3   Platelet Autoantibodies;
Comprehensive   each   [***]* 5996   85292   Prekallikrein [PKK]   each   [***]*
5998   85130   Heparin Co-factor II [HCII]   each   [***]* 7221   86606x3;
86612; 86635x3; 86698x3   Fungal IgG & IgM Abs [EIA]   each   [***]* 7224  
86606; 86612; 86635; 86698   Fungal IgG Abs   each   [***]* 7437   87491  
Chlamydia trachomatis DNA LCR   each   [***]* 7439   87491; 87591   Ur-Sure
Chlamydia trachomatis/Neisseria gonorrhoeae by LCR   each   [***]* 7441   83520
  Pyruvate Dehydrogenase IgG Autoabs   each   [***]* 7447   82523; 82570; 83937
  Osteoporosis Monitor   each   [***]* 7452   82523x2; 82570; 83937; 84075  
Osteoporosis EvaluatR   each   [***]* 7458   86677   Helicobacter pylori
Cytotoxin A IgG Abs   each   [***]* 7460   86677x4   Helicobacter pylori IgG;
IgM & IgA Abs and Cytotoxin A IgG   each   [***]* 7470   87556   Mycobacterium
Tuberculosis GenotypR   each   [***]* 7472   87522   Hepatitis C Virus RNA
Quantitation by Branched DNA   each   [***]* 7473   83891x3; 83898x2; 83904;
83912   Hepatitis C Virus SubtypR   each   [***]* 7475   87556   Mycobacterium
Tuberculosis DNA PCR   each   [***]* 7476   87522   Hepatitis C Virus RNA
AccuQuant reflex GenotypR   each   [***]* 7477   83891x14; 83898x4; 83904x6;
83912   HIV-1 GenotypR (Reverse Transcriptase Inhibitor)   each   [***]* 7478  
87536   HIV-1 RNA UltraQuant reflx to HIV GenotypR (RTI)   each   [***]*

30

--------------------------------------------------------------------------------

7479   83891x4; 83898x2; 83904x2; 83912   HIV-1 GenotypR (Protease Inhibitor)  
each   [***]* 7480   83891x13; 83898x5; 83904x8; 83912   HIV-1 GenotypR PLUS
(Rev Trans & Prot Inhib)   each   [***]* 7481   86677   Helicobacter pylori
Total Abs   each   [***]* 7482   87536   HIV-1 RNA UltraQuant reflx to HIV
GenotypR PLUS (RTI&PI)   each   [***]* 7483   87536   HIV-1 RNA UltraQuant reflx
to HIV GenotypR (PI)   each   [***]* 7486   87522   Hepatitis C Virus RNA
AccuQuant   each   [***]* 7491   86804   Hepatitis C Virus RIBA Evaluation +
reflex PCR   each   [***]* 7494   87532   Herpesvirus-6 Human DNA DetectR   each
  [***]* 7496   86790x2   Hantavirus Puumala IgG & IgM Abs   each   [***]* 7501
  86790x2   Hantavirus Hantaan IgG & IgM Abs   each   [***]* 7506   86790x4  
Hantavirus Hantaan & Puumala IgG & IgM Abs   each   [***]* 7507   86790x2  
Hantavirus Hantaan & Puumala IgG Abs   each   [***]* 7508   86790x2   Hantavirus
Hantaan & Puumala IgM Abs   each   [***]* 7511   87472   Bartonella quintana DNA
DetectR   each   [***]* 7514   87798   Hepatitis Delta Virus RNA DetectR   each
  [***]* 7516   87521   Hepatitis C Virus RNA DetectR   each   [***]* 7518  
87522   Hepatitis C Virus RNA Detector with reflex Quant   each   [***]* 7521  
87798   Toxoplasma DNA DetectR   each   [***]* 7522   86812   Respiratory
Synctyial Virus RNA DetectR   each   [***]* 7526   87328  
Giardia/Cryptosporidium Ag Detection [EIA]   each   [***]* 7531   86021; 86038;
86812   Primary Sclerosing Cholangitis Evaluation   each   [***]* 7536   87301;
87324; 87328x2; 87425   Infectious Gastroenteritis Evaluation   each   [***]*
7546   86720   Leptospira IgG Abs   each   [***]* 7551   86720   Leptospira IgM
Abs   each   [***]* 7555   82040; 82784x2; 83883; 86781x2   Treponema pallidum
IgG Antibody Index   each   [***]* 7560   86781   Treponema pallidum IgG
Antibodies; FTA-ABS Quantitative   each   [***]* 7561   86781   Treponema
pallidum IgG Abs   each   [***]* 7565   86781x2   Treponema pallidum IgG & IgM
Abs   each   [***]* 7565   86781   Treponema pallidum IgG Abs   each   [***]*
7566   86781   Treponema pallidum IgM Abs   each   [***]* 7570   87476  
Borrelia burgordorferi DNA DetectR   each   [***]* 7573   87798   Tropheryma
Whippelii DNA DetectR   each   [***]* 7574   83891x3; 83898x2; 83904; 83912  
Cytomegalovirus GenotypR   each   [***]* 7575   87496   Cytomegalovirus DNA
Detector   each   [***]* 7576   87522   Hepatitis C Virus RNA UltraQuant   each
  [***]* 7578   87522   Hepatitis C Virus RNA UltraQuant reflex to HCV Genotyper
  each   [***]* 7581   87529x2   Herpes Simplex Virus DNA DetectR   each  
[***]* 7583   87798   Epstein-Barr Virus DNA Detector   each   [***]* 7584  
87799   Epstein-Barr Virus DNA UltraQuant   each   [***]*

31

--------------------------------------------------------------------------------

7585   87798   Varicella-zoster Virus DNA DetectR   each   [***]* 7587   87798  
Histoplasma DNA DetectR   each   [***]* 7589   87798   Advenovirus DNA DetectR  
each   [***]* 7596   86790   Japanese Encephalitis Virus Total Abs   each  
[***]* 7598   83891x2; 83898; 83904; 83912; 87798   Aseptic
Meningitis/Encephalitis DetectR   each   [***]* 7601   86790   Dengue Virus
Total Abs   each   [***]* 7602   83891x2; 83898; 83904; 83912;   Dengue Virus
RNA DetectR/Speciaton Types 1-4   each   [***]* 7621   86720x2   Leptospira IgG
& IgM Abs   each   [***]* 7626   86720x2; 87070; 87166   Leptospirosis
Evaluation   each   [***]* 7631   86768x3   Salmonella IgG; IgM & IgA Abs   each
  [***]* 7646   86790   Dengue Virgus IgM Abs   each   [***]* 7661   86778  
Toxoplasma IgM Abs [SAGA]   each   [***]* 7666   86777   Toxoplasma IgA Abs  
eac   [***]* 7670   87230; 87324   Clostridium difficile Toxin Evaluation   each
  [***]* 7672   87075; 87230; 87324   Clostridium difficile Culture & Toxin
Evaluation   each   [***]* 7675   86778   Toxoplasma IgM Abs [MAC EIA]   each  
[***]* 7685   82040; 82784x2; 83883; 86723x2   Listeria monocytogenes IgG
Antibodiy Index   each   [***]* 7691   87324   Clostridium difficile Toxin A
Detection   each   [***]* 7695   82040; 82784x2; 83883; 86622x2   Brucella
abortus IgG Antibody Index   each   [***]* 7700   82040; 82784x2; 83883; 86603x3
  Advenovirus IgG Antibody Index   each   [***]* 7705   82040; 82784x2; 83883;
86698x2   Histoplasma IgG Antibody Index   each   [***]* 7711   86617x2  
Borrelia burgdorferi IgG & IgM Abs [IB]   each   [***]* 7716   86617x2; 86618x2
  Borrelia burgdorferi IgG & IgM Abs with IB   each   [***]* 7726   86674  
Giardia lamblia IgG Abs   each   [***]* 7736   86677   Helicobacter pylori IgM
Abs   each   [***]* 7741   86677x3   Helicobacter pylori IgG; IgM & IgA Abs  
each   [***]* 7742   86677x3; 87338   Helicobacter pylori EvaluateR   each  
[***]* 7744   86677x3; 87081   Helicobacter pylori Evaluation   each   [***]*
7745   87299   Pneumocystis carinii Ag Detection   each   [***]* 7751   86674x3
  Giardia lamblia IgG; IgM & IgA Abs   each   [***]* 7756   86705; 86709; 87340
  Hepatitis A & B Virus Acute Evaluation   each   [***]* 7757   80074  
Hepatitis Acute Profile   each   [***]* 7758   86704; 86706; 86708; 86803; 87340
  Hepatitis A; B & C Virus Post Exposure Panel   each   [***]* 7760   87328  
Giardia Lamblia Ag Detection   each   [***]* 7761   86677   Helicobacter pylori
IgG Abs   each   [***]* 7762   86674x3; 87328   Giardiasis Evaluation   each  
[***]* 7770   82040; 82784x2; 83883; 86762x2   Rubella IgG Antibody Index   each
  [***]* 7774   82040; 82784x2; 83883; 86790x2   Herpesvirus-6 Human IgG
Antibody Index   each   [***]* 7775   86790   Herpesvirus 7 Human IgG Abs   each
  [***]* 7776   86790x2   Herpesvirus-6 Human Early Ag IgG & IgM Abs   each  
[***]*

32

--------------------------------------------------------------------------------

7777   86790x2   Herpesvirus-7 Human IgG & IgM Abs   each   [***]* 7778   86790
  Herpesvirus-7 Human IgM Abs   each   [***]* 7780   86689   HTLV-I / II Abs
Confirmation   each   [***]* 7784   86790   Herpesvirus-8; Human Antibodies  
each   [***]* 7785   87798   Herpesvirus-8; Human DNA DetectR   each   [***]*
7786   86790   Herpesvirus-6 Human Early Ag IgG Abs   each   [***]* 7796   86790
  Herpesvirus-6 Human Early Ag IgM Abs   each   [***]* 7800   82040; 82784x2;
83883; 86651x2; 86652x2; 86653x2; 86654x2   Arbovirus IgM Antibody Index   each
  [***]* 7810   82040; 82784x2; 83883; 86653x2   St. Louis Encephalitis IgM
Antibody Index   each   [***]* 7820   82040; 82784x2; 83883; 86651x2  
California-La Crosse Encephalitis IgM Antibody Index   each   [***]* 7830  
82040; 82784x2; 83883; 86654x2   Western Equine Encephalitis IgM Antibody Index
  each   [***]* 7840   82040; 82784x2; 83883; 86652x2   Eastern Equine
Encephalitis IgM Antibody Index   each   [***]* 7844   86609x2   Ehrlichia equi
IgG & IgM (HGE) Abs   each   [***]* 7846   86609x2; 86618x2   Ehrlichiosis
(Granulocytic) & Lyme Disease Evaluation   each   [***]* 7848   86609x4  
Ehrlichia chaffeensis (HME) & E. equi (HGE) IgG & IgM Abs Ev   each   [***]*
7851   86609x2   Ehrlichia chaffeensis (HME) IgG & IgM Abs;   each   [***]* 7856
  86759   Rotavirus Abs   each   [***]* 7871   86609x2   Rickettsia ricketsii &
R typhi IgG Abs Evaluation   each   [***]* 7876   86609x4   Rickettsia ricketsii
& R. typhi IgG & IgM Abs Eval   each   [***]* 7881   86609x2   Rickettsia
ricketsii & R. typhi IgM Abs Evaluation   each   [***]* 7886   86609  
Rickettsia ricketsii IgG Abs   each   [***]* 7891   86609   Rickettsia ricketsii
IgM Abs   each   [***]* 7896   86609x2   Rickettsia ricketsii IgG & IgM Abs  
each   [***]* 7901   86609   Rickettsia typhi IgG Abs   each   [***]* 7906  
86609   Rickettsia typhi IgM Abs   each   [***]* 7911   86609x2   Rickettsia
typhi IgG & IgM Abs   each   [***]* 7951   86609x2   Rickettsia conorii IgG &
IgM Abs   each   [***]* 7960   82040; 82784x4; 83883; 86618x4; 87476  
Neuroborreliosis AccuDx   each   [***]* 7965   82040; 82784x4 83883; 86618x4  
Neuroborreliosis Evaluation   each   [***]* 7970   82040; 82784x4; 83883;
86618x4   Borrelia burgdorferi IgG & IgM Antibody Index   each   [***]* 7975  
82040; 82784x2; 83883; 86618x2   Borrelia burgdorferi IgM Antibody Index   each
  [***]* 7980   82040; 82784x2; 83883; 86787x2   Varicella-zoster Virus IgG
Antibody Index   each   [***]* 7986   86677   Helicobacter pylori IgA Abs   each
  [***]* 8006   86631x4; 86632x3   Chlamydia spp. Abs Evaluation   each   [***]*

33

--------------------------------------------------------------------------------

8011   86632x4   Chlamydia spp IgM Abs   each   [***]* 8016   86631x4  
Chlamydia spp. Total Abs [MICRO-IF]   each   [***]* 8021   86632   Chlamydia
psittaci IgM Abs   each   [***]* 8026   86631   Chlamydia psittaci Total Abs  
each   [***]* 8031   86631; 86632   Chlamydia psittaci Total & IgM Abs   each  
[***]* 8036   86631x3; 86632x3   Chlamydia trachomatis Total & IgM Abs   each  
[***]* 8041   86631x3   Chlamydia trachomatis Total Abs   each   [***]* 8046  
86632x3   Chlamydia tracomatis IgM Abs [MICRO-IF]   each   [***]* 8051   86694;
86695x3   Herpes Simplex Virus Types 1 & 2 IgG & IgM Abs   each   [***]* 8056  
86603   Advenovirus IgG Abs   each   [***]* 8061   86631x4; 86632x4  
Lymphogranuloma Venereum Abs Panel   each   [***]* 8066   86631x4; 86632x4  
Chlamydia spp. Total & IgM Abs   each   [***]* 8071   86631; 86632   Chlamydia
pneumoniae Total & IgM Abs   each   [***]* 8076   86631   Chlamydia pneumoniae
Total Abs   each   [***]* 8081   86632   Chlamydia pneumoniae IgM Abs   each  
[***]* 8091   86658x3   Polovirus Abs   eacg   [***]* 8126   86609   Rickettsia
tsutsugamushi IgG Abs   each   [***]* 8131   87380   Hepatitis Delta Virus Ag  
each   [***]* 8137   87517   Hepatitis B Virus DNA UltraQuant   each   [***]*
8141   87516   Hepatitis B Virus DNA Detector   each   [***]* 8143   87517  
Hepatitis B Virus DNA Quantitation by Branched DNA   each   [***]* 8145   87798
  JC Virus DNA DetectR   each   [***]* 8147   87799   JC Virus Ultraquant   each
  [***]* 8151   86744   Nocardia IgG Abs   each   [***]* 8156   83520x9; 86005;
86331x6; 86606   Hypersensitivity Pneumonitis Evaluation   each   [***]* 8157  
86331x5; 86606   Hypersensitivity Evaluation II   each   [***]* 8158   86331  
Pigeon Serum Antibodies   each   [***]* 8166   86668   Francisella tularensis
Total Abs [Agglutinins]   each   [***]* 8171   86668x3   Francisella tularensis
IgG; IgM & IgA Abs   each   [***]* 8176   86651   California-La Crosse
Encephalitis IgM Abs   each   [***]* 8181   86652   Eastern Equine Encephalitis
IgM Abs   each   [***]* 8186   86653   St. Louis Encephalitis IgM Abs   each  
[***]* 8191   86654   Western Equine Encephalitis IgM Abs   each   [***]* 8221  
86747x2   Parvovirus B19 IgG & IgM Abs [EIA]   each   [***]* 8226   86651;
86652; 86653; 86654   Arbovirus IgM Abs [IFA]   each   [***]* 8236   86747x2  
Parvovirus B19 IgG & IgM Abs [IB]   each   [***]* 8241   86609x2   Abs   each  
[***]* 8246   86713   6   each   [***]* 8251   86723   Listeria monocytogenes
IgG Abs   each   [***]* 8260   83891; 83896x2; 83898x2; 83912   Parvovirus B19
DNA UltraQuant   each   [***]* 8261   86747x2; 87798   Parvovirus B19 Evaluation
  each   [***]* 8266   87798   Parvovirus B19 DNA DetectR   each   [***]* 8286  
86671x3   Sporothrix IgG; IgM & IgA Abs   each   [***]* 8311   86698x3  
Histoplasma IgG; IgM & IgA Abs   each   [***]* 8312   86698   Histoplasma IgG
Abs   each   [***]* 8313   86698   Histoplasma IgM Antibodies   each   [***]*

34

--------------------------------------------------------------------------------

8316   86635   Coccidioides IgM Abs   each   [***]* 8321   86635   Coccidioides
IgM Abs   each   [***]* 8326   86682   Schistosoma IgG Abs   each   [***]* 8331
  86635x3   Coccidioides IgG IgM & IgA Abs   eacg   [***]* 8336   86003; 86682x2
  Schistosoma IgG; IgM & IgE Abs   each   [***]* 8340   82040; 82784x2; 83883;
86612x2   Blastomyces IgG Antibody Index   each   [***]* 8346   86612  
Blastomyces IgG Abs   each   [***]* 8351   86682x2   Schistosoma IgG and IgM Abs
  each   [***]* 8370   87798x2   Malaria DNA DetectR   each   [***]* 8371  
86750x2   Malaria IgG & IgM Abs   each   [***]* 8386   82784; 82787; 86003;
86682x2   Schistosoma Abs Evaluation   each   [***]* 8421   86682   Fasciola IgG
Abs [EIA]   each   [***]* 8426   86682x2   Fasciola IgG & IgM Abs   each  
[***]* 8441   86753x3   Entamoeba histolytica IgG; IgM & IgA Abs   each   [***]*
8451   86682   Echinococcus IgG Abs   each   [***]* 8456   86003; 86682x2  
Echinococcus IgG; IgM & IgE Abs   each   [***]* 8476   86682x6; 86784x2   Fever
of Unknown Origin Antibody Panel   each   [***]* 8516   86710x6   Influenza
Virus A & B IgG; IgM & IgA Abs   each   [***]* 8521   86710x6; 87276; 87299  
Influenza Evaluation   each   [***]* 8560   82040; 82784x2; 83883; 86644x2  
Cytomegalovirus IgG Antibody Index   each   [***]* 8562   82040; 82784x2; 83883;
86644x2; 87496   Cytomegalovirus CNS Infection AccuDx   each   [***]* 8566  
86682   Strongyloides IgG Abs   each   [***]* 8576   86771x4   Shigella Abs  
each   [***]* 8581   86771   Shigella IgG Abs   each   [***]* 8600   82040;
82784x2; 83883; 86765x3   Measles IgG Antibody Index   each   [***]* 8636  
86790   Colorado Tick Fever Total Abs   each   [***]* 8660   82040; 82784x2;
83883; 86738x2   Mycroplasma pnemoniae IgG Antibody Index   each   [***]* 8666  
86658x10; 86710x2   Myopericarditis Viral Antibodies Evaluation   each   [***]*
8676   86793   Yersinia enterocolitica Abs Serotype 0:3   each   [***]* 8681  
86793   Yersinia enterocolitica Abs Serotype 0:8   each   [***]* 8686   86793  
Yersinia enterocolitica Abs Serotype 0:9   each   [***]* 8691   86756x2  
Respiratory Syncytial Virus IgG & IgM Abs   each   [***]* 8696   86793x3  
Yersinia enterocolitica Abs Serotypes 0:3; 0:8; 0:9   each   [***]* 8711   86793
  Yersinia pseudotuberculosis Total Abs   each   [***]* 8721   86793   Yersinia
enterocolitica IgA Abs   each   [***]* 8731   86738   Mycoplasma pneumoniae IgA
Abs   each   [***]* 8736   86738x3   Mycoplasma pneumoniae IgG; IgM & IgA Abs
SeroDx   each   [***]* 8741   86738x2   Mycoplasma pneumoniae IgG & IgM Abs  
each   [***]* 8746   86738   Mycoplasma pneumoniae IgG Abs   each   [***]* 8751
  86738   Mycoplasma pneumoniae IgM Abs   each   [***]* 8756   86787x2  
Varicella-zoster Virus SeroDx; IgG & IgM Abs   each   [***]*

35

--------------------------------------------------------------------------------

8760   83891x2; 83898x2; 83912   Varicella-Zoster Virus DNA Ultraquant   each  
[***]* 8761   86787   Varicella-zoster Virus IgG Abs   each   [***]* 8766  
86787   Varicella-zoster Virus IgM Abs   each   [***]* 8771   86765x2   Measles
IgG & IgM Abs   each   [***]* 8776   86765   Measles IgG Abs   each   [***]*
8781   86765   Measles IgM Abs   each   [***]* 8831   86622x3   Brucella abortus
IgG; IgM & IgA Abs   each   [***]* 8836   86622   Brucella abortus IgG Abs  
each   [***]* 8841   86723   Listeria monocytogenes Abs   each   [***]* 8851  
86317x2   Bartonella henselae IgG & IgM Abs   each   [***]* 8855   82040;
82784x4; 83883; 86317x4   Bartonella henselae IgG & IgM Antibody Index   each  
[***]* 8857   82040; 82784x4; 83883; 86317x4; 87472   Bartonella henselae CNS
Infection Evaluation   each   [***]* 8861   87471   Bartonella henselae & B.
quintana DNA DetectR   each   [***]* 8863   86317x4   SeroDx   each   [***]*
8864   86317x2   Bartonella quintana IgG & IgM Abs   each   [***]* 8866   86625
  Campylobacter jejuni Total Abs [EIA]   each   [***]* 8881   86625  
Campylobacter fetus Total Abs   each   [***]* 8886   86625   Campylobacter
jejuni Total Abs [CF]   each   [***]* 8921   86653   St. Louis encephalitis
Total Abs   each   [***]* 8926   86651   California-La Crosse Encephalitis Total
Abs   each   [***]* 8931   86654   Western Equine Encephalitis Total Abs   each
  [***]* 8936   86652   Eastern Equine Encephalitis Total Abs   each   [***]*
8941   86618x2   Borrelia burgdorferi IgG & IgM Abs [EIA]   each   [***]* 8942  
86618x2   bands   each   [***]* 8945   82040; 82784x2; 83883; 86618x2   Borrelia
burgdorferi IgG Antibody Index   each   [***]* 8951   86618   Borrelia
burgdorferi IgG Abs   each   [***]* 8961   86618   Borrelia burgdorferi IgM Abs
  each   [***]* 8968   86609x2; 86618; 86753   Lyme Co-infection Panel   each  
[***]* 8970   82040; 82784x2; 83883; 86777x2   Toxoplasma IgG Antibody Index  
each   [***]* 8972   82040; 82784x2; 83883; 86777x2; 87798   Toxoplasma
Encephalitis AccuDx   each   [***]* 8981   86665   Epstein-Barr Virus Viral
Capsid Ag (VCA) IgA Abs   each   [***]* 9014   87186   Aerobic Suscept:
Nocardia/Streptomyces MIC Panel   each   [***]* 9015   87186; 87187   Aerobic
Suscept: Nocardia/Streptomyces MIC & MBC Panel   each   [***]* 9022   86781  
Treponema pallidum Abs; TP-PA   each   [***]* 9026   86157   Cold Agglutinins  
each   [***]* 9076   86768x4   WIDAL Evaluation; Salmonella spp. Abs   each  
[***]* 9095   86308   Heterophile Agglutination   each   [***]* 9099   86641  
Cryptococcus Abs   each   [***]* 9101   86000x3; 86622; 86668; 86768x4   Febrile
Agglutinins   each   [***]* 9121   86000x3   Weil-Felix Test   each   [***]*

36

--------------------------------------------------------------------------------

9151   86671   Sporothrix Abs   each   [***]* 9166   86635   Coccidioides Total
Abs[LPA]   each   [***]* 9189   87449   Cryptococcus Ag   each   [***]* 9190  
87449   Candida Ag Detection   each   [***]* 9301   86682x2   Filaria IgG & IgM
Abs   each   [***]* 9316   86753   Trypanosoma cruzi IgG Abs   each   [***]*
9326   86619   Borrelia hermsii IgG Abs   each   [***]* 9331   86619   Borrelia
hermsii IgM Abs   each   [***]* 9371   86638x2   Coxiella burnetii IgG Abs;
Phase 1 & 2   each   [***]* 9376   86638x2   Coxiella burnetii IgM Abs; Phase 1
& 2   each   [***]* 9381   86638x6   Coxiella burnetii IgG; IgM; & IgA Abs;
Phase 1 & 2   each   [***]* 9386   86784   Trichinella IgG Abs   each   [***]*
9391   86631   Chlamydia trachomatis IgA Abs   each   [***]* 9396   86619x2  
Borrelia hermsii IgG & IgM Abs   each   [***]* 9401   86631x2; 86632   Chlamydia
trachomatis IgG; IgM & IgA Abs   each   [***]* 9406   86631   Chlamydia
trachomatis IgG Abs [EIA]   each   [***]* 9411   86632   Chlamydia trachomatis
IgM Abs [EIA]   each   [***]* 9416   86762   Rubella IgG Abs   each   [***]*
9421   86762x2   Rubella IgG & IgM Abs   each   [***]* 9426   86777   Toxoplasma
IgG Abs   each   [***]* 9430   87497   Cytomegalovirus DNA UltraQuant   each  
[***]* 9431   86644   Cytomegalovirus IgG Abs   each   [***]* 9436   86644;
86645   Cytomegalovirus IgG & IgM Abs   each   [***]* 9437   86631   Chlamydia
pneumoniae Abs UltraQuant   each   [***]* 9446   86695x2   Herpes Simplex Virus
Types 1 & 2 IgG Abs   each   [***]* 9451   86695   Herpes Simplex Virus Type 1
IgG Abs   each   [***]* 9456   86695   Herpes Simplex Virus Type 1 IgM Abs  
each   [***]* 9461   86695   Herpes Simplex Virus Type 2 IgG Abs   each   [***]*
9466   86694   Herpes Simplex Virus Type 2 IgM Abs   each   [***]* 9471   86694;
86695   Herpes Simplex Virus Types 1 & 2 IgM Abs   each   [***]* 9474   87530x2
  Herpes Simplex Virus DNA UltraQuant   each   [***]* 9476   86695x2   Herpes
Simplex Virus Type 1 IgG & IgM Abs   each   [***]* 9481   86694; 86695   Herpes
Simplex Virus Type 2 IgG & IgM Abs   each   [***]* 9491   86694; 86695   Herpes
Simplex Virus SeroDx; Types 1 & 2-specific IgG Abs   each   [***]* 9496   86694;
86695; 87529x2   Herpes Simplex Virus Types 1 & 2 AccuDx [EIA]   each   [***]*
9501   87449   Legionella pneumophila Ag Detection Urine   each   [***]* 9510  
82040; 82784x2; 83883; 86317x2   Viral Antibody Index; CSF   each   [***]* 9515
  82040; 82784x2; 83883; 86694; 86695x3   Herpes Simplex Virus IgG Antibody
Index   each   [***]* 9517   82040; 82784x2; 83883; 86694; 86695x3; 87530x2  
Herpes Simplex Virus Encephalitis AccuDx   each   [***]* 9521   86651; 86652;
86653; 86654   Arbovirus Total Abs   each   [***]*

37

--------------------------------------------------------------------------------

9525   83891x2; 83898x3; 83912   Arbovirus RNA DetectR   each   [***]* 9530  
83901x2; 83912; 87496; 87529x2   Viral Encephalitis DetectR   each   [***]* 9601
  86588x2; 87449x7   Bacterial Ag Detection   each   [***]* 9606   87449  
Haemophilus influenzae b Ag   each   [***]* 9617   83516   Bladder Tumor Antigen
  each   [***]* 9620   83516   NMP22 Bladder Tumor marker   each   [***]* 9636  
86588   Streptococcus pneumoniae Ag   each   [***]* 9641   86588   Streptococcus
Group B Ag   each   [***]* 9671   86615   Bordetella pertussis / parapertussis
IgG Abs   each   [***]* 9676   86615x3   Abs   each   [***]* 9681   86615x2  
Bordetella pertussis / parapertussis IgM & IgA Abs   each   [***]* 9686   86615
  Bordetella pertussis / parapertussis IgM Abs   each   [***]* 9711   86735x2  
Mumps IgG & IgM Abs   each   [***]* 9716   86735   Mumps IgG Abs   each   [***]*
9721   86735   Mumps IgM Abs   each   [***]* 9728   87798   Mumps RNA DetectR  
each   [***]* 9741   86784x3   Trichinella IgG; IgM & IgA Abs   each   [***]*
9745   82040; 82784x2; 83883; 86784x2   Trichinella IgG Antibody Index   each  
[***]* 9751   86793x3   Yersinia enterocolitica IgG; IgM & IgA Abs   each  
[***]* 9761   86682x3   Toxocara IgG; IgM; & IgA Abs   each   [***]* 9766  
86682   Toxocara IgG Abs   each   [***]* 9816   86682   Cysticercus IgG Abs  
each   [***]* 9846   87390   HIV-1 Total Ag; Immune Complex Disruption (ICD)  
each   [***]* 9848   87390x2   HIV-1 Free & Total Ag   each   [***]* 9850  
82040; 82784x2; 83883; 86317x2   Antibody Index   each   [***]* 9861   86684  
Haemophilus influenzae b IgG Abs Single Serum   each   [***]* 9866   87390  
HIV-1 Ag Neutralization Confirmation Test   each   [***]* 9872   85048; 85595;
86361; 87536   HIV-1 RNA UltraQuant & CD4 Cell Count   each   [***]* 9874  
87536   HIV-1 RNA UltraQuant   each   [***]* 9876   87539   HIV-2 DNA DetectR  
each   [***]* 9881   87390   HIV-1 Free Ag   each   [***]* 9882   87390   HIV-1
Ag without Neutralization   each   [***]* 9885   87535   HIV-1 DNA DetectR  
each   [***]* 9886   87536   HIV-1 RNA Quantitation by Branched DNA   each  
[***]* 9896   87798x2   HTLV-1/ II DNA DetectR   each   [***]* 9898   86790  
HTLV I/II IgG Abs   each   [***]* 9899   86790   HTLV I/II IgG Abs w/reflex HTLV
I/II IB + bands   each   [***]* 9901   80090; 86695x3; 86778   TORCH IgG & IgM
Abs Evaluation   each   [***]* 9911   86695x2; 86777   TORCH IgG Abs Evaluation
  each   [***]* 9915   86703   HIV-1/HIV-2 Antibodies Plus Confirmation   each  
[***]* 9921   86702   HIV-2 IgG Abs w/ reflex IB   each   [***]* 9926   86689  
HIV-2 IgG Abs; Confirmation   each   [***]*

38

--------------------------------------------------------------------------------

9932   82040; 82784x2; 83883; 86606x2   Aspergillus IgG Antibody Index   each  
[***]* 9941   86003; 86606x3   Aspergillus Abs Panel [EIA]   each   [***]* 9946
  86606   Aspergillus IgM Abs   each   [***]* 9961   86606   Aspergillus IgG Abs
[EIA]   each   [***]* 12990   88233   Fibroblast Culture   each   [***]* 1015F  
86431x2   Fluid   each   [***]* 1020F   83883; 86160x2   Complement Panel Fluid
  each   [***]* 1040F   86332x4   Circulating Immune Complex Detector Fluid  
each   [***]* 1043/12   86609x12; 86648; 86774   Humoral Immune Evaluation
(Pneumo 12)   each   [***]* 1043P   86609x8; 86648x2; 86774x2   Humoral Immune
Evaluation Pre/Post Vacc   each   [***]* 1043P/12   86609x24; 86648x2; 86774x2  
Humoral Immune Evaluation (Pneumo 12) Pre-Post Vacc   each   [***]* 1045C  
82784x3   IgA; IgG & IgM Immunoglobulin Quantitation CSF   each   [***]* 1048/12
  82784x3; 82785; 82787; 86609x12; 86648; 86774   Humoral Immune Status Survey
(Pneumo 12)   each   [***]* 1048P   82784x3; 82785; 82787; 86609x8; 86648x2;
86774x2   Humoral Immune Status Survey (Pneumo 4) Pre/Post Vacc   each   [***]*
1048P/12   82784x3; 82785; 82787; 86609x24; 86648x2; 86774x2   Humoral Immune
Status Survey (Pneumo 12) Pre/Post Vacc   each   [***]* 1056C   83873   Myelin
Basic Protein Autoantibodies CSF (MBP-CSF)   each   [***]* 1070S   86618x2;
86625; 86631; 86632; 86768x3; 86771; 86793x3   Reactive Arthritis Evaluation
Serum (without HLA-B27)   each   [***]* 1080S   86147x3; 86148x3  
Antiphospholipid Syndrome Evaluation w/o LA   each   [***]* 1086/12   86609x12;
86648; 86684; 86774   Humoral Immune Eval + Pneumo 12 & H. influenzae b   each  
[***]* 1086P   86609x8; 86648x2; 86684x2; 86774x2   Humoral Immune Eval + H.
influenzae b Pre/Post Vacc   each   [***]* 1086P/12   86609x24; 86648x2;
86684x2; 84774x2   Humoral Immune Eval + Pneumo 12 & H. influenzae b Pre/Post  
each   [***]* 1100F   86038   Antinuclear Abs w/ International Units & Pattern
Body Fluid   each   [***]* 1145F   82784   IgD Fluid   each   [***]* 1168C  
86256   Neuronal Nuclear IgG Abs Type 1 (Hu) CSF   each   [***]* 1168CS  
86256x2   Neuronal Nuclear IgG Abs Type 1 (Hu) Serum & CSF   each   [***]* 1171C
  86256x2   Paraneoplastic Syndrome Evaluation CSF   each   [***]* 1171CS  
86256x4   Paraneoplastic Syndrome Evaluation Serum & CSF   each   [***]* 1176C  
86256   CSF   each   [***]* 1176CS   86256x2   Purkinje Cell Cytoplasmic IgG Abs
Type 1 (Yo) Serum & CSF   each   [***]*

39

--------------------------------------------------------------------------------

1186C   84181   Neuronal Nuclear Abs Type 1 (Hu) CSF   each   [***]* 1187C  
84181   Purkinje Cell Cytoplasmic Autoabs Type 1 (Yo) CSF   each   [***]* 1198C
  88180   Neuronal IgG Autoabs for CNS Lupus CSF   each   [***]* 1198CS   83520;
88180   Neuronal IgG Autoabs for CNS Lupus Serum & CSF   each   [***]* 1230F  
86332   Immune Complex Assay; Raji Cell Fluid   each   [***]* 1240P   85810  
Viscosity Plasma   each   [***]* 1245F   82785   IgE Fluid   each   [***]* 1271C
  83520   Ribosomal P Protein IgG Autoabs CSF   each   [***]* 1271CS   83520x2  
Ribosomal P Protein IgG Autoabs Serum & CSF   each   [***]* 12995W   86890  
Isolation of Lymphocytes (Cellular Immunology)   each   [***]* 1320U   82570  
Creatinine 24hr Urine   each   [***]* 1320UR   82570   Creatinine Random Urine  
each   [***]* 1324C   84165   Protein; Total CSF   each   [***]* 1324F   84155  
Protein; Total Fluid   each   [***]* 1324SF   84155   Protein; Total Synovial
Fluid   each   [***]* 1324U   84165   Protein; Total 24 hour Urine   each  
[***]* 1324UR   84165   Protein; Total Urine Random   each   [***]* 1331P  
86648x2; 86774x2   Tetanus & Diptheria Toxoid IgG Abs Pre/Post Vaccination  
each   [***]* 1334P   86774x2   Tetanus Toxoid IgG Abs Pre/Post Vaccination  
each   [***]* 1401F   86332   Fluid   each   [***]* 1402F   86332   Conglutinin
Solid Phase Immune Complex Assay Fluid   each   [***]* 1403F   86332   Immune
Complex Assay; Polyethylene Glycol Fluid   each   [***]* 1415P   86648x2  
Diptheria Toxoid IgG Abs Pre/Post Vaccination   each   [***]* 1441C   83520  
Ganglioside Monosialic Acid Autoabs CSF   each   [***]* 14505W   86890  
Lymphocytes Isolation and Storage   each   [***]* 1461C   82784   IgM; low
concentrations <1.1 mg/dL CSF   each   [***]* 1466C   82784   IgA; Low
Concentrations (<1.1 mg/dL) CSF   each   [***]* 1481F   83520   Hyaluronic Acid
Fluid   each   [***]* 1486C   86160   Complement Split Product Concentration:
C3a CSF   each   [***]* 1498C   83520x2   IgA (Autoantibodies) IgG & IgM Ab
Panel CSF   each   [***]* 1501F   86160   Complement Protein Concentration: C3
Body Fluid   each   [***]* 1504F   86160   Complement protein Concentration: C4
Fluid   each   [***]* 1505C   82784   IgG CSF   each   [***]* 1505F   82784  
IgG Fluid   each   [***]* 1505U   82784   IgG 24hr Urine   each   [***]* 1505UR
  82784   IgG Urine Random   each   [***]* 1506F   82784   IgA Fluid   each  
[***]* 1506U   82784   IgA 24hr Urine   each   [***]* 1506UR   82784   IgA Urine
Random   each   [***]*

40

--------------------------------------------------------------------------------

1508F   82784   IgM Fluid   each   [***]* 1508U   82784   IgM 24hr Urine   each
  [***]* 1508UR   82784   IgM Urine Random   each   [***]* 1510C   83883  
Albumin CSF   each   [***]* 1510F   83883   Albumin Fluid   each   [***]* 1511F
  83883   Complement Protein Concentration: Factor B Fluid   each   [***]* 1512U
  83883   Alpha-2-Macroglobulin Urine   each   [***]* 1535C   86140   C-Reactive
Protein CSF   each   [***]* 1540F   86431   Rheumatoid Factor IgM Abs [NEPH]
Fluid   each   [***]* 1580C   84165   Electrophoresis; Protein CSF   each  
[***]* 1580U   84165   Electrophoresis; Protein Urine Random   each   [***]*
1588U   84165   Bence-Jones Protein; Qualitative Urine   each   [***]* 1600F  
86162   Fluid   each   [***]* 1600SF   86162   Complement Functional Activity:
Total CH50 Synovial Fluid   each   [***]* 1615F   83883   Complement Protein
Concentration: C1q Fluid   each   [***]* 1656NY   85048; 85595; 86361   CBC  
each   [***]* 1656SR   85048; 85595; 86361   Lymphocyte Enumeration;
Helper/Inducer w/ Serial Report   each   [***]* 1657NY   85048; 85595; 86360  
CBC   each   [***]* 1678C   88180   Additional Surface Marker [Oncology]   each
  [***]* 1678C2   88180x2   Additional Surface Marker -2 [Oncology]   each  
[***]* 1694W   88180   Terminal Deoxynucleotidyl Transferase Whole Blood   each
  [***]* 1711C   86148x3   CSF   each   [***]* 1731U   83883   Kappa Light
Chain; Quant 24hr Urine   each   [***]* 1731UR   83883   Kappa Light Chain Urine
Random   each   [***]* 1736U   83883   Lambda Light Chain; Quant 24hr Urine  
each   [***]* 1736UR   83883   Lambda Light Chain Urine Random   each   [***]*
1741U   83883x2   Kappa & Lambda Light Chain; Quant 24hr Urine   each   [***]*
1741UR   83883x2   Kappa & Lambda Light Chain Urine Random   each   [***]* 1751C
  83520x3   Phosphatidylcholine IgG; IgM & IgA Abs CSF   each   [***]* 1771C  
83520x3   Phosphatidic Acid IgG; IgM & IgA Abs CSF   each   [***]* 1791C  
83520x3   Phosphatidylethanolamine IgG; IgM & IgA Abs CSF   each   [***]* 1804T
  84233; 84234; 88182   Non-breast Cancer Profile 1- Paraffin   each   [***]*
1926C   83520   CSF   each   [***]* 1992C   83520   Complement Split Product
Concentration: SC5b-9 Complex CSF   each   [***]* 2102C   86781   Treponema
pallidum IgM Abs; FTA CSF   each   [***]* 2104C   86781   Treponema pallidum
Total Abs; FTA CSF   each   [***]* 2106U   87299   Cytomegalovirus
Immediate-early Ag Urine   each   [***]* 2116F   86665   Fluid   each   [***]*
2121F   86665   Fluid   each   [***]* 2126F   86663   Fluid   each   [***]*

41

--------------------------------------------------------------------------------

2131F   86663   Epstein-Barr Virus Early Ag (EA) IgA Abs Fluid   each   [***]*
2156F   86713x12   Legionella pneumophila IgG & IgM Abs; Serotypes 1-6 Fluid  
each   [***]* 2161C   86753x2   Babesia microti IgG & IgM Abs CSF   each  
[***]* 2211E   86663; 86664; 86665x2   Epstein-Barr Virus Evalution Endpoint  
each   [***]* 2211F   86663; 86664; 86665x2   Epstein-Barr Virus Evaluation;
Fluid   each   [***]* 2231C   86645; 86694; 86695; 86762; 86778   TORCH IgM Abs
Evaluation CSF   each   [***]* 2261C   86777x2; 86778x2   Toxoplasma Antibody
Evaluation CSF   each   [***]* 2261F   86777x2; 86778x2   Toxoplasma Antibody
Evaluation Fluid   each   [***]* 2266F   86664   Epstein-Barr Virus Nuclear Ag
(EBNA) IgG Abs Fluid   each   [***]* 2271F   86664   Epstein-Barr Virus Nuclear
Ag (EBNA) IgM Abs Fluid   each   [***]* 2321F   86185   Teichoic Acid Abs Fluid
  each   [***]* 2326C   86606   Aspergillus Total Abs [DD] CSF   each   [***]*
2328C   86612   Blastomyces Total Abs [DD] CSF   each   [***]* 2332C   86635  
Coccidioides Total Abs [DD] CSF   each   [***]* 2334C   86698x2   Histoplasma
Abs [DD] CFS   each   [***]* 2366C   86592   VDRL CSF   each   [***]* 2370P  
86609x8   Pre/Post   each   [***]* 2386P   86609x24   Pre/Post   each   [***]*
2445B   86803   Hepatitis C Virus IgG Abs w/ reflex RIBA + bands   each   [***]*
2447B   86804   Hepatitis C Virus Abs RIBA Confirmation + bands   each   [***]*
2450R   86708   Hepatitis A Virus Total Abs w/ reflex IgM   each   [***]* 2475C
  86762   Rubella IgM Abs CSF   each   [***]* 2486C   86645   Cytomegalovirus
IgM Abs CSF   each   [***]* 2491C   86793   Yersinia enterocolitica IgG Abs CSF
  each   [***]* 2496C   86793   Yersinia enterocolitica IgM Abs CSF   each  
[***]* 2501C   86603   Adenovirus Abs CSF   each   [***]* 2506C   86606  
Aspergillus Total Abs [CF] CSF   each   [***]* 2511C   86612   Blastomyces total
Abs [CF] CSF   each   [***]* 2516C   86609   Neisseria gonorrhoeae Abs CSF  
each   [***]* 2521C   86631   Chlamydia spp. Total Abs [CF] CSF   each   [***]*
2526C   86635   Coccidioides Total Abs [CF] CSF   each   [***]* 2536C   86658x4
  Coxsackievirus A Abs; Serotypes 7; 9; 10; 16 CSF   each   [***]* 2541C  
86658x6   Coxsackievirus B Abs; Serotypes 1-6 CSF   each   [***]* 2546C  
86658x10   Coxsackievirus A & B Abs Evaluation CSF   each   [***]* 2551C   86664
  Cytomegalovirus Total Abs CSF   each   [***]* 2566C   86658x4   Echovirus Abs;
Serotypes 4; 9; 11 & 30 CSF   each   [***]* 2571C   86694   Herpes Simplex Virus
Total Abs CSF [CF]   each   [***]* 2581C   86698x2   Histoplasma Abs [CF] CSF  
each   [***]* 2586C   86710   Influenza Virus Abs; Type A CSF   each   [***]*
2591C   86710   Influenza Virus Abs; Type B CSF   each   [***]* 2601C   86727  
Lymphocytic Choriomeningitis Abs CSF   each   [***]* 2606C   86729  
Lymphogranuloma Venereum Abs CSF   each   [***]* 2621C   86710x3   Parainfluenza
Virus Types 1-3 Abs CSF   each   [***]*

42

--------------------------------------------------------------------------------

2626C   86658x3   Poliovirus Abs Serotypes 1-3 CSF   each   [***]* 2631C   86631
  Chlamydia spp. Abs CSF   each   [***]* 2641C   86790   Reovirus Antibodies CSF
[CF]   each   [***]* 2646C   86756   Respiratory Syncytial Virus Abs CSF   each
  [***]* 2676C   86790   Polyomavirus Abs CSF   each   [***]* 2701C   86603;
86631; 86710x5; 86738   Respiratory Infection Abs; Adult CSF   each   [***]*
2711C   86603; 86631; 86710x5; 86738; 86756   Respiratory Infection Abs;
Child/Infant CSF   each   [***]* 2726C   86694; 86727; 86735x2; 86765x2; 86787x2
  Encephalitis Viral Abs CSF   each   [***]* 2731C   86606; 86612; 86635;
86698x2   Fungal Abs [CF] CSF   each   [***]* 2741C   86710x2   Influenza Virus
Abs; Types A & B CSF   each   [***]* 2746C   86658x17   Paralytic Viral Ab
Evaluation CSF   each   [***]* 2771C   86603; 86644; 86651; 86652; 86653; 86654;
86658x14; 86694; 86710x2; 86727; 86735x2; 86765x2; 86787x2  
Meningoencephalomyelitis Viral Ab Evaluation CSF   each   [***]* 2771CS  
86603x2; 86644x2; 86651x2; 86652x2; 86653x2; 86654x2; 86658x28; 86694x2;
86710x4; 86727x2; 86735x4; 86765x4; 86787x4   Meningoencephalomyelitis Viral Ab
Evaluation CSF & Serum   each   [***]* 2780C   86612; 86635; 86698x2   Fungal
Antibody Panel: Invasive CSF   each   [***]* 2785C   86606; 86612; 86635; 86641;
86698x2; 87449   Fungal Antibody Panel: Opportunistic CSF   each   [***]* 2790C
  86612; 86635; 86641; 86698x2; 87449   Fungal Antibody Panel: Systemic CSF  
each   [***]* 3012B   86689   HIV-1 Abs Confirmation Immunoblot + bands   each  
[***]* 3012C   86689   HIV-1 Abs Confirmation Immunoblot CSF   each   [***]*
3012NY   86689   HIV-1 Abs Confirmation Immunoblot; New York   each   [***]*
3012NYB   86689   York   each   [***]* 3013B   86689   HIV-1 Abs Confirmation +
bands w/ reflex to HIV-2 + bands   each   [***]* 3015B   86689x2   HIV-1 & 2 Abs
Confirmation [IB] + Bands   each   [***]* 3017SR   84275; 86316   Uterine Cancer
Monitor w/ Serial Graphics   each   [***]* 3091B   85613   HIV-1 IgG Abs w/
Reflex Ib + Bands (Priority)   each   [***]* 3021B   86689   HIV-1 Abs
Confirmation Immunoblot + Bands Plus HIV-2 Conf IB   each   [***]* 3024SR  
82378; 86316   Colorectal Cancer Monitor w/ Serial Graphics   each   [***]*
3028SR   82105; 84702   Alpha-Fetoprotein & Human Chorionic Gonadotropin w/
Serial Gr   each   [***]*

43

--------------------------------------------------------------------------------

3032F   84066; 84153   Prostate Cancer Monitor Fluid   each   [***]* 3032SR  
84066; 84153   Prostate Cancer Monitor w/ Serial Graphics   each   [***]* 3038BK
  88182; 88342x2   Ovarian Cancer Prognosis—Paraffin   each   [***]* 3038FZ  
88182; 88342x2   Ovarian Cancer Prognosis—Frozen   each   [***]* 3100F   84066  
Prostatic Acid Phosphatase Fluid   each   [***]* 3100SR   84066   Prostatic Acid
Phosphatase w/ Serial Graphics   each   [***]* 3104U   82088   Aldosterone; 24hr
Urine   each   [***]* 3104UR   82088   Aldosterone; Urine Random   each   [***]*
3109C   82105   Alpha-Fetoprotein CSF   each   [***]* 3109F   82106  
Alpha-Fetoprotein Body Fluid—not for prenatal testing   each   [***]* 3109SR  
82105   Alpha-Fetoprotein—Tumor Marker w/ Serial Graphics   each   [***]* 3114C
  82164   Angiotensin Converting Enzyme CSF   each   [***]* 3119SR   86316   CA
15-3 w/ Serial Graphics   each   [***]* 3120F   86316   CA 19-9 Fluid   each  
[***]* 3120NY   86316   CA 19-9 New York   each   [***]* 3120 SR   86316   CA
19-9 w/ Serial Graphics   each   [***]* 3121F   86316   CA 125 Fluid   each  
[***]* 3121NY   86316   CA 125 New York   each   [***]* 3121SR   86316   CA 125
w/ Serial Graphics   each   [***]* 3123PL   82482   Cholinesterase Plasma   each
  [***]* 3123PLSR   82482   Cholinesterase Plas Serial Graphics   each   [***]*
3123R   82482   Cholinesterase; RBC   each   [***]* 3123RSR   82482  
Cholinesterase; RBC w/ Serial Graphics   each   [***]* 3123SR   82480  
Cholinesterase w/ Serial Graphics   each   [***]* 3125C   86334   Monoclonal
Gammopathies; CSF   each   [***]* 3125U   86334   Monoclonal Gammopathies; Urine
  each   [***]* 3128U   82530; 82570   Cortisol; Free 24hr Urine   each   [***]*
3128UR   82530   Cortisol Free Urine Random   each   [***]* 3134NY   86316  
CA27.29 New York   each   [***]* 3134SR   86316   CA27.29 w/ Serial Graphics  
each   [***]* 3140U   82570; 84681   C-Peptide Urine   each   [***]* 3143C  
82232   Beta-2-Microglobulin CSF   each   [***]* 3143F   82232  
Beta-2-Microglobulin Fluid   each   [***]* 3143SR   82232   Beta-2-Microglobulin
w/ Serial Graphics   each   [***]* 3143U   82232   Beta-2-Microglobulin Urine  
each   [***]* 3158U   82570; 82677   Estriol; Total 24hr Urine   each   [***]*
3172SR   82728; 86316   Neuroblastoma Monitor w/ Serial Graphics   each   [***]*
3182MO   83003   Growth Hormone Response Test; Timed   each   [***]* 3182M1  
83003   Growth Hormone Response Test; Timed Sample #1   each   [***]* 3182M2  
83003   Growth Hormone Response Test; Timed Sample #2   each   [***]* 3182M3  
83003   Growth Hormone Response Test; Timed Sample #3   each   [***]* 3182M4  
83003   Growth Hormone Response Test; Timed Sample #4   each   [***]* 3182M5  
83003   Growth Hormone Response Test; Timed Sample #5   each   [***]*

44

--------------------------------------------------------------------------------

3182M6   83003   Growth Hormone Response Test; Timed Sample #6   each   [***]*
3182M7   83003   Growth Hormone Response Test; Timed Sample #7   each   [***]*
3184C   84702   Human Chorionic Gonadotropin CSF   each   [***]* 3184F   84702  
Human Chorionic Gonadotropin Fluid   each   [***]* 3184SR   84702   Human
Chorionic Gonadotropin w/ Serial Graphics   each   [***]* 3204U   83935  
Osmolality Urine   each   [***]* 3204UR   83935   Osmolality; Random Urine  
each   [***]* 3214M   80408   Saline Suppression Test   each   [***]* 3258C  
82378   Carcinoembyronic Ag CSF   each   [***]* 3258F   83278   Carcinoembryonic
Ag Body Fluid   each   [***]* 3258NY   82378   Carcinoembryonic Ag New York  
each   [***]* 3258SR   82378   Carcinoembryonic Ag w/ Serial Graphics   each  
[***]* 3270U   82382   Epinephrine 24hr Urine   each   [***]* 3275I   84202  
Zinc Protoporphyrin; Industrial   each   [***]* 3282C   83520   Neopterin CSF  
each   [***]* 3286U   84260   5-Hydroxytryptamine 24hr Urine [Serotonin]   each
  [***]* 3286UR   84260   5-Hydroxytryptamine Urine Random [Serotonin]   each  
[***]* 3290C   83520   Interferon-alpha CSF   each   [***]* 3294BW   82397  
Tumor Necrosis Factor-alpha Bronchial Wash   each   [***]* 3294C   82397   Tumor
Necrosis Factor-alpha CSF   each   [***]* 3304U   82384   Catecholamines;
Fractionated 24hr Urine   each   [***]* 3304UR   82384   Catecholamines;
Fractionation Urine Random   each   [***]* 3310UR   82570; 83497  
5-Hydroxyindoleacetic Acid Urine Random   each   [***]* 3315UR   82570; 83835  
Metanephrines; Fractionation Urine Random   each   [***]* 3316UR   82570; 83835
  Metanephrines; Total Urine Random   each   [***]* 3318U   84585  
Vanillylmandelic Acid; 24hr Urine   each   [***]* 3318UR   84585  
Vanillylmandelic Acid; Urine Random   each   [***]* 3334U   82131  
Homocyst(e)ine UltraQuant Urine   each   [***]* 3369U   83690   Lipase; Urine  
each   [***]* 3446E   82172   Lipoprotein (a); Endpoint   each   [***]* 3496U  
83918   Methylmalonic Acid Urine   each   [***]* 3515F   84425   Vitamin B1
Fluid   each   [***]* 3515W   84425   Vitamin B1 Whole Blood   each   [***]*
3522B   82747   Folate RBC   each   [***]* 3546F   84153   Prostate-Specific Ag
Fluid   each   [***]* 3546NY   84153   Prostate-Specific Ag New York   each  
[***]* 3546SR   84153   Prostate-Specific Ag w/ Serial Graphics   each   [***]*
3547SR   84153; 84154   Graphics   each   [***]* 3624C   83520   Endotoxin CSF  
each   [***]* 3624F   85130   Endotoxin Fluid   each   [***]* 3822BW   83520  
Interleukin-8 Bronchial Wash   each   [***]* 3832C   83520   Interleukin-2
Receptor CSF   each   [***]* 3832SF   83520   Interleukin-2 Receptor; Soluble
Synovial Fluid   each   [***]* 3857SR   84275; 86316   Melanoma Monitor w/
Serial Graphics   each   [***]*

45

--------------------------------------------------------------------------------

3858SR   84275   Lipid-Associated Sialic Acid w/ Serial Graphics   each   [***]*
3860C   84999   Neuron-specific Enolase CSF   each   [***]* 3868C   83520  
Interleukin-1 beta CSF   each   [***]* 3870C   83520   Interleukin-2 CSF   each
  [***]* 3872 UR   83520   Pancreatitis DetectR; Urine Random   each   [***]*
3908C   83520   Tumor Necrosis Factor-binding Proteins CSF   each   [***]*
3943SR   82310; 83970   Graph   each   [***]* 3946UR   83150   Homovanillic
Acid; Urine Random   each   [***]* 3970U   82507; 82570   Citrate; 24hr Urine  
each   [***]* 3970UR   82507; 82570   Citrate Urine Random   each   [***]* 4011C
  83520   Ganglioside Asialo-GM1 Autoabs CSF   each   [***]* 4021C   83520x4;
86256; 86334   Motor & Sensory Neuropathy Evaluation CSF   each   [***]* 4026C  
83520x7; 86334   Motor Neuropathy Evaluation CSF   each   [***]* 4041C   83520  
Ganglioside GD1b Autoabs CSF   each   [***]* 4080U   82175; 83655; 83825   Heavy
Metal Screen 24hr Urine   each   [***]* 4080UR   82175; 83655; 83825   Heavy
Metal Screen Urine Random   each   [***]* 4080W   82175; 83655; 83825   Heavy
Metal Screen Whole Blood   each   [***]* 4099UR   83520   Leukotriene B4 (LTB4)
  each   [***]* 4102U   82055   Alcohol; Ethyl Urine   each   [***]* 4102W  
82055   Alcohol; Ethyl Whole Blood   each   [***]* 4103U   80101   Lysergic Acid
Diethylamide (LSD) Screen; Urine   each   [***]* 4106U   82145  
Amphetamine/Methamphetamine Urine   each   [***]* 4108U   80101   Barbiturates
Urine   each   [***]* 4110U   80101   Benzodiazepine Screen Urine   each  
[***]* 4118U   80101   Cocaine Metabolites Urine   each   [***]* 4125U   80101  
Drugs of Abuse Screen Urine   each   [***]* 4132U   80101   Cannabinoids Urine  
each   [***]* 4134U   83840   Methadone Urine   each   [***]* 4138U   83925  
Opiates Urine   each   [***]* 4140U   83992   Phencyclidine Urine   each  
[***]* 4149U   80299   Propoxyphene Urine   each   [***]* 4266U   82523; 82570  
N-Telopeptides w/ Creatinine   each   [***]* 4311SR   80158   Cyclosporin A &
Metabolites Whole Blood [FPIA-Monoclonal] w/ SR   each   [***]* 4332U   83945  
Oxalate 24hr Urine   each   [***]* 4332UR   83945   Oxalate Random Urine   each
  [***]* 4333U   84560   Uric Acid; 24hr Urine   each   [***]* 4333UR   84560  
Uric Acid Random Urine   each   [***]* 4397U   83018   Antimony 24hr Urine  
each   [***]* 4397UR   83018   Antimony Urine Random   each   [***]* 4397W  
83018   Antimony Whole Blood   each   [***]* 4500UR   82232; 82300x2; 82570  
Cadmium Exposure Panel—OSHA—Random Urine   each   [***]* 4501U   82232; 82300;
82570   Cadmium Exposure Panel 24hr Urine   each   [***]* 4501UR   82232; 82300;
82570   Cadmium Exposure Panel Urine Random   each   [***]* 4502U   82300; 82570
  Cadmium Exposure Panel 24hr Urine—Limited   each   [***]*

46

--------------------------------------------------------------------------------

4502UR   82300; 82570   Cadmium Exposure Panel Urine Random—Limited   each  
[***]* 4836U   82340   Calcium; Total 24hr Urine   each   [***]* 4836UR   82340
  Calcium; Urine Random   each   [***]* 48611   83655   Lead Industrial (OSHA)
Whole Blood   each   [***]* 4861NY   83655   Lead Whole Blood New York   each  
[***]* 4861U   83655   Lead 24hr Urine   each   [***]* 4861UR   83655   Lead
Urine Random   each   [***]* 4861W   83655   Lead Whole Blood   each   [***]*
4862D   82108   Aluminum Dialysate   each   [***]* 4862SR   82108   Aluminum
Serial Graphics   each   [***]* 4862U   82108   Aluminum 24hr Urine   each  
[***]* 4862UR   82108   Aluminum Urine Random   each   [***]* 4862W   82108  
Aluminum Whole Blood   each   [***]* 4866R   83735   Magnesium RBC   each  
[***]* 4866U   83735   Magnesium 24hr Urine   each   [***]* 4866UR   83735  
Magnesium Urine Random   each   [***]* 4867L   82175   Arsenic; Liquid   each  
[***]* 4867U   82175   Arsenic 24hr Urine   each   [***]* 4867UI   82175; 82570
  Arsenic Urine Industrial   each   [***]* 4867UR   82175   Arsenic Urine Random
  each   [***]* 4867W   82175   Arsenic Whole Blood   each   [***]* 4868U  
82300   Cadmium 24hr Urine   each   [***]* 4868UR   82300   Cadmium Urine Random
  each   [***]* 4868W   82300   Cadmium Whole Blood   each   [***]* 4870PL  
82525   Copper Plasma   each   [***]* 4870R   82525   Copper RBC   each   [***]*
4870U   82525   Copper 24hr Urine   each   [***]* 4870UR   82525   Copper Urine
Random   each   [***]* 4871U   80178   Lithium 24hr Urine   each   [***]* 4871UR
  80178   Lithium Urine Random   each   [***]* 4872R   83785   Manganese RBC  
each   [***]* 4872U   83785   Manganese 24hr Urine   each   [***]* 4872UR  
83785   Manganese Urine Random   each   [***]* 4872W   83785   Manganese Whole
Blood   each   [***]* 4873U   83825   Mercury 24hr Urine   each   [***]* 4873UI
  82570; 83825   Mercury Urine Industrial   each   [***]* 4873UR   83825  
Mercury Urine Random   each   [***]* 4873W   83825   Mercury Whole Blood   each
  [***]* 4874R   84132   Potassium RBC   each   [***]* 4875R   84255   Selenium
RBC   each   [***]* 4875U   84255   Selenium 24hr Urine   each   [***]* 4875UR  
84255   Selenium Random Urine   each   [***]* 4875W   84255   Selenium Whole
Blood   each   [***]* 4877PL   84630   Zinc Plasma   each   [***]* 4877R   84630
  Zinc RBC   each   [***]* 4877U   84630   Zinc 24hr Urine   each   [***]*
4877UR   84630   Zinc Urine Random   each   [***]* 4880W   83018   Molybdenum;
Whole blood   each   [***]* 4900P   80150x2   Amikacin Peak & Trough   each  
[***]* 4901P   80170x2   Gentamicin Peak & Trough   each   [***]*

47

--------------------------------------------------------------------------------

                each

4902P   80200x2   Tobramycin Peak & Trough   each   [***]* 4903P   80202x2  
Vancomycin Peak & Trough   each   [***]* 4908P   80299x2   5-Fluorocytosine Peak
& Trough   each   [***]* 4915P   80299x2   Isoniazid Peak & Trough   each  
[***]* 4919P   80299x2   Rifampin Peak & Trough   each   [***]* 4925P   80201x2
  Topiramate Peak & Trough   each   [***]* 4988UR   83874   Myoglobin Urine
Random   each   [***]* 5301C   82947   Glucose; CSF   each   [***]* 5301P  
82947   Glucose; Plasma   each   [***]* 5303C   82438   Chloride CSF   each  
[***]* 5303U   82436   Chloride; 24hr Urine   each   [***]* 5303UR   82436  
Chloride; Urine Random   each   [***]* 5306U   84300   Sodium; 24hr Urine   each
  [***]* 5306UR   84300   Sodium Urine ISE Random   each   [***]* 5308U   84105
  Phosphorus; 24Hr Urine   each   [***]* 5311C   84999   Potassium; CSF   each  
[***]* 5311U   84133   Potassium; 24hr Urine   each   [***]* 5311UR   84133  
Potassium Urine Random   each   [***]* 5400BK   88182   DNA Ploidy & Cell Cycle
Analysis Block   each   [***]* 5400FZ   88182   DNA Ploidy & Cell Cycle Analysis
Frozen   each   [***]* 5400NI   88182   DNA Analysis [FC; No Interpretation]  
each   [***]* 5400TBK   88182   NonBreast DNA Ploidy & Cell Cycle Analysis Block
  each   [***]* 5400TFZ   88182   NonBreast DNA Ploidy & Cell Cycle Analysis
Frozen   each   [***]* 5400U   88182   DNA Ploidy & Cell Cycle Analysis
Bladder/Urine   each   [***]* 5402NI   88182   DNA Analysis [IA; No
Interpretation]   each   [***]* 5652CLA   87190   AFB Suscept: Custom Disk
Diffusion-Clarithromycin   each   [***]* 5652ETH   87190   AFB Suscept: Custom
Disk Diffusion-Ethambutol   each   [***]* 5652MIN   87190   AFB Suscept: Custom
Disk Diffusion-Minocycline   each   [***]* 5652RIF   87190   AFB Suscept: Custom
Disk Diffusion-Rifampin   each   [***]* 5652TRI   87190   AFB Suscept: Custom
Disk Diffusion-Trim/Sulfa   each   [***]* 5654AM   87190   Amikacin   each  
[***]* 5654CA   87190   AFB Suscept: Custom Drug Radiometric Assay-Capreomycin  
each   [***]* 5654CI   87190   AFB Suscept: Custom Drug Radiometric
Assay-Ciprofloxacin   each   [***]* 5654CL   87190   AFB Suscept: Custom Drug
Radiometric Assay-Clofazamine   each   [***]* 5654ET1   87190   AFB Suscept:
Custom Drug Radiometric Assay-Ethambutol   each   [***]* 5654ET2   87190   AFT
Suscept: Custom Drug Radiometric Assay-Ethionamide   each   [***]* 5654IS  
87190   Isoniazid   each   [***]* 5654KA   87190   Kanamycin   each   [***]*

48

--------------------------------------------------------------------------------

5654PAS   87190x2   AFT Suscept: Custom Drug Radiomet Assay-p-Aminosalic Acid  
each   [***]* 5654PY   87190   AFB Suscept: Custom Drug Radiometric
Assay-Pyrazinamide   each   [***]* 5654RI   87190   Rifampin   each   [***]*
5654ST   87190   AFB Suscept: Custom Drug Radiometic Assay-Streptomycin   each  
[***]* 5655AMI   87190   Amikacin   each   [***]* 5655CEF   87190   Cefoxitin  
each   [***]* 5655CIP   87190   AFB Suscept: Custom Drug for Rapid
Growers-Ciprofloxacin   each   [***]* 5655CLA   87190   AFB Suscept: Custom Drug
for Rapid Growers-Clarithromycin   each   [***]* 5655DOX   87190   AFB Suscept:
Custom Drug for Rapid Growers-Doxycycline   each   [***]* 5655ERY   87190   AFB
Suscept: Custom Drug for Rapid Growers-Erythromycin   each   [***]* 5655GEN  
87190   Gentamicin   each   [***]* 5655IMI   87190   Imipenem   each   [***]*
5655KAN   87190   Kanamycin   each   [***]* 5655MIN   87190   AFB Suscept:
Custom Drug for Rapid Growers-Minocycline   each   [***]* 5655OFL   87190  
Ofloxacin   each   [***]* 5655TOB   87190   AFB Suscept: Custom Drug for Rapid
Growers-Tobramycin   each   [***]* 5661AM   87192   Fungus Susceptibility:
Custom MIC-Amphotericin B   each   [***]* 5661FC   87192   Fungus
Susceptibility: Custom MIC-5-Fluorocytosine   each   [***]* 5661FL   87192  
Fungus Susceptibility: Custom MIC-Fluconazole   each   [***]* 5661IT   87192  
Fungus Susceptibility: Custom MIC-Itraconazole   each   [***]* 5661KE   87192  
Fungus Susceptibility: Custom MIC-Ketoconazole   each   [***]* 5661MI   87192  
Fungus Susceptibility: Custom MIC-Miconazole   each   [***]* 5662AM   87187;
87192   Fungus Susceptibility: Custom MIC & MFC-Amphotericin B   each   [***]*
5662FC   87187; 87192   Fungus Susceptibility: Custom MIC & MFC-5-Fluorocytosine
  each   [***]* 5662FL   87187; 87192   Fluconazole   each   [***]* 5662IT  
87187; 87192   Itraconazole   each   [***]* 5662KE   87187; 87192   Ketoconazole
  each   [***]* 5662MI   87187; 87192   Fungus Susceptibility: Custom MIC &
MFC-Miconazole   each   [***]* 5668AMD   87181   Aerobic Suscept: Custom
Drug-Amdinocillin   each   [***]* 5668AMI   87181   Aerobic Suscept: Custom
Drug-Amikacin   each   [***]* 5668AMP1   87181   Aerobic Suscept: Custom
Drug-Ampicillin   each   [***]* 5668AUG   87181   Aerobic Suscept: Custom
Drug-Augmentin   each   [***]* 5668AZI   87181   Aerobic Suscept: Custom
Drug-Azithromycin   each   [***]*

49

--------------------------------------------------------------------------------

5668AZT   87181   Aerobic Suscept: Custom Drug-Aztreonam   each   [***]* 5668CAR
  87181   Aerobic Suscept: Custom Drug-Carbenicillin   each   [***]* 5668CEF1  
87181   Aerobic Suscept: Custom Drug-Cefaclor   each   [***]* 5668CEF3   87181  
Aerobic Suscept: Custom Drug-Cefazolin   each   [***]* 5668CEF4   87181  
Aerobic Suscept: Custom Drug-Cefixime   each   [***]* 5668CEF5   87181   Aerobic
Suscept: Custom Drug-Cefonicid   each   [***]* 5668CEF6   87181   Aerobic
Suscept: Custom Drug-Cefoperazone   each   [***]* 5668CEF8   87181   Aerobic
Suscept: Custom Drug-Cefotetan   each   [***]* 5668CEF9   87181   Aerobic
Suscept: Custom Drug-Cefoxitin   each   [***]* 5668CF10   87181   Aerobic
Suscept: Custom Drug-Ceftazidime   each   [***]* 5668CF11   87181   Aerobic
Suscept: Custom Drug-Ceftizoxime   each   [***]* 5668CF12   87181   Aerobic
Suscept: Custom Drug-Ceftriaxone   each   [***]* 5668CF13   87181   Aerobic
Suscept: Custom Drug-Cefuroxime   each   [***]* 5668CF14   87181   Aerobic
Suscept: Custom Drug-Ceftibuten   each   [***]* 5668CF15   87181   Aerobic
Suscept: Custom Drug-Cefpodoxime   each   [***]* 5668CHL   87181   Aerobic
Suscept: Custom Drug-Chloramphenicol   each   [***]* 5668CIP   87181   Aerobic
Suscept: Custom Drug-Ciprofloxacin   each   [***]* 5668CLA   87181   Aerobic
Suscept: Custom Drug-Clarithromycin   each   [***]* 5668CLI   87181   Aerobic
Suscept: Custom Drug-Clindamycin   each   [***]* 5668ERY   87181   Aerobic
Suscept: Custom Drug-Erythromycin   each   [***]* 5668GEN   87181   Aerobic
Suscept: Custom Drug-Gentamicin   each   [***]* 5668IMI   87181   Aerobic
Suscept: Custom Drug-Imipenem   each   [***]* 5668LEV   87181   Aerobic Suscept:
Custom Drug-Levofloxacin   each   [***]* 5668NET   87181   Aerobic Suscept:
Custom Drug-Netilmicin   each   [***]* 5668NIT   87181   Aerobic Suscept: Custom
Drug-Nitrofurantoin   each   [***]* 5668NOR   87181   Aerobic Suscept: Custom
Drug-Norfloxacin   each   [***]* 5668OXA   87181   Aerobic Suscept: Custom
Drug-Oxacillin   each   [***]* 5668PEN   87181   Aerobic Suscept: Custom
Drug-Penicillin G   each   [***]* 5668PIP1   87181   Aerobic Suscept: Custom
Drug-Piperacillin   each   [***]* 5668RIF   87181   Aerobic Suscept: Custom
Drug-Rifampin   each   [***]* 5668STR   87181   Aerobic Suscept: Custom
Drug-Streptomycin   each   [***]* 5668TET   87181   Aerobic Suscept: Custom
Drug-Tetracycline   each   [***]* 5668TIC   87181   Aerobic Suscept: Custom
Drug-Ticarcillin   each   [***]* 5668TOB   87181   Aerobic Suscept: Custom
Drug-Tobramycin   each   [***]* 5668TRI   87181   Aerobic Suscept: Custom
Drug-Trimethoprim/Sulfamethoxazole   each   [***]* 5668VAN   87181   Aerobic
Suscept: Custom Drug-Vancomycin   each   [***]* 5675AMI   87186   Aerobic
Suscept: Custom MIC—Amikacin   each   [***]* 5675AMP1   87186   Aerobic Suscept:
Custom MIC—Ampicillin   each   [***]* 5675AMP2   87186   Aerobic Suscept: Custom
MIC—AMP/Sulbactam   each   [***]* 5675AUG   87186   Aerobic Suscept: Custom
MIC—Augmentin   each   [***]* 5675AZI   87186   Aerobic Suscept: Custom
MIC—Azithromycin   each   [***]* 5675AZT   87186   Aerobic Suscept: Custom
MIC—Aztreonam   each   [***]* 5675BEN   87186   Aerobic Suscept: Custom
MIC—Benzylpenicillin   each   [***]* 5675CAR   87186   Aerobic Suscept: Custom
MIC—Carbenicillin   each   [***]*

50

--------------------------------------------------------------------------------

5675CEF1   87186   Aerobic Suscept: Custom MIC—Cefaclor   each   [***]* 5675CEF3
  87186   Aerobic Suscept: Custom MIC—Cefazolin   each   [***]* 5675CEF4   87186
  Aerobic Suscept: Custom MIC—Cefixime   each   [***]* 5675CEF6   87186  
Aerobic Suscept: Custom MIC—Cefoperazone   each   [***]* 5675CEF7   87186  
Aerobic Suscept: Custom MIC—Cefotaxime   each   [***]* 5675CEF8   87186  
Aerobic Suscept: Custom MIC—Cefotetan   each   [***]* 5675CEF9   87186   Aerobic
Suscept: Custom MIC—Cefoxitin   each   [***]* 5675CEP   87186   Aerobic Suscept:
Custom MIC—Cephalothin   each   [***]* 5675CF10   87186   Aerobic Suscept:
Custom MIC—Ceftazidime   each   [***]* 5675CF11   87186   Aerobic Suscept:
Custom MIC—Ceftizoxime   each   [***]* 5675CF12   87186   Aerobic Suscept:
Custom MIC—Ceftriaxone   each   [***]* 5675CF13   87186   Aerobic Suscept:
Custom MIC—Cefuroxime   each   [***]* 5675CF14   87186   Aerobic Suscept: Custom
MIC—Cefepime   each   [***]* 5675CF15   87186   Aerobic Suscept: Custom
MIC—Cefpodoxime   each   [***]* 5675CHL   87186   Aerobic Suscept: Custom
MIC—Chloramphenicol   each   [***]* 5675CIP   87186   Aerobic Suscept: Custom
MIC—Ciprofloxacin   each   [***]* 5675CLA   87190   Aerobic Suscept: Custom
MIC—Clarithromycin   each   [***]* 5675CLI   87186   Aerobic Suscept: Custom
MIC—Clindamycin   each   [***]* 5675ERY   87186   Aerobic Suscept: Custom
MIC—Erythromycin   each   [***]* 5675GEN   87186   Aerobic Suscept: Custom
MIC—Gentamicin   each   [***]* 5675IMI   87186   Aerobic Suscept: Custom
MIC—Imipenem   each   [***]* 5675LEV   87186   (Levaquin)   each   [***]*
5675LOM   87186   Aerobic Suscept: Custom MIC—Lomefloxacin   each   [***]*
5675MEZ   87186   Aerobic Suscept: Custom MIC—Mezlocillin   each   [***]*
5675MIN   87186   Aerobic Suscept: Custom MIC—Minocycline   each   [***]*
5675NIT   87186   Aerobic Suscept: Custom MIC—Nitrofurantoin   each   [***]*
5675NOR   87186   Aerobic Suscept: Custom MIC—Norfloxacin   each   [***]*
5675OFL   87186   Aerobic Suscept: Custom MIC—Ofloxacin   each   [***]* 5675OXA
  87186   Aerobic Suscept: Custom MIC—Oxacillin   each   [***]* 5675PEN   87186
  Aerobic Suscept: Custom MIC—Penicillin G   each   [***]* 5675PIP1   87186  
Aerobic Suscept: Custom MIC—Piperacillin   each   [***]* 5675PIP2   87186  
Piperacillin/Tazobactam   each   [***]* 5675QUI   87186  
Quinupristin/Dalfopristin   each   [***]* 5675RIF   87186   Aerobic Suscept:
Custom MIC—Rifampin   each   [***]* 5675STR   87186   Aerobic Suscept: Custom
MIC—Streptomycin   each   [***]* 5675SUL1   87186   Aerobic Suscept: Custom
MIC—Sulfadiazine   each   [***]* 5675TET   87186   Aerobic Suscept: Custom
MIC—Tetracycline   each   [***]* 5675TIM   87186   Aerobic Suscept: Custom
MIC—Timentin   each   [***]* 5675TOB   87186   Aerobic Suscept: Custom
MIC—Tobramycin   each   [***]* 5675TRI   87186   Aerobic Suscept: Custom
MIC—Trim/Sulfa   each   [***]* 5675TRO   87186   Aerobic Suscept: Custom
MIC—Trovafloxacin   each   [***]*

51

--------------------------------------------------------------------------------

5675VAN   87186   Aerobic Suscept: Custom MIC—Vancomycin   each   [***]* 5676AMI
  87186; 87187   Aerobic Suscept: Custom MIC & MBC—Amikacin   each   [***]*
5676AMP1   87186; 87187   Aerobic Suscept: Custom MIC & MBC—Ampicillin   each  
[***]* 5676AMP2   87186; 87187   AMP/Sulbactam   each   [***]* 5676AZT   87186;
87187   Aerobic Suscept: Custom MIC & MBC—Aztreonam   each   [***]* 5676CAR  
87186; 87187   Aerobic Suscept: Custom MIC & MBC—Carbenicillin   each   [***]*
5676CEF1   87186; 87187   Aerobic Suscept: Custom MIC & MBC—Cefaclor   each  
[***]* 5676CEF3   87186; 87187   Aerobic Suscept: Custom MIC & MBC—Cefazolin  
each   [***]* 5676CEF4   87186; 87187   Aerobic Suscept: Custom MIC &
MBC—Cefixime   each   [***]* 5676CEF6   87186; 87187   Aerobic Suscept: Custom
MIC & MBC—Cefoperazone   each   [***]* 5676CEF7   87186; 87187   Aerobic
Suscept: Custom MIC & MBC—Cefotaxime   each   [***]* 5676CEF8   87186; 87187  
Aerobic Suscept: Custom MIC & MBC—Cefotetan   each   [***]* 5676CEF9   87186;
87187   Aerobic Suscept: Custom MIC & MBC—Cefoxitin   each   [***]* 5676CEP  
87186; 87187   Aerobic Suscept: Custom MIC & MBC—Cephalothin   each   [***]*
5676CF10   87186; 87187   Aerobic Suscept: Custom MIC & MBC—Ceftazidime   each  
[***]* 5676CF11   87186; 87187   Aerobic Suscept: Custom MIC & MBC—Ceftizoxime  
each   [***]* 5676CF12   87186; 87187   Aerobic Suscept: Custom MIC &
MBC—Ceftriaxone   each   [***]* 5676CF13   87186; 87187   Aerobic Suscept:
Custom MIC & MBC—Cefuroxime   each   [***]* 5676CF14   87186; 87187   Aerobic
Suscept: Custom MIC & MBC—Cefepime   each   [***]* 5676CF15   87186; 87187  
Aerobic Suscept: Custom MIC & MBC—Cefpodoxime   each   [***]* 5676CHL   87186;
87187   Chloramphenicol   each   [***]* 5676CIP   87186; 87187   Aerobic
Suscept: Custom MIC & MBC—Ciprofloxacin   each   [***]* 5676CLA   87187; 87190  
Aerobic Suscept: Custom MIC & MBC—Clarithromycin   each   [***]* 5676CLI  
87186; 87187   Aerobic Suscept: Custom MIC & MBC—Clindamycin   each   [***]*
5676ERY   87186; 87187   Aerobic Suscept: Custom MIC & MBC—Erythromycin   each  
[***]* 5676GEN   87186; 87187   Aerobic Suscept: Custom MIC & MBC—Gentamicin  
each   [***]* 5676IMI   87186; 87187   Aerobic Suscept: Custom MIC &
MBC—Imipenem   each   [***]*

52

--------------------------------------------------------------------------------

5676LEV   87186; 87187   Aerobic Suscept: Custom Mic & Mbc—Levofloxacin
(Levaquin)   each   [***]* 5676NIT   87186; 87187   Aerobic Suscept: Custom MIC
& MBC—Nitrofurantoin   each   [***]* 5676NOR   87186; 87187   Aerobic Suscept:
Custom MIC & MBC—Norfloxacin   each   [***]* 5676OFL   87186; 87187   Aerobic
Suscept: Custom MIC & MBC—Ofloxacin   each   [***]* 5676OXA   87186; 87187  
Aerobic Suscept: Custom MIC & MBC—Oxacillin   each   [***]* 5676PEN   87186;
87187   Aerobic Suscept: Custom MIC & MBC—Penicillin G   each   [***]* 5676PIP1
  87186; 87187   Aerobic Suscept: Custom MIC & MBC—Piperacillin   each   [***]*
5676PIP2   87186; 87187   Aerobic Suscept: Custom MIC &
MBC—Piperacillin/Tazobactam   each   [***]* 5676QUI   87186; 87187   Aerobic
Suscept: Custom MIC & MBC—Quinupristin/Dalfopristin   each   [***]* 5676RIF  
87186; 87187   Aerobic Suscept: Custom MIC & MBC—Rifampin   each   [***]*
5676STR   87186; 87187   Aerobic Suscept: Custom MIC & MBC—Streptomycin   each  
[***]* 5676TET   87186; 87187   Aerobic Suscept: Custom MIC & MBC—Tetracycline  
each   [***]* 5676TOB   87186; 87187   Aerobic Suscept: Custom MIC &
MBC—Tobramycin   each   [***]* 5676TRI   87186; 87187   Aerobic Suscept: Custom
MIC & MBC—Trimethoprim/Sulfa   each   [***]* 5676TRO   87186; 87187   Aerobic
Suscept: Custom MIC & MBC—Trovafloxacin   each   [***]* 5676VAN   87186; 87187  
Aerobic Suscept: Custom MIC &MBC—Vancomycin   each   [***]* 5721AZT   87252  
HIV-1 Anti-Viral Drug Study: AZT IC50 Value   each   [***]* 5721DDC   87252  
HIV-1 Anti-Viral Drug Study;: ddC IC50 Value   each   [***]* 5721DDI   87252  
HIV-1 Anti-Viral Drug Study: ddI IC50 Value   each   [***]* 5768AMI   87190  
Amikacin   each   [***]* 5768ANS   87190   AFB Suscept: Custom Drug
Mycobacterium spp.—Ansamycin   each   [***]* 5768AZI   87190   AFB Suscept:
Custom Drug Mycobacterium spp.—Azithromycin   each   [***]* 5768CAP   87190  
AFB Suscept: Custom Drug Mycobacterium spp.—Capreomycin   each   [***]* 5768CIP
  87190   AFB Suscept: Custom Drug Mycobacterium spp.—Ciprofloxacin   each  
[***]* 5768CLA   87190   AFB Suscept: Custom Drug Mycobacterium
spp.—Clarithromycin   each   [***]* 5768CLO   87190   AFB Suscept: Custom Drug
Mycobacterium spp.—Clofazimine   each   [***]*

53

--------------------------------------------------------------------------------

5768CYC   87190   AFB Suscept: Custom Drug Mycobacterium spp.—Cycloserine   each
  [***]* 5768ET1   87190   AFB Suscept: Custom Drug Mycobacterium
spp.—Ethambutol   each   [***]* 5768ET2   87190   AFB Suscept: Custom Drug
Mycobacterium spp.—Ethionamide   each   [***]* 5768ISO   87190   Isoniazid  
each   [***]* 5768PAS   87190   AFB Suscept: Custom Drug Mycobacterium spp.—p
Aminosalicylic   each   [***]* 5768PYR   87190   AFB Suscept: Custom Drug
Mycobacterium spp.—Pyrazinamide   each   [***]* 5768RIF   87190   Rifampin  
each   [***]* 5768STR   87186   AFB Suscept: Custom Drug Mycobacterium
spp.—Streptomycin   each   [***]* 5946AD   85576   Platelet Aggregation; ADP  
each   [***]* 5946AR   85576   Platelet Aggregation; Arachidonic Acid   each  
[***]* 5946CO   85576   Platelet Aggregation; Collagen   each   [***]* 5946EP  
85576   Platelet Aggregation; Epinephrine   each   [***]* 5946RT   85576  
Platelet Aggregation; Ristocetin   each   [***]* 5946SP   85576   Platelet
Aggregation; Spontaneous   each   [***]* 7221C   86606x3; 86612; 86635x3;
86698x3   Fungal Abs [EIA] CSF   each   [***]* 7224C   86606; 86612; 86635;
86698   Fungal IgG Abs CSF   each   [***]* 7476SR   87522   Hepatitis C Virus
RNA AccuQuant rflx GenotypR w/Serial Graph   each   [***]* 7477NY   83891x14;
83898x4; 83904x6; 83912   HIV-1 GenotypR (Reverse Transcriptase Inhibitor) New
York   each   [***]* 7478A   87536   HIV-1 RNA Quant by Roche rflx
Ultrasensitive+GenotypeR (RTI)   each   [***]* 7478ASR   87536   HIV-1 RNA Quant
by Roche rfx Ultrasens+GenotypR RTI w/SerRep   each   [***]* 7478NY   87536  
HIV-1 RNA Quant by Roche reflex HIV GenotypR (RTI) New York   each   [***]*
7478NYSR   87536   HIF-1 RNA Quant by Roche rfx HIV GenotypR RTI New York w/SR  
each   [***]* 7478SR   87536   HIV-1 RNA UltraQuant reflx to HIV GenotypR (RTI)
w/Ser Rep   each   [***]* 7479NY   83891x4; 83898x2; 83904x2; 83912   HIV-1
GentypR (Protease Inhibitor) New York   each   [***]* 7480NY   83891x13;
83898x5; 83904x8; 83912   HIV-1 GenotypR PLUS (Rev Trans & Prot Inhib) New York
  each   [***]* 7482A   87536   HIV-1 RNA Quant by Roche rfx to
Ultrasensitive+GenotypR PLUS   each   [***]* 7482ASR   87536   HIV-1 RNA Quant
by Roche rflx Ultrasens + GentypR PLUS w/SR   each   [***]* 7482NY   87536  
HIV-1 RNA Quant by Roche reflex HIV GenotypR PLUS New York   each   [***]*
7482NYSR   87536   HIV-1 RNA Quant by Roche rfx HIV GenotypR PLUS New York w/SR
  each   [***]*

54

--------------------------------------------------------------------------------

7482SR   87536   HIV-1 RNA UltraQuant reflx to HIV GenotypR PLUS w/ Serial Rep  
each   [***]* 7483A   87536   HIV-1 RNA Quant by Roche reflx Ultrasens +
GenotypR (PI)   each   [***]* 7483ASR   87536   HIV-1 RNA Quant by Roche reflx
Ultrasens + GenotypR (PI); Ser R   each   [***]* 7483NY   87536   HIV-1 RNA
UltraQuant reflx to HIV GenotypR (PI) New York   each   [***]* 7483NYSR   87536
  HIV-1 RNA UltraQuant rfx HIV GenotypR (PI) New York w/ Serial   each   [***]*
7483SR   87536   HIV-1 RNA UltraQuant reflex to HIV GenotypR (PI) w/ Ser Rep  
each   [***]* 7485A   87536   HIV-1 RNA Quant by Roche Ultrasensitive   each  
[***]* 7485ASR   87536   HIV-1 RNA Quant by Roche Ultrasensitive with Serial
Graphics   each   [***]* 7486SR   87522   Hepatitis C Virus RNA AccuQuant w/
Serial Graphics   each   [***]* 7491B   86804   Hepatitis C Virus RIBA
Evaluation with reflex PCR   each   [***]* 7560C   86781   CSF   each   [***]*
7561C   86781   Treponema Pallidum IgG Abs CSF   each   [***]* 7565F   86781x2  
Treponema Pallidum IgG & IgM Abs Fluid   each   [***]* 7566C   87285   Treponema
Pallidum IgM Abs CSF   each   [***]* 7576SR   87522   Hepatitis C Virus RNA
UltraQuant w/ Serial Graph   each   [***]* 7578SR   87522   Hepatitis C Virus
RNA UltraQuant w/ Serial Graph reflex to HCV Genotyper   each   [***]* 7584C  
87799   Epstein-Barr Virus Dna UltraRapid CSF   each   [***]* 7584PL   87799  
Epstein-Barr Virus DNA UltraQuant Plasma   each   [***]* 7596C   86790  
Japanese Encephalitis Virus Total Abs CSF   each   [***]* 7601C   86790   Dengue
Virus Total Abs CSF   each   [***]* 7621C   86720x2   Leptospira IgG & IgM Abs
CSF   each   [***]* 7646C   86790   Dengue Virus IgM Abs CSF   each   [***]*
7661C   86778   Toxoplasma IgM Abs [ISAGA] CSF   each   [***]* 7661F   86778  
Toxoplasma IgM Abs [ISAGA] Fluid   each   [***]* 7675C   86778   Toxoplasma IgM
Abs [MAC EIA] CSF   each   [***]* 7675F   86778   Toxoplasma IgM Abs [MAC EIA]
Fluid   each   [***]* 7711B   86617x2   Borrelia Burgdorferi IgG & IgM Abs [IB]
+ bands   each   [***]* 7711BNY   86618x2   bands   each   [***]* 7711C  
86617x2   Borrelia Burgdorferi IgG & IgM Abs [IB] CSF   each   [***]* 7711CB  
86617x2   Borrelia Burgdorferi IgG & IgM Abs [IB] CSF + bands   each   [***]*
7711SF   86617x2   Borrelia Burgdorferi IgG & IgM Abs [IB] Syn Fluid   each  
[***]* 7711SFB   86617x2   bands   each   [***]* 7716B   86617x2; 86618x2  
Borrelia Burgdorferi IgG & IgM Abs with IB + bands   each   [***]* 7716BNY  
86618x4   Borrelia Burgdorferi IgG & IgM Abs with IB + bands   each   [***]*

55

--------------------------------------------------------------------------------

7716C   86617x2; 86618x2   Borrelia Burgdorferi IgG & IgM Abs with IB CSF   each
  [***]* 7716CB   86617x2; 86618x2   bands   each   [***]* 7716SF   86617x2;
86618x2   Borrelia Burgdorferi IgG & IgM Abs with Ib Syn Fluid   each   [***]*
7751C   86674x3   Giardia Lamblia IgG; IgM & IgA Abs CSF   each   [***]* 7776C  
86790x2   Herpesvirus-6 Human Early Ag IgG & IgM Abs CSF   each   [***]* 7780B  
86689   HTLV-I/II Abs Confirmation + bands   each   [***]* 7780C   86689  
HTLV-I/II Abs Confirmation CSF   each   [***]* 7780CB   86689   HTLV-I/II Abs
Confirmation + bands CSF   each   [***]* 7786C   86790   Herpesvirus-6 Human
Early Ag IgG Abs CSF   each   [***]* 7796C   86790   Herpesvirus-6 Human Early
Ag IgM Abs CSF   each   [***]* 7844C   86609x2   Ehrlichia equi IgG & IgM (HGE)
Abs CSF   each   [***]* 7844NY   86609x2   Ehrlichia equi IgG & IgM Abs; HGE New
York   each   [***]* 7848NY   86609x4   Ehrlichia chaffeensis (HME) & E. equi
(HGE) IgG & IgM Abs—NY   each   [***]* 7856C   86759   Rotavirus Abs CSF   each
  [***]* 7876C   86609x4   Rickettsia rickettsii & R. typhi IgG & IgM Abs Eval
CSF   each   [***]* 7896C   86609x2   Rickettsia rickettsii IgG & IgM Abs CSF  
each   [***]* 7911C   86609x2   Rickettsia typhi IgG & IgM Abs CSF   each  
[***]* 7951C   86609x2   Rickettsia conorii IgG & IgM Abs CSF   each   [***]*
7960SF   82784x4; 86618x4; 87476   Neuroborreliosis AccuDx; Synovial Fluid  
each   [***]* 7970SF   82784x4; 86618x4   Borrelia Burgdorferi IgG & IgM
Antibody Index Synovial Fluid   each   [***]* 8051C   86694x2; 86695x2   Herpes
Simplex Virus Types 1 and 2 IgG & IgM Abs CSF   each   [***]* 8056C   86603  
Adenovirus IgG Abs CSF   each   [***]* 8071P   86631x2; 86632x2   Chlamydia
pneumoniae Total & IgM Abs Paired   each   [***]* 8076P   86631x2   Chlamydia
pneumoniae Total Abs Paired   each   [***]* 8091P   86658x6   Poliovirus Abs
Paired   each   [***]* 8147C   87799   JC Virus UltraRapid CSF   each   [***]*
8151C   86744   Nocardia IgG Abs CSF   each   [***]* 8171C   86668x3  
Francisella Tularensis IgG; IgM & IgA Abs CSF   each   [***]* 8176C   86651  
California-LaCrosse Encephalitis IgM Abs CSF   each   [***]* 8181C   86652  
Eastern Equine Encephalitis IgM Abs CSF   each   [***]* 8186C   86653   St.
Louis Encephalitis IgM Abs CSF   each   [***]* 8191C   86654   Western Equine
Encephalitis IGM Abs CSF   each   [***]* 8221C   86747x2   Parvovirus B19 IgG &
IgM Abs [EIA] CSF   each   [***]* 8226C   86651; 86652; 86653; 86654   Arbovirus
IgM Abs CSF [IFA]   each   [***]* 8236C   86747x2   Parvovirus B19 IgG & IgM Abs
[IB] CSF   each   [***]*

56

--------------------------------------------------------------------------------

8241C   86609x2   Burkholderia (Pseudomonas) pseudomallei IgG & IgM Abs CSF  
each   [***]* 8246C   86713   CSF   each   [***]* 8251C   86723   Listeria
Monocytogenes IgG Abs CSF   each   [***]* 8261C   86747x2; 87798   Parvovirus
B19 Evaluation CSF   each   [***]* 8286C   86671x3   Sporothrix IgG; IgM & IgA
Abs CSF   each   [***]* 8311C   86698x3   Histoplasma IgG; IgM & IgA Abs CSF  
each   [***]* 8315UR   87449   Histoplasma Antigen In Urine   each   [***]*
8316C   86635   Coccidioides IgM Abs CSF   each   [***]* 8321C   86635  
Coccidioides IgG Abs CSF   each   [***]* 8331C   86635x3   Coccidioides IgG; IgM
& IgA Abs CSF   each   [***]* 8346C   86612   Blastomyces IgG Abs CSF   each  
[***]* 8351C   86682x2   Schistosoma IgG and IgM Abs CSF   each   [***]* 8371C  
86750x2   Malaria Antibodies IgG & IgM Abs CSF [EIA]   each   [***]* 8421C  
86682   Fasciola IgG Abs CSF   each   [***]* 8426C   86682x2   Fasciola IgG &
IgM Abs CSF   each   [***]* 8441C   86753x3   Entamoeba Histolytica IgG; IgM &
IgA Abs CSF   each   [***]* 8451C   86682   Echinococcus IgG Abs CSF   each  
[***]* 8516C   86710x6   Influenza Virus A & B IgG; IgM & IgA Abs CSF   each  
[***]* 8566C   86682   Strongyloides IgG Abs CSF   each   [***]* 8576C   86771x4
  Shigella Abs CSF   each   [***]* 8666C   86658x10; 86710x2   Myopericarditis
Viral Antibodies Evaluation CSF   each   [***]* 8676C   86793   Yersinia
enterocolitica Abs Serotype 0:3 CSF   each   [***]* 8681C   86793   Yersinia
enterocolitica Abs Serotype 0:8 CSF   each   [***]* 8686C   86793   Yersinia
enterocolitica Abs Serotype 0:9 CSF   each   [***]* 8691C   86756x2  
Respiratory Synctyial Virus IgG & IgM Abs CSF   each   [***]* 8696C   86793x3  
Yersinia Enterocolitica Abs Serotypes 0:3; 0:8; 0:9 CSF   each   [***]* 8711C  
86793   Yersinia Pseudotuberculosis Total Abs CSF   each   [***]* 8721C   86793
  Yersinia enterocolitica IgA Abs CSF   each   [***]* 8731C   86738   Mycoplasma
Pneumoniae IgA Abs CSF   each   [***]* 8736C   86738x3   CSF   each   [***]*
8741C   86738x2   Mycoplasma pneumoniae IgG & IgM Abs CSF   each   [***]* 8741P
  86738x4   Mycoplasma pneumoniae IgG & IgM Abs Paired   each   [***]* 8746C  
86738   Mycoplasma pneumoniae IgG Abs CSF   each   [***]* 8751C   86738  
Mycoplasma pneumoniae IgM Abs CSF   each   [***]* 8756C   86787x2  
Varicella-zoster Virus SeroDx; IgG & IgM Abs CSF   each   [***]* 8760C   87799  
Varicella-Zoster Virus Dna UltraRapid CSF   each   [***]* 8761C   86787  
Varicella-zoster Virus IgG Abs CSF   each   [***]* 8766C   86787  
Varicella-zoster Virus IgM Abs CSF   each   [***]* 8771C   86765x2   Measles IgG
& IgM Abs CSF   each   [***]* 8776C   86765   Measles IgG Abs CSF   each  
[***]* 8781C   86765   Measles IgM Abs CSF   each   [***]*

57

--------------------------------------------------------------------------------

8831C   86622x3   Brucella abortus IgG; IgM & IgA Abs CSF   each   [***]* 8836C
  86622   Brucela abortus IgG Abs CSF   each   [***]* 8841C   86723   Listeria
Monocytogenes Abs CSF   each   [***]* 8851C   86317x2   Bartonella henselae IgG
7 IgM Abs CSF   each   [***]* 8866C   86625   Campylobacter jejuni Total Abs
[EIA] CSF   each   [***]* 8881C   86625   Campylobacter fetus Total Abs CSF  
each   [***]* 8886C   86625   Campylobacter jejuni Total Abs [CF] CSF   each  
[***]* 8921C   86653   St. Louis Encephalitis Total Abs CSF   each   [***]*
8926C   86651   California-La Crosse Encephalitis Total ABS CSF   each   [***]*
8931C   86654   Western Equine Encephalitis Total Abs CSF   each   [***]* 8936C
  86652   Eastsern Equine Encephalitis Total Abs CSF   each   [***]* 8941C  
86618x2   Borrelia burgdorferi IgG & IgM Abs [EIA] CSF   each   [***]* 8941SF  
86618x2   Borrelia burgdorferi IgG & IgM Abs [EIA] Syn Fluid   each   [***]*
8945SF   82784x2; 86618x2   Borrelia burgdorferi IgG Antibody Index Synovial
Fluid   each   [***]* 8951C   86618   Borrelia burgdorferi IgG Abs CSF   each  
[***]* 8951SF   86618   Borrelia burgdorferi IgG Abs Syn Fluid   each   [***]*
8961C   86618   Borrelia burgdorferi IgM Abs CSF   each   [***]* 8961SF   86618
  Borrelia burgdorferi IgGM Abs Syn Fluid   each   [***]* 8981F   86665   Fluid
  each   [***]* 9099C   86641   Cryptococcus Abs CSF   each   [***]* 9189C  
87449   Cryptococcus Ag CSF   each   [***]* 9189U   87449   Cryptococcus Ag
Urine   each   [***]* 9301C   86682x2   Filaria IgG & IgM Abs CSF   each  
[***]* 9371C   86638x2   Coxiella burnetii IgG Abs; Phase 1 & 2 CSF   each  
[***]* 9376C   86638x2   Coxiella burnetii IgM Abs; Phase 1 & 2 CSF   each  
[***]* 9381C   86638x6   Coxiella burnetii IgG; IgM; & IgA Abs; Phase 1 & 2 CSF
  each   [***]* 9386C   86784   Trichinella IgG Abs CSF   each   [***]* 9391C  
86631   Chlamydia trachomatis IgA Abs CSF   each   [***]* 9396C   86619x2  
Borrelia hermsii IgG & IgM Abs CSF   each   [***]* 9401C   86631x2; 86632  
Chlamydia trachomatis IgG; IgM & IgA Abs CSF   each   [***]* 9406C   86631  
Chlamydia trachomatis IgG Abs [EIA] CSF   each   [***]* 9411C   86632  
Chlamydia trachomatis IgM Abs [EIA] CSF   each   [***]* 9416F   86762   Rubella
IgG Abs Fluid   each   [***]* 9421C   86762x2   Rubella IgG & IgM Abs CSF   each
  [***]* 9426C   86777   Toxoplasma IgG Abs CSF   each   [***]* 9426F   86777  
Toxoplasma IgG Abs Fluid   each   [***]* 9430C       Cytomegalovirus Dna
Ultraquant CSF   each   [***]* 9430SR   87497   Cytomegalovirus DNA Ultraquant
w/ Serial Graphics   each   [***]* 9431C   86644   Cytomegalovirus IgG Abs CSF  
each   [***]* 9436C   86644; 86645   Cytomegalovirus IgG & IgM Abs CSF   each  
[***]* 9446C   86694; 86695   Herpes Simplex Virus Types 1 & 2 IgG Abs CSF  
each   [***]* 9451C   86695   Herpes SimplexVirus Type 1 IgG Abs CSF   each  
[***]* 9456C   86695   Herpes Simplex Virus Type 1 IgM Abs CSF   each   [***]*

58

--------------------------------------------------------------------------------

9461C   86694   Herpes Simplex Virus Type 2 IgG Abs CSF   each   [***]* 9466C  
86694   Herpes Simplex Virus Type 2 IgM Abs CSF   each   [***]* 9471C   86694;
86695   Herpes Simplex Virus Type 1 & 2 IgM Abs CSF   each   [***]* 9474C  
87530   Herpes Simplex Virus Dna Ultraquant CSF   each   [***]* 9476C   86695x2
  Herpes Simplex Virus Type 1 IgG & IgM Abs CSF   each   [***]* 9481C   86694x2
  Herpes Simplex Virus Type 2 IgG & IgM Abs CSF   each   [***]* 9521C   86651;
86652; 86653; 86654   Arbovirus Total Abs CSF   each   [***]* 9601C   86588x2;
87449x7   Bacterial Ag Detection cSF   each   [***]* 9601U   86588x2; 87449x7  
Bacterial Ag Detection—Urine   each   [***]* 9606C   87449   Haemophilus
influenzae b Ag CSF       [***]* 9606U   87449   Haemophilus influenzae b Ag
Urine   each   [***]* 9636C   86588   Streptococcus pheumoniae Ag CSF   each  
[***]* 9636U   86588   Streptococcus pneumoniae Ag Urine   each   [***]* 9641C  
86588   Streptococcus Group B Ag CSF   each   [***]* 9641U   86588  
Streptococcus Group B Ag Urine   each   [***]* 9671C   86615   Bordetella
pertussis/parapertussis IgG Abs CSF   each   [***]* 9676C   86615x3   Bordetella
pertussis/parapertussis IgG; IgM && IgA Abs CSF   each   [***]* 9681C   86615x2
  CSF   each   [***]* 9711C   86735x2   Mumps IgG & IgM Abs CSF   each   [***]*
9716C   86735   Mumps IgG Abs CSF   each   [***]* 9721C   86735   Mumps IgM Abs
CSF   each   [***]* 9741C   86784x3   Trichinella IgG; IgM & IgA Abs CSF   each
  [***]* 9751C   86793x3   Yersinia enterocolitica IgG; IgM & IgA Abs CSF   each
  [***]* 9761F   86682x3   Toxocara IgG; IgM & IgA Abs Fluid   each   [***]*
9816C   86682   Cysticercus IgG Abs CSF   each   [***]* 9816CS   86682x2  
Cysticercus IgG Abs Evaluation [Serum & CSF]   each   [***]* 9861P   86684x2  
Vaccination   each   [***]* 9866c   86311   HIV-1 Ag Neutralization Confirmation
Test CSF   each   [***]* 9872SR   85048; 85595; 86361; 87536   HIV-1 RNA
UltraQuant & CD4 Cell Count w/ Serial Report   each   [***]* 9874A   87536  
HIV-1 RNA Quant by Roche reflx Ultrasensitive   each   [***]* 9874ASR   87536  
HIV-1 RNA Quant by Roche w/ reflx Ultrasensitive w/ Serial Rep   each   [***]*
9874NY   87536   HIV-1 RNA UltraQuant New York   each   [***]* 9874NYSR   87536
  HIV-1 RNA UltraQuant New York w/Serial Reporting   each   [***]* 9874SR  
87536   HIV-1 RNA UltraQuant with Serial Reporting   each   [***]* 9876NY  
87539   HIV-2 DNA Detector Qual New York   each   [***]* 9881C   87390   HIV-1
Free Ag CSF   each   [***]* 9881NYD   86311   HIV-1 Free Ag New York Diagnostic
  each   [***]*

59

--------------------------------------------------------------------------------

9881NYP   86311   HIV-1 Free Ag New York Prognostic   each   [***]* 9884A  
87536   HIV-1 RNA Quant by Roche Amplicor   each   [***]* 9884ASR   87536  
Reporting   each   [***]* 9884NYP   87536   HIV-1 RNA Quantitation New York
Prognostic   each   [***]* 9884NYPS   87536   HIV-1 RNA Quantitation New York
Prognostic w/ Serial Report   each   [***]* 9885N   87535   HIV-1 DNA DetectR
Non-blood   each   [***]* 9885NYP   87535   HIV-1 DNA Detector New York
Prognostic   each   [***]* 9886NY   87536   York   each   [***]* 9898C   86849  
HTLV I/II IgG Abs CSF   each   [***]* 9901C   80090; 86645; 86695x2; 86778  
TORCH IgG & IgM Abs Evaluation CSF   each   [***]* 9911C   80090; 86695   TORCH
IgG Abs Evaluation CSF   each   [***]* 9915B   86703   HIV-1/ HIV-2 Antibodies
Plus Confirmation W/ Bands   each   [***]* 9915NY   86703   HIV-1/HIV-2
Antibodies Plus Confirmation New York   each   [***]* 9915NYB   86703  
HIV-1/HIV-2 Antibodies Plus Confirmation W/Bands New York   each   [***]* 9921B
  86702   HIV-2 IgG Abs w/ reflex IB + bands   each   [***]* 9921C   86702  
HIV-2 IgG Abs w/ reflex IB CSF   each   [***]* 9921NY   86702   HIV-2 IgG Abs w/
reflex IB New York   each   [***]* 9926B   86689   HIV-2 IgG Abs; Confirmation +
bands   each   [***]* 9926C   86689   HIV-2 IgG Abs; Confirm; CSF   each  
[***]* 9941C   86606x3   Aspergillus Abs Panel CSF [EIA]   each   [***]* 9946C  
86606   Aspergillus IgM Abs CSF   each   [***]* 9961C   86606   Aspergillus IgG
Abs CSF [EIA]   each   [***]* EX1   86005   RAST-Animal Mix: EX1   each   [***]*
EX2   86005   RAST-Animal Mix: EX2   each   [***]* EX70   86003  
RAST-Animal-Rodent Mix: EX70   each   [***]* EX71   86003   RAST-Animal-Feather
Mix: EX71   each   [***]* EX72   86003   RAST-Animal-Caged Bird Mix: EX72   each
  [***]* EX73   86003   RAST-Animal-Feather Mix: EX73   each   [***]* FX1  
86005   RAST-Food-Nut Mix: FX1   each   [***]* FX2   86005   RAST-Food-Seafood
Mix: FX2   each   [***]* FX3   86003   RAST-Food-Cereal Mix: FX3   each   [***]*
FX5   86005   RAST-Food-Children's Food Mix: FX5   each   [***]* FX70   86005  
RAST-Food-Spice Mix: FX70   each   [***]* FX71   86005   RAST-Food-Spice Mix:
FX71   each   [***]* FX72   86005   RAST-Food-Spice Mix: FX72   each   [***]*
FX73   86005   RAST-Food-Meat Mix: FX73   each   [***]* FX74   86005  
RAST-Food-Fish Mix: FX74   each   [***]* GX1   86005   RAST-Grass Mix: GX1  
each   [***]* GX2   86005   RAST-Grass Mix: GX2   each   [***]* GX3   86005  
RAST-Grass Mix: GX3   each   [***]* GX4   86005   RAST-Grass Mix: GX4   each  
[***]* HX2   86005   RAST-House Dust Mix: HX3   each   [***]* IHC00   88342  
IHC Marker   each   [***]* IHC00A   88342   IHC Marker   each   [***]* IHC00B  
88342   IHC Marker   each   [***]*

60

--------------------------------------------------------------------------------

IHC00C   88342   IHC Marker   each   [***]* IHC01BK   88342   IHC Estrogen
Receptor Block   each   [***]* IHC02BK   88342   IHC Progesterone Receptor Block
  each   [***]* IHC04BK   88342   IHC HER-1/neu Oncoprotein Block   each  
[***]* IHC06BK   88342   IHC Ki-67 Block   each   [***]* IHC07BK   88342   IHC
pS2 Block   each   [***]* IHC08BK   88342   IHC p53 Block   each   [***]* IHC1  
88342   IHC Assay [Pathologist Interpretation]   each   [***]* IHC10BK   88342  
IHC PCNA block   each   [***]* IHC130BK   88342   IHC HAM 56 Macrophage Block  
each   [***]* IHC131BK   88342   IHC Lysozyme Block   each   [***]* IHC14BK  
88342   IHC BCL-2 Block   each   [***]* IHC153BK   88342   IHC Cytokeratin 7
Block   each   [***]* IHC161BK   82024   IHC ACTH Block   each   [***]* IHC162BK
  88342   IHC FSH Block   each   [***]* IHC163BK   88342   IHC GH Block   each  
[***]* IHC164BK   88342   IHC LH Block   each   [***]* IHC165BK   88342   IHC
Prolactin Block   each   [***]* IHC166BK   88342   IHC TSH Block   each   [***]*
IHC170BK   88342   IHC Thyroglobulin Block   each   [***]* IHC171BK   88342  
IHC Calcitonin Block   each   [***]* IHC184BK   88342   IHC Amyloid A Block  
each   [***]* IHC185BK   88342   IHC Collagen Type IV Block   each   [***]*
IHC21BK   88342   IHC CD45 (LCA) Block   each   [***]* IHC22BK   88342   IHC
CD20 (Pan-B Cell) Block   each   [***]* IHC23BK   88342   IHC CD3 (Pan-T Cell)
Block   each   [***]* IHC24BK   88342   IHC CD43 Block   each   [***]* IHC25BK  
88342   IHC CD4 (T-Helper Cell) Block   each   [***]* IHC26BK   88342   IHC CD68
Block   each   [***]* IHC28BK   88342   IHC MAC387 Block   each   [***]* IHC29BK
  88342   IHC CD30 (Ki-1) Block   each   [***]* IHC30BK   88342   IHC CD15 Block
  each   [***]* IHC31BK   88342   IHC Kappa Light Chain Block   each   [***]*
IHC32BK   88342   IHC Lambda Light Chain Block   each   [***]* IHC33BK   88342  
IHC CD45RA Block   each   [***]* IHC35BK   88342   IHC CD45RO Block   each  
[***]* IHC39BK   88342   IHC CD57 Block   each   [***]* IHC41BK   88342   IHC
PSA (Prostate-Specific Ag) Block   each   [***]* IHC42BK   88342   IHC Pap Block
  each   [***]* IHC43BK   88342   IHC CEA Block   each   [***]* IHC45BK   88342
  IHC Cytokeratin (HMW) Block   each   [***]* IHC46BK   88342   IHC Cytokeratin
(LMW) Block   each   [***]* IHC47BK   88342   IHC Vimentin Block   each   [***]*
IHC48BK   88342   IHC NSE Block   each   [***]* IHC49BK   88342   IHC EMA Block
  each   [***]* IHC50BK   88342   IHC Pancreatic Amylase Block   each   [***]*
IHC55BK   88342   IHC Pan-Cytokeratin Block   each   [***]* IHC57BK   88342  
IHC OC125 Block   each   [***]* IHC61BK   88342   IHCS-100 Block   each   [***]*
IHC62BK   88342   IHC HMB-45 (Melanoma) Block   each   [***]* IHC71BK   82105  
IHC AFP Block   each   [***]*

61

--------------------------------------------------------------------------------

IHC73BK   88342   IHC Beta-hCG Block   each   [***]* IHC74BK   88342   IHC
Placental Alkaline Phosphatase Block   each   [***]* IHC81BK   88342   IHC
Chromogranin Block   each   [***]* IHC82BK   88342   IHC Serotonin Block   each
  [***]* IHC84BK   88342   IHC GFAP Block   each   [***]* IHC85BK   88342   IHC
Neurofilament   each   [***]* IHC86BK   88342   IHC Synaptophysin Block   each  
[***]* IHC87BK   88342   IHC Insulin Block   each   [***]* IHC88BK   88342   IHC
Glucagon Block   each   [***]* IHC89BK   88342   IHC Gastrin Block   each  
[***]* ICH92BK   88342   IHC Smooth Muscle Block   each   [***]* IHC93BK   88342
  IHC Desmin Block   each   [***]* IHC95BK   88342   IHC Myoglobin Block   each
  [***]* IHC97BK   88342   IHC Factor VIII Ag Block   each   [***]* IHCSTAIN1  
88342   IHC1 Stain   each   [***]* MX1   86005   RAST-Mold Mix: MX1   each  
[***]* MX2   86005   RAST-Mold Mix: MX2   each   [***]* PAX1   86005   RAST
Combination Mix: PAX1   each   [***]* PAX2   86005   RAST-Storage Mite Mix: PAX2
  each   [***]* PAX3   86005   RAST Combination Mix: PAX3   each   [***]* PAX4  
86005   RAST Combination Mix: PAX4   each   [***]* PAX5   86005  
RAST-Occupational Mix: PAX5   each   [***]* PAX6   86005   RAST-Occupational
Mix: PAX6   each   [***]* RAST1   86003   RAST-Allergen Testing-Single Allergen
  each   [***]* RFX10   86005   FAST-Food-Meat & Egg Mix: RFX10   each   [***]*
RFX11   86005   RAST-Food-Vegetable Mix: RFX11   each   [***]* RFX12   86005  
RAST-Food-Vegetable & Grain Mix: RFX12   each   [***]* RFX13   86005  
RAST-Food-Vegetable Mix: RFX13   each   [***]* RFX14   86005  
RAST-Food-Vegetable Mix: RFX14   each   [***]* RFX15   86005   RAST-Food-Fruit
Mix: RFX15   each   [***]* RFX16   86005   RAST-Food-Fruit Mix: RFX16   each  
[***]* RFX17   86005   RAST-Food-Fruit Mix: RFX17   each   [***]* RFX18   86005
  RAST-Food-Vegetable Mix: RFX18   each   [***]* RFX19   86005  
RAST-Food-Vegetable Mix: RFX19   each   [***]* RFX20   86005   RAST-Food-Grain
Mix: RFX20   each   [***]* RFX21   86005   RAST-Food-Fruit Mix: RFX21   each  
[***]* RFX22   86005   RAST-Food-Nut Mix RFX22   each   [***]* RFX8   86003  
RAST-Food-Fruit & Nut Mix: RFX8   each   [***]* RFX9   86005   RAST-Food-Fruit &
Nut Mix: RFX9   each   [***]* RGX6   86005   RAST-Grass Mix: RGX6   each  
[***]* RRX1   86005   RAST-Grass; Weed; & Tree Mix: RRX1   each   [***]* RRX2  
86005   RAST-Mite; Epidermal; & Mold Mix: RRX2   each   [***]* RRX3   86005  
RAST-Grass; Weed; & Tree Mix: RRX3   each   [***]* RRX4   86005  
RAST-Grass;Weed; & Tree Mix: RRX4   each   [***]* RTX10   86005   RAST-Tree Mix:
RTX10   each   [***]* RW209   86005   RAST-Weed Mix: RW209   each   [***]* TX1  
86005   RAST-Tree Mix: TX1   each   [***]* TX2   86005   RAST Tree Mix: TX2  
each   [***]* TX3   86005   RAST Tree Mix: TX3   each   [***]* TX4   86005  
RAST Tree Mix: TX4   each   [***]* TX5   86005   RAST Tree Mix: TX5   each  
[***]*

62

--------------------------------------------------------------------------------

TX6   86005   RAST Tree Mix: TX6   each   [***]* TX7   86005   RAST Tree Mix:
TX7   each   [***]* TX8   86005   RAST Tree Mix: TX8   each   [***]* TX9   86005
  RAST Tree Mix: TX9   each   [***]* WX1   86005   RAST-Weed Mix:WX1   each  
[***]* WX2   86005   RAST-Weed Mix:WX2   each   [***]* WX3   86005   RAST-Weed
Mix:WX3   each   [***]* WX4   86005   RAST-Weed Mix:WX4   each   [***]* WX5  
86005   RAST-Weed Mix:WX5   each   [***]* WX6   86005   RAST-Weed Mix:WX6   each
  [***]* WX7   86005   RAST-Weed Mix:WX7   each   [***]*

63

--------------------------------------------------------------------------------

                each

EXHIBIT B

NON-PRICE SPECIFICATIONS

Term:   Three year agreement beginning May 1, 2001 through April 30, 2004 with
two one-year option years at Novation's option.
Marketing Fee:
 
[***]* on all sales.
 
 
Baseline Sales = May 1, 2000 through April 30, 2001 Years 1, 2, & 3: Target
Sales = [***]* Measurement Sales for each year = May 1 - April 30
 
 
Measurement sales in excess of target sales, as defined above, will be paid at a
[***]* marketing fee (an [***]* on any dollar above target sales). Upon
achievement, the [***]* will be payable to Novation no later than 90 days after
the end of the measurement sales year (due by July 31).
 
 
Should Novation elect to exercise one or both of the optional extension years,
Target Sales will be defined as:
 
 
Year 4: Target Sales = [***]*
Year 5: Target Sales = [***]*
 
 
Upon achievement, the [***]* will be payable to Novation no later than 90 days
after the end of the measurement sales year (due by July 31).
 
 
Example:
Baseline Sales (May 1, 2000 - April 30, 2001) = [***]*
Target Sales: [***]*
Measurement Sales: May 1, 2001 - April 30, 2002: [***]*
[***]* marketing fee on sales of [***]*
[***]* marketing fee on sales above target [***]*
Total marketing fee for year: [***]*
Information Services Offering:
 
The following offering will be available to Members and considered included as
part of the service by meeting the following minimum monthly volumes:

    Interface Type   Client Minimum
Monthly Sales
 
 
DataPassport™:
 
[***]*     Traditional CPU-to-CPU Interface:   [***]*     DataPassportMD™ with
hardware:   [***]*     DataPassportMD™ without hardware:   [***]*     Flash Link
Printer:   [***]*

    Test result reports are provided back to Members either by manual or
electronic reporting. Hardcopy test results are available through flashlink
printers, fax transmission, or U.S. mail

* CONFIDENTIAL TREATMENT IS REQUESTED FOR CONFIDENTIAL INFORMAITON ENCLOSED IN
THE BRACKETS AND UNDERLINED.

1

--------------------------------------------------------------------------------

Coverage:
 
Supplier will provide reference laboratory testing to all Members as defined in
Section 2a of the Supplier Agreement.
Courier Service:
 
Supplier will provide specimen pick-up services to Members. Supplier will work
with Members to establish pick up times that meet business and turn-around time
needs. Supplier will add additional services as appropriate to properly service
members that best optimizes its assay schedules and sample preparation. Supplier
will not charge any additional fees to Members for standard courier services of
specimens to Supplier. All specimens will be shipped by same day or overnight
services to Supplier's laboratory at Supplier's expense. Members will ship
specimens via same day or overnight services at no additional charge where a
courier service is not available. Supplier does not provide STAT service or
charge STAT fees due to the specialized nature of Supplier's standard testing
services.
Supplies:
 
All supplies required for the collection, processing, handling and
transportation of specimens will be paid for by Supplier. Supplies can be
ordered by calling client services at (800) 421-4449 or by faxing a copy of the
order form to (310) 828-5213.
Consultations:
 
Supplier provides consultative services as part of the service to Participating
Members through a team of expert physicians and doctoral level scientists.
Conversion Assistance:
 
Supplier will provide, but arc not limited to, the following assistance to a
Participating Member that is converting from a competitive reference laboratory:

 
 
1.
 
Test Methodology Verification: Samples may be submitted to verify methodologies
and reference ranges. While it is generally acceptable that Supplier provides
the "gold standard" for which other reference laboratories verify their assays,
comparison samples will be analyzed at [***]*. This comparison discount will be
available for ninety (90) days from the date the Letter of Participation is
received by Supplier.
 
 
2.
 
Sample Reports: Most test procedures have standard report formats. Some assays
have multiple parameters and customized reporting is necessary. Samples of these
reports will be made available to the medical director at each facility, if
required.
 
 
3.
 
Information Systems Conversion Reimbursement: In order to off-set the cost
incurred by any Novation member, Supplier will credit [***]* that is revised in
the laboratory's information system. This will be in the form of a credit on the
invoice of the first full month of use. For Meditech users, a "Test Building
Utility" has been developed and this credit will not apply.

2

--------------------------------------------------------------------------------

 
 
4.
 
Physician Education: As part of Supplier's on-going efforts to transfer the
technological advances developed through research and development, physician
education programs will be made available. These may include but will not be
limited to lectures, teleconferences, technical notes, etc.
 
 
5.
 
Staff Development: Each local Supplier sales representative will work with the
Technical Services department to insure that laboratory staff are sufficiently
trained in all aspects of specimen processing, report retrieval and other
functions associated with referral testing.

Cost Containment:
 
Supplier provides the following as part of the service to Participating Members:
 
 
Clinical Consultation: Supplier's Medical Directors and Scientific staff are
available for development of alternative clinical pathways, standing orders and
treatment monitoring. As with all cost reduction initiatives, these programs are
available to all Participating Members. Cost savings vary from case to case.
 
 
Utilization Review: Statistical review of physician orders and utilization can,
provide each facility with information regarding any series of tests that may be
out-dated or non-contributory.
 
 
Secondary Lab Consolidation: For facilities that utilize several reference labs,
Supplier provides the opportunity to consolidate these sources for esoteric
testing. Existing staff, dedicated to specimen processing, shipping and report
retrieval can be re-assigned.
 
 
Advanced Test Introduction: Participating Members receive information updates on
new tests on a regular basis. These advances in laboratory science lead to
better patient management and cost reductions.
 
 
Improved Turn-around time: Supplier's assay schedule is more aggressive than any
other laboratory. Providing testing in one unified location, complex tests are
resulted faster, reducing the time needed for clinical decision making by
individual physicians.
 
 
Test Selection: With over 3,700 tests in the active test menu, fewer samples are
referred to other laboratories. This reduces overall processing time, expedites
result verification and reduces specimen shipping errors.
 
 
On-Site Lab Technical Support for Participating Members: Additional support will
be provided as deemed necessary on a case by case basis. For those facilities
that require on-site technical support, staff will be available.
 
 
CEU Programs: Continuing education programs exist and are encouraged. Every
effort will be made to provide qualified speakers and materials to meet existing
CEU schedules, These include seminars for CE programs, grand rounds and
Supplier's Conferences.

3

--------------------------------------------------------------------------------

 
 
Training Seminars and/or Training Implementation Teams: All necessary training
and education, complete with documentation and test data will be provided at
each facility.
 
 
Joint Marketing Services: An entire menu of joint marketing services is
available for enhancing a hospital's outreach program. Federal regulations
require Supplier to charge the fair market value for these services. These
include, but are not limited to;

 
 
•
 
Market opportunity assessment     •   Managed care program development     •  
Joint directory of services     •   Joint sales calls     •   Sales training    
•   Sales management training     •   Client service training     •   Courier
network development     •   Marketing materials development     •   Laboratory
operations assessment     •   Regulatory compliance services     •   Billing
consultation     •   Continuing education     •   Consulting services     •  
Inter-institutional connectivity     •   Continuing Education     •   Consulting
Services     •   Inter-institutional Connectivity

4

--------------------------------------------------------------------------------

EXHIBIT B-1

Specialty Laboratories, Inc.—Clinical Reference Laboratory Testing LB00051

LETTER OF PARTICIPATION

Health Care Organization:        

--------------------------------------------------------------------------------

Member Street Address:        

--------------------------------------------------------------------------------

Member City, State and ZIP Code:        

--------------------------------------------------------------------------------

Effective Date:            

--------------------------------------------------------------------------------

   

I agree to participate as a designated VHA, HPPI or UHC member or affiliate
under the terms of the Clinical Reference Laboratory Testing Agreement dated
            ,            , between Novation and Specialty Laboratories with no
commitment on the part of the health care organization. Pricing will not be
effective until this Letter of Participation has been received by Specialty
Laboratories.

In the case of a conflict between the individual health care organization's
purchase order terms and the terms of this Agreement, this Agreement will
control. The Letter of Participation may be terminated by Member with 30 days
written notice to Novation. Novation will then notify the Supplier to remove
Novation pricing.

Health Care Organization:

By:            

--------------------------------------------------------------------------------

   

Print Name:            

--------------------------------------------------------------------------------

   

Title:            

--------------------------------------------------------------------------------

   

Date:            

--------------------------------------------------------------------------------

   

Copy and fax this letter of participation to Novation at (972) 581-5764
Attn: Laboratory

* CONFIDENTIAL TREATMENT IS REQUESTED FOR CONFIDENTIAL INFORMATION ENCLOSED IN
THE BRACKETS AND UNDERLINED.

--------------------------------------------------------------------------------

EXHIBIT C

SPECIAL CONDITIONS
[Final Special Conditions]

--------------------------------------------------------------------------------

EXHIBIT D

AWARD LETTER

[Final Letter of Award]

--------------------------------------------------------------------------------

NovationTM
The Supply Company of VHA & UHC

125 East John Carpenter Freeway
Suite 1500
Irving, TX 75062-2324
P.O. Box 140909
Irving, TX 75014-0909
972-581-5000

March 5, 2001

Mr. Otto Schaefer
Manager of Group Purchasing and Managed Care
Specialty Laboratories, Inc.
2211 Michigan Ave.
Santa Monica, CA 90404-3900

Subject:  Acceptance of Bid (Supplier Agreement # LB00051)

Dear Mr. Schaefer,

    Novation, LLC ("Novation"), acting in its capacity as agent for VHA, UHC,
and HPPI, respectively (and not collectively) and certain of their respective
subsidiaries and affiliates, accepts your multi-source proposal for clinical
reference laboratory testing in response to our Invitation To Bid for Clinical
Reference Laboratory Testing dated March 31, 2000, which was signed and dated by
you on May 4, 2000. Also, attached to this Award Letter is Exhibit F (Exceptions
to Supplier Agreement # LB00051).

    The "Agreed Percentage" for the Marketing Fee will be [***]*. In addition,
if during the time period of May 1 through April 30 of each year of the
Agreement, Novation achieves sales in excess of the target sales [***]*, dollars
in excess of target sales will be paid an [***]* marketing fee.

    The term of this Agreement will be for a period of three years, effective
May 1, 2001, with two one-year renewal options at Novation's discretion.

    Novation looks forward to a successful implementation of this Agreement.

Sincerely,

Eldon Petersen
Group Senior Vice President
Novation, LLC

* CONFIDENTIAL TREATMENT IS REQUESTED FOR CONFIDENTIAL INFORMATION ENCLOSED IN
THE BRACKETS AND UNDERLINED.

--------------------------------------------------------------------------------

EXHIBIT E

OTHER INFORMATION REQUIREMENTS

    Novation and Supplier desire to facilitate contract administration
transactions ("Transactions") by electronically transmitting and receiving data
in agreed formats in substitution for conventional paper-based documents and to
assure that such Transactions are not legally invalid or unenforceable as a
result of the use of available electronic technologies for the mutual benefit of
the parties.

    The parties agree as follows:

1.  PREREQUISITES.

    a.  Documents; Standards.  Each party will electronically communicate to or
receive from the other party all «f the required documents listed in the
Novation Electronic Communication Requirements Schedule attached hereto
(collectively "Documents"). All Documents will be communicated in accordance
with the standards set forth in the applicable sections of the Novation
Information Requirements Guidebook ("Guidebook"). Supplier agrees that the
Guidebook is the Confidential Information of Novation and will not disclose
information contained therein to any other party.

    b.  Third Party Service Providers.  Documents will be communicated
electronically to each party, as specified in the Guidebook, through any third
party service provider ("Provider") with which either party may contract or
VHAseCure.net™. Either party may modify its election to use, not use or change a
Provider upon thirty (30) days' prior written notice. Each party will be
responsible for the costs of any Provider with which it contracts, unless the
parties otherwise mutually agree in writing.

    c.  Signatures.  Each party will adopt as its signature an electronic
identification consisting of symbol(s) or code(s) which are to be affixed to or
contained in each Document transmitted by such party ("Signatures"). Each party
agrees that any Signature of such party affixed to or contained in any
transmitted Document will be sufficient to verify such party originated and
intends to be bound by such Document. Neither party will disclose to any
unauthorized person the Signatures of the other party.

2.  TRANSMISSIONS.

    a.  Verification.  Upon proper receipt of any Document, the receiving party
will promptly and properly transmit a functional acknowledgment in return,
unless otherwise specified in the Guidebook.

    b.  Acceptance.  If acceptance of a Document is required by the Guidebook,
any such Document which has been properly received will not give rise to any
obligation unless and until the party initially transmitting such Document has
properly received in return an Acceptance Document (as specified in the
Guidebook).

    c.  Garbled Transmission.  If any properly transmitted Document is received
in an unintelligible or garbled form, the receiving party will promptly notify
the originating party (if identifiable from the received Document) in a
reasonable manner. In the absence of such a notice, the originating party's
records of the contents of such Document will control.

* CONFIDENTIAL TREATMENT IS REQUESTED FOR CONFIDENTIAL INFORMAITON ENCLOSED IN
THE BRACKETS AND UNDERLINED.

1

--------------------------------------------------------------------------------

3.  TRANSACTION TERMS.

    a.  Confidentiality.  No information contained in any Document or otherwise
exchanged between the parties will be considered confidential, except to the
extent provided by written agreement between the parties, or by applicable law.

    b.  Validity, Enforceability.  Any Document properly transmitted pursuant to
this Agreement will be considered, in connection with any Transaction, to be a
"writing" or "in writing"; and any such Document when containing, or to which
there is affixed, a Signature ("Signed Documents") will be deemed for all
purposes to have been "signed" and to constitute an "original" when printed from
electronic files or records established and maintained in the normal course of
business.

4.  STANDARDS.

ASC × 12—Novation Information Requirements Guidebook

5.  THIRD PARTY SERVICE PROVIDERS.

(If the parties will be transmitting Documents directly, insert "NONE")

Company

--------------------------------------------------------------------------------

  VAN Name

--------------------------------------------------------------------------------

  Address
Number

--------------------------------------------------------------------------------

  Telephone

--------------------------------------------------------------------------------

Novation   AT&T   12976 Hollander Drive   800/624-5672     Bridgeton, MO 63044  
     

6.  CONTRACT PRICING (PHARMACY).  Supplier will transmit contract pricing
information electronically, to include new contracts, contract renewals and any
changes to a current contract. This will be sent in a timely manner and in
compliance with ANSI ASC X12-845 (Price Authorization) and Novation Contract
Pricing Guidelines. Contract pricing information will include the following:

Supplier Identification Number
HIN (Health Industry Number if Supplier is a HIN subscriber)
DEA Number (if HIN is not available)
Supplier Assigned Number (if HIN and DEA are not available)

Supplier Name
Supplier Contract Number
MFG Contract Number
Contract Effective Date
Contract Expiration Date
Member(s) (Member name, HIN or DEA number, Member start/stop dates)
Product Identifier
    NDC
    UPC (if NDC is not available)
Trade Name
Package Count
Package UOM
Selling Unit Price
Item Contract Effective Date
Item Contract Expiration Date

7.  CONTRACT PRICING (MEDICAL/SURGICAL).  Supplier will communicate contract
pricing information electronically, to include new contracts, contract renewals
and any changes to the current contract. This will be sent in a timely manner
and in compliance with the Guidebook.

2

--------------------------------------------------------------------------------

Novation Electronic Communication
Requirements Schedule

Company Name: 

--------------------------------------------------------------------------------

  Date: 

--------------------------------------------------------------------------------

Your Name: 

--------------------------------------------------------------------------------

 
Your Title 

--------------------------------------------------------------------------------

Phone: 

--------------------------------------------------------------------------------

 
Fax: 

--------------------------------------------------------------------------------

 
E-mail 

--------------------------------------------------------------------------------

Technical Contact: 

--------------------------------------------------------------------------------

 
Title 

--------------------------------------------------------------------------------

Phone: 

--------------------------------------------------------------------------------

 
Fax 

--------------------------------------------------------------------------------

 
E-mail: 

--------------------------------------------------------------------------------

NOVATION REQUIREMENT

--------------------------------------------------------------------------------

  NOVATION EXPECTATION

--------------------------------------------------------------------------------

  MANDATORY DUE DATES
& FORMATS TO BE USED

--------------------------------------------------------------------------------

Requirement 1:
New Contract Launch

Section 4.1, page 21 of the 2000 Guidebook   This only applies to new contacts,
unless your company never provided this information. If needed, your Novation
product manager will contact you. UPN must be included with all line item files.
  Due 60 days prior to the Contract Effective Date
Requirement 2:
Ongoing Contract Maintenance

Section 4.2, page 27 of the 2000 Guidebook
 
Novation must receive contract item and pricing updates as prices change, and
when items are added or deleted from contract.
 
Due 60 days prior to the effective date of the line item add/delete/change

Information will be sent via
(check one):

( ) EDI 832
( ) Interim File Format (Excel Spreadsheet)
Requirement 3
Summary Sales Reporting

Section 4.3, page 43 of the 2000 Guidebook
 
Current paper reports must be converted to electronic reporting immediately.
 
Due at the first contract reporting period
Requirement 4:
Detailed Line Item Sales Reporting

Section 4.4, page 51 of the 2000 Guidebook
 
Plan for a 90-day testing for this requirement.
 
Begin testing within 120 days of Contract Effective Date
Information will be sent via
(check one):

( ) EDI 867
( ) Other

3

--------------------------------------------------------------------------------

Requirement 5:
Membership

Section 4.5, page 63 of the 2000 Guidebook
 
You must be able to receive and process monthly membership updates.
 
Due immediately
Requirement 6:
Commitment Forms

Section 4.6, page 73 of the 2000 Guidebook
 
Details which members have and have not signed your contract enrollment forms,
if needed.
 
Due immediately, if applicable
Requirement 7:
Sales Representative
Contact Information

Section 4.7, page 77 of the 2000 Guidebook
 
Able to update Sales Representative Information from a Business Partner
Repository System download.
 
Due within 30 days of the Contract Effective Date
Requirement 8:
Product Cross-referencing

Section 4.8, pages 81 of the 2000 Guidebook
 
Must to update the items on contract with competitive cross-reference
information
 
Due within 90 days of the Contract Effective Date.
Business Partner Repository System
(BPRS)

Access

Section 3, page 13 of the 2000 Guidebook
 
Able to connect to Novation BPRS via the VHAseCURE.net™
 
Due within 60 days of the Contract Effective Date

4

--------------------------------------------------------------------------------

EXHIBIT F

SUPPLIER AGREEMENT EXCEPTION RESPONSE FORM

SUPPLIER NAME:  Specialty Laboratories, Inc.    
PRINTED NAME:  Michael K. Bond
 
 
AUTHORIZED SIGNATURE:
 

--------------------------------------------------------------------------------

TITLE:  Director, Contract Administration
 
DATE  March 6, 2001

Page #

--------------------------------------------------------------------------------

  Para #

--------------------------------------------------------------------------------

  Define Exception Being Taken

--------------------------------------------------------------------------------

1   1b   Supplier.

Delete paragraph and replace with "Supplier is the manufacturer of products
listed on Exhibit A, the provider of installation, training and maintenance
service for such products, or the provider of any other services listed on
Exhibit A (such products and/or services are collectively referred to herein as
"Products")."
2
 
2a
 
Letter of Award.

Insert after first sentence: "Supplier agrees to extend pricing to all Members
(VHA, UHC Members and HPPI Clients and Members) with the exception of long term
care facilities, home health agencies and any competitor of Supplier which is a
VHA, UHC Member or HPPI Client and/or Member that has a current or will have a
future Agreement with Novation, VHA, UHC or HPPI in its capacity as a supplier,
during the term of this Novation Agreement."
2
 
2c
 
Market Competitive Terms.

Delete the second and third sentences and replace with "In the event that a
significant amount of Supplier's business is conducted with any customer of
Supplier pursuant to an arrangement with terms which, considered [***]*
hereunder, Supplier shall notify Novation of such arrangement. In the event that
Novation shall notify Supplier that maintaining [***]* so requires, Supplier
then shall [***]* to Novation members who purchase [***]* from Supplier as is
necessary to ensure market competitiveness. Additionally, any Member eligible
for governmental pricing or research-related endeavors through a university
based project, shall have such [***]* by Supplier."
* CONFIDENTIAL TREATMENT IS REQUESTED FOR CONFIDENTIAL INFORMAITON ENCLOSED IN
THE BRACKETS AND UNDERLINED.

1

--------------------------------------------------------------------------------

2
 
2f
 
Underutilized Businesses.

In line five, replace "provide, on request" with "develop a system to provide".
3
 
3b
 
Change (1) to "Supplier materially breaches this Agreement; or"
3
 
3c
 
Termination by Supplier.

Delete paragraph and replace with "Supplier may terminate the Agreement at any
time for any reason whatsoever by delivering not less than ninety (90) days'
prior written notice thereof to Novation."
3
 
4a
 
Delivery and Invoicing'

Delete third sentence and replace with "Payment terms are [***]*."
4
 
4d
 
Discontinuation of Product.

Delete 4(d) and substitute the following: "Supplier reserves the right to add,
delete, or modify test offerings, methods, and related services whenever
Supplier's medical personnel make a professional judgement that such changes are
in the best interest of' patient care. Supplier continually develops new tests
and evaluates existing methodologies for improvement. Supplier will notify each
Member of planned changes to existing methodology and/or reference ranges and
provide method comparison data, upon request of the Member. Supplier agrees that
it will not make changes to its test offerings, methods, and related services
except for changes made based upon good faith professional judgment. Supplier
will not utilize this provision to make broad changes in the scope of its
services for the purpose of directly or indirectly changing its overall
commitment to Members within the scope of the Supplier Agreement between
Supplier and Novation. Whenever Supplier determines that it is reasonable to do
so from a professional and practical standpoint, Supplier shall give Member the
option to continue with an existing methodology."

2

--------------------------------------------------------------------------------

11
 
12a
 
Policy Requirements.

Delete second sentence and replace with "Such insurance will contain a minimum
combined single limit of liability for bodily injury and property damage in the
amounts of not less than [***]*; will name Novation and the Clients, as their
interests may appear, as additional insureds, and will contain an endorsement
providing that the carrier will provide directly to all named insured copies of
all notices and endorsements."
12
 
14
 
Release and Indemnity.

Delete second sentence and replace with "Such indemnification, hold harmless and
right to defense will not be applicable to the extent the claim, liability,
damage, action, cost or expense arises as a result of an act or failure to act
of Indemnitees."
14
 
18a
 
Choice of Law.

In line two, strike "the Texas courts", and replace with "the state and federal
courts in the state of Texas"
15
 
18g
 
Entire Agreement.

Delete paragraph and replace with "This Agreement, together with the exhibits
listed below and each Member's purchase order and Letter of Participation will
constitute the entire agreement between each Member and Supplier. In the event
of any inconsistency between this Agreement and a Member's purchase order or
Letter of Participation, the terms of this Agreement will control, except that
the Member's purchase order will supersede Sections 4 and 5 of this Agreement in
the event of any inconsistency with such Sections. No other terms and conditions
in any document, acceptance, or acknowledgement will be effective or binding
unless expressly agreed to in writing."

3

--------------------------------------------------------------------------------

QuickLinks

Exhibit 10.1

INDEX OF DEFINED TERMS
EXHIBIT A PRODUCT AND SERVICE DESCRIPTION AND PRICING
Exhibit A Specialty Laboratories, Inc.
EXHIBIT B NON-PRICE SPECIFICATIONS
EXHIBIT B-1 Specialty Laboratories, Inc.—Clinical Reference Laboratory Testing
LB00051 LETTER OF PARTICIPATION
EXHIBIT C SPECIAL CONDITIONS [Final Special Conditions]
EXHIBIT D AWARD LETTER [Final Letter of Award]

Novation Acceptance of Bid Letter

EXHIBIT E OTHER INFORMATION REQUIREMENTS
Novation Electronic Communication Requirements Schedule
EXHIBIT F SUPPLIER AGREEMENT EXCEPTION RESPONSE FORM